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  ABSTRACT 
Be Eaten to Stay Healthy: 
Elucidating the mechanisms of mitochondrial quality control by mitophagy. 
Rosa Leonora Andrea de Vries 
Mitochondria are essential organelles that provide the cell with energy and are involved in many 
housekeeping processes. Maintaining a healthy population of mitochondria is vital for the proper 
functioning of cells and the presence of dysfunctional mitochondria may lead to cellular damage and cell 
death. Neurons are particularly susceptible to the consequences of mitochondrial damage as they have 
high energy needs and are post-mitotic. The clearance of damaged mitochondria by autophagy, or 
mitophagy, has emerged as an important quality control mechanism. The Parkinson’s disease related 
proteins phosphatase and tensin homolog-induced putative kinase 1 (PINK1) and Parkin have been 
identified as important regulators of mitophagy in mammalian cells, directly linking mitophagy to 
neurodegeneration. The role of these two proteins in this mitophagy is further explored in the first part of 
this dissertation. We propose a model whereby a cleavage product of PINK1 in the cytosol binds Parkin 
and prevents its translocation to mitochondria, which is regarded as the initiating step in Parkin/PINK1 
mitophagy. Upon the occurrence of mitochondrial damage, however, full-length PINK1 accumulates on 
the mitochondrial outer membrane (MOM) and recruits Parkin, marking the damaged mitochondria for 
mitophagy.  
In the second part, we assess mitophagy in a cellular model based on disease caused by 
mutations in mitochondrial DNA (mtDNA). We find that the mere presence of damaged mitochondria in 
the cell does not activate mitophagy. Rather, this process is a complex interplay between mitochondrial 
membrane potential, levels of PINK1/Parkin and the activation of general macroautophagy. 
The final part of this dissertation describes the development and validation of a new method to 
study mitophagy. MitophaGFP, a red-green tandem fluorescent protein targeted to the MOM, changes 
color from yellow to red once mitochondria enter lysosomes, the final step of the mitophagy process. This 
new probe allows us to quantitatively and qualitatively assess mitophagy and fulfills a need in the 
mitophagy field. 
	  The work described in this dissertation contributes to elucidate the mechanisms underlying 
mitophagy regulation in mammalian cells. Its findings can serve as a basis to further explore the 
importance of mitophagy as a quality control mechanism and the role of its defect in in 
neurodegeneration. 
	   i 
TABLE OF CONTENTS 
List of Figures ............................................................................................................................................ iii 
List of Abbreviations .................................................................................................................................. v 
Acknowledgements ................................................................................................................................. viii 
Dedication ................................................................................................................................................... x 
Chapter 1: Introduction .............................................................................................................................. 1 
1.1 Autophagy .......................................................................................................................................... 1 
1.2 Mitochondria ...................................................................................................................................... 8 
1.3 Mitophagy ........................................................................................................................................ 12 
1.4 Methods to study mitophagy ............................................................................................................ 22 
1.5 Dissertation outline .......................................................................................................................... 23 
Chapter 2: PINK1 and Parkin regulate mitophagy in mammalian cells  ............................................. 25 
2.1 Introduction ...................................................................................................................................... 26 
2.2 Results part I: PINK1-dependent recruitment of Parkin to mitochondria in mitophagy  ................... 27 
2.3 Results part II: The dual localization of PINK1 modulates Parkin translocation to mitochondria ..... 43 
2.4 Conclusions and discussion ............................................................................................................. 51 
2.5 Methods ........................................................................................................................................... 57 
Chapter 3: Mitophagy in mitochondrial disease  .................................................................................. 63 
3.1 Introduction ...................................................................................................................................... 64 
3.2 Results ............................................................................................................................................. 66 
3.3 Conclusions and discussion ............................................................................................................. 79 
3.4 Materials and methods ..................................................................................................................... 81 
3.5 Acknowledgements .......................................................................................................................... 83 
3.6 Supplementary figures ..................................................................................................................... 84 
 
	   ii 
Chapter 4: A new tool to study mitophagy  ........................................................................................... 88 
4.1 Introduction ...................................................................................................................................... 89 
4.2 Results ............................................................................................................................................. 91 
4.3 Discussion ........................................................................................................................................ 99 
4.4 Materials and methods ................................................................................................................... 100 
4.5 Acknowledgements ........................................................................................................................ 102 
4.6 Supplementary figures ................................................................................................................... 103 
Chapter 5: Conclusions and discussion .............................................................................................. 108 
5.1 Summary of results ........................................................................................................................ 108 
5.2 Outstanding questions on PINK1 and Parkin ................................................................................. 113 
5.3 Mitophagy in neurodegeneration: where do we go from here? ...................................................... 117 
5.4 Concluding remarks ....................................................................................................................... 120 
References .............................................................................................................................................. 121 	  	  
  
	   iii 
LIST OF FIGURES  
 
Figure 1.1.  Three major forms of autophagy.  
Figure 1.2.  Regulation of mammalian autophagy.  
Figure 1.3.  Mitochondrial electron transport chain  
Figure 1.4.  Three scenarios for the role of PINK1/Parkin in mitophagy. 
Figure 1.5.  Methods to study mitophagy 
Figure 2.1. CCCP exposure alters the subcellular distribution of Parkin from the cytosol to the 
mitochondria. 
Figure 2.2. Mitochondrial depolarization recruits WT Parkin to mitochondria. 
Figure 2.3. PINK1 knockdown prevents Parkin recruitment to depolarized mitochondria. 
Figure 2.4. Overexpression of PINK1 suffices to recruit Parkin to mitochondriawith normal ΔΨm. 
Figure 2.5. PINK1-dependent recruitment of Parkin to mitochondria is independent of ΔΨm but 
requires PINK1 kinase activity. 
Figure 2.6. Parkin interacts with PINK1 in mammalian cells. 
Figure 2.7. Parkin and PINK1 co-overexpression induces the formation of perinuclear mitochondrial 
clusters in SH-SY5Y cells. 
Figure 2.8. PINK1 PD mutations mitigate the formation of perinuclear mitochondrial clusters.  
Figure 2.9. Co-overexpression of PINK1K219M (KD)/Parkin, PINK1/ParkinΔR2 (ΔR2), PINK1/DJ-1, and 
DJ-1/Parkin in SH-SY5Y cells do not produce perinuclear mitochondrial clustering. 
Figure 2.10.  Mitochondrial clusters dissipate upon microtubule depolymerization. 
Figure 2.11. Effects of PINK1/Parkin cotransfection 
Figure 2.12. Perinuclear mitochondrial clusters undergo mitochondrial autophagy. 
Figure 2.13. Subcellular distribution of cleaved PINK1. 
Figure 2.14. Identification of the PINK1-Parkin binding site and assessment of mitophagy. 
Figure 2.15. Proposed model for the regulation of mitophagy by PINK1 and Parkin.  
Figure 3.1. Autophagic status of cybrid cell lines. 
Figure 3.2. Confocal microscopy of mitochondria and autophagosomes from WT and  Δ cells. 
Figure 3.3. Confocal fluorescence microscopy of Parkin and p62 in mitochondrial autophagy. 
	   iv 
Figure 3.4. Analysis of mitochondrial transmembrane potential in cybrid cell lines. 
Figure 3.5. Autophagy and mTORC1 signaling. 
Figure 3.6. CCCP-mediated uncoupling and autophagy. 
Figure 3.7. PINK1 and Parkin mRNAs in cybrid cell lines. 
Figure 3.S1.  Rapamycin treatment of cybrids. 
Figure 3.S2. Analysis of autophagic flux. 
Figure 3.S3. CCCP and macroautophagy. 
Figure 3.S4. PINK1 and Parkin expression in rapamycin-treated cybrids. 
Figure 4.1.  Mitochondrial localization of MitophaGFP. 
Figure 4.2.  MitophaGFP is pH sensitive. 
Figure 4.3.  Detection of mitophagy with MitophagGFP. 
Figure 4.4.  Mitophagy is Parkin dependent 
Figure 4.S1.  Map of construct with restriction sites used. 
Figure 4.S2.  Mitochondrial localization of MitophaGFP. 
Figure 4.S3.  MitophaGFP does not change color at neutral pH. 
Figure 4.S4.  MitophaGFP turns red at low pH. 
Figure 4.S5.  Inhibition of autophagy prevents formation of red-only puncta. 
 
  
	   v 
LIST OF ABBREVIATIONS 
 
3MA 3-methyladenine 
AD Alzheimer's disease 
AMP adenosine monophosphate 
AP autophagosome 
ATG autophagy related gene 
ATP adenosine triphosphate 
AV autophagic vacuole 
CCCP carbonyl cyanide m-chlorophenylhydrazone  
CFP cyan fluorescent protein 
DMSO dimethylsulfide 
DRP1 dynamin-related protein 1 
EGFP enhanced green fluorescent protein 
EM electron microscopy 
ER endoplasmic reticulum 
FCCP carbonyl cyanide p-trifluoromethoxyphenylhydrazone  
FLIM fluorescence-lifetime imaging microscopy 
FM fluorescence microscopy 
GFP green fluorescent protein 
HD Huntington's disease 
Htt Huntingtin protein 
IMS intermembrane space 
IP immunoprecipitation 
KSS Kearns-Sayre Syndrome 
LIR LC3 interacting region 
MEF mouse embryonic fibroblast 
MELAS mitochondria encephalopathy, lactic acidosis,strokelike episodes 
	   vi 
MFN mitofusin 
MIM mitochondrial inner membrane 
MOM mitochondrial outer membrane 
MPP mitochondrial processing peptidase  
mtDNA mitochondrial DNA 
mTor mammalian target of rapamycin 
mTORC1 mTor complex 1 
MTS mitochondrial targeting sequence 
NARP neuropathy, ataxia, retinitis pigmentosa 
OPA1 optic atrophy 1 
OxPhos oxidative phosphorylation system 
PAM presequence translocase associated motor 
PARL presenilin-associated rhomboid-like protease  
PAS phagophore assembly site 
PBS phosphate buffered saline 
PD Parkinson's disease 
PE Phosphatidylethanolamine  
PI3K phosphatidylinositol-3 kinase  
PINK1 phosphatase and tensin homolog-induced putative kinase 1  
PK proteinase K 
qRT-PCR quantitative reverse transcription polymerase chain reaction 
ROS reactive oxygen species 
SAM sorting and assembly machinery 
SOD superoxide dismutase 
TCA tricarboxylix acid 
TFAM transcription factor A 
TIM translocase of the inner membrane 
TMD transmembrane domain 
	   vii 
TMRE tetramethyl rhodamine este 
TOM translocase of the outer membrane 
ULK unc-51-like kinase 
UPS ubiquitin-proteasome system 
WB Western Blot 
WT wild-type 
YFP yellow fluorescent protein 
ΔΨm mitochondrial membrane potential 
  
	   viii 
ACKNOWLEDGEMENTS 
 
First and foremost, I would to thank my mentor, Serge Przedborski. Over the past four years, he has 
allowed me to follow my own path and pursue my own research interests, even though these sometimes 
lead nowhere. His guidance and encouragement (and at times telling me the brutal truth) have helped me 
become a better scientist and more confident person. His passion for science is a true inspiration. 
I am very grateful to my thesis committee members Liza Pon, Richard Kessin and Gilbert Di Paolo for 
thoughtful discussions, helpful advice and providing direction for my project. Also, I would like to thank 
Giovanni Manfredi for agreeing to serve as the outside reader for my thesis defense. 
Many thanks to the members of the Przedborski lab, who have made it a pleasure to come to work in the 
past four years: Christina Guardia, Yuhui Liu, Javier Blesa, Zhezheng Li, Diane Re, Virginia Le Verche, 
Kristin Politi, Rhadika Pradhan, Bobby Yu and Arnaud Jacquier. Sudarshan Phani, thank you for all your 
Photoshop help. Thank you to Vernice Jackson-Lewis for bringing so much positive energy to the lab, to 
Norma Romero and James Caceido for your assistance with all my lab needs, and Burcin Ikiz for being 
my fellow graduate student. Maja Fedorowicz, thank you for all your support, both on a scientific and 
personal level. 
I am indebted to David Sulzer, who encouraged me to pursue a PhD at Columbia University and helped 
make that happen. 
To my fellow autophagy-enthusiasts in the Di Paolo lab, Claudia Dall’Armi and Kelly Devereaux, thank 
you for your help with experiments, for providing reagents and for helpful discussions. Kimberly Point du 
Jour, thank you for your friendship. 
I would not have been able to complete the work presented in this thesis without some great 
collaborators, including Robert Gilkerson and Eric Schon, who allowed me to take part in the cybrid study 
in Chapter 3. Theresa Swayne and Adam White have taught me everything I needed to know about 
confocal microscopy and without their assistance I would not have been able to develop my new tool. 
I would like to thank the Pathology program and in particular Zaia Sivo and Ron Liem for their support. 
Finally, I feel fortunate to have a family who believes in me and has encouraged and supported me 
throughout my endeavors in the United States. In the Netherlands, my parents Dwight and Jeannette, my 
	   ix 
brothers Ruben and Rutger and my grandmothers. In the USA, my parents-in-law Paul and Renee, my 
sister-in-law Carrie, and last but not least, my husband Andrew and son Aidan, who make my life 
worthwhile. 
  















Mijn eigen kleine onderzoeker 
	   1 
 
CHAPTER 1: INTRODUCTION 
 
1.1. AUTOPHAGY 
1.1.1.Two routes to protein degradation 
Cells possess two major routes of breaking down excess or improperly assembled proteins. Most 
short-lived proteins are selectively degraded by the ubiquitin-proteasome system (UPS). The first step in 
this pathway is the activation of ubiquitin by the ubiquitin-activating enzyme E1. E1 transfers ubiquitin to 
the carrier protein E2. The resulting ubiquitin-E2 complex is then conjugated to the target protein by 
means of a ubiquitin-ligase enzyme (E3). The ubiquitinated protein is broken down by the 26S 
proteasome, which is formed from the coupling of the 20S and 19S subunits. This process results in the 
release of ubiquitin and the cleavage of proteins into peptides and amino acids (Glickman and 
Ciechanover, 2002). 
The second route is through autophagy, or ‘self eating’, from the Greek words autos (self) and 
phago (to eat). This term was first coined in 1963 by Christian de Duve to describe a phenomenon 
observed in electron microscopy studies, namely the presence of cytosolic content and whole organelles 
in novel single- or double-membrane vesicles (Klionsky, 2007). In morphologic studies, these so-called 
autophagosomes were found to fuse with lysosomes, where the intracellular cargo consisting of mostly 
long-lived proteins and organelles is degraded.  
 The pathways regulating autophagy did not start to unravel for another thirty years when a 1992 
study by Yoshinori Oshumi’s laboratory showed that autophagy in Saccharomyces cerevisiae was similar 
to that in mammals (Takeshige et al., 1992). Genetic screens in yeast have since uncovered some 33 
autophagy related genes (ATG) (Inoue and Klionsky, 2010). Seventeen of these genes, ATG1-10, 
ATG12-16, ATG18 and ATG22 are necessary for autophagosome formation and are considered 
components of the ‘core’ autophagic machinery. They are highly conserved and their homologues or 




	   2 
 
1.1.2. Three major forms of autophagy in mammalian cells 
In mammalian cells, three intracellular autophagic pathways deliver cargo to lysosomes for 
degradation: macroautophagy, chaperone mediated autophagy, and microautophagy (see Figure 1.1). 
The macroautophagic pathway is the most thoroughly characterized and is usually referred to simply as 
‘autophagy’. In microautophagy, cytosolic content is engulfed directly at the lysosomal surface by 
invagination or protrusion of the lysosomal membrane. In contrast to micro- and macroautophagy, 
chaperone-mediated autophagy is a pathway of lysosomal proteolysis that degrades only a specific 
subset of proteins. It is activated during conditions of prolonged nutrient starvation and is restricted to the 
elimination of proteins that possess an amino acid sequence biochemically related to the pentapeptide 
Lys-Phe-Glu-Arg-Gln (KFERQ).  This sequence is recognized by the cytosolic chaperone Hsc73. The 
resulting complex binds to the lysosomal receptor Lamp2a, the proteins are unfolded and transported into 
the lumen of the lysosome (Cuervo, 2004). 
During macroautophagy, cargo is sequestered in a double-membraned structure called an 
autophagosome. Once activated, macroautophagy occurs via several steps (see Figure 1.2): First, during 
initiation, a cup-shaped structure referred to as an isolation membrane, or phagophore, forms at the 
phagophore assembly site (PAS). While the origin of the phagophore is still under debate, membranes 
from mitochondria, endoplasmic reticulum (ER) and the Golgi have all been suggested as sites for 
phagophore formation (Tooze and 
Yoshimori, 2010). The phagophore 
undergoes elongation and expansion and 
engulfs cytosolic components including 
proteins, organelles and lipids. It 
eventually closes and forms an 
autophagosome (AP) surrounded by a 
double membrane. Maturation involves the 
fusion of the autophagosome with an 
endosome or lysosome. Upon the fusion 
of the autophagosome with a primary 
	  
Figure 1.1. Three major forms of autophagy.  
Taken from (Cuervo, 2004) 
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lysosome, the outer membrane becomes part of the lysosomal membrane and the contents of the 
autophagosome are delivered into the lysosome. The newly formed complex acidifies and matures into 
an autophagolysosome. Acidification allows the activation of hydrolytic enzymes and consequent 
degradation of the engulfed cellular components. The autophagosome and autophagolysosome are 
collectively referred to as autophagic vacuoles (AVs) (Yang and Klionsky, 2010). 
 
1.1.3. Regulation of macro-autophagy in mammalian cells 
Macroautophagy, herafter referred to as autophagy, is constitutively active in cells and plays a 
role in homeostasis through the elimination of damaged organelles or protein aggregates and the 
turnover of long-lived proteins. The level of autophagy is highly increased under conditions of cellular 
stress, such as nutrient deprivation, hypoxia, infection or oxidative stress. The catabolism of cellular 
components under these circumstances supplies amino acids and substrates for the production of 
adenosine triphosphate (ATP) through the tricarboxylic acid cycle (TCA cycle) (Murrow and Debnath, 
2013). The regulation of autophagy is very complex and involves several different interacting pathways. 
Below I will discuss some of the main players. For an extensive review, see e.g. (Kroemer et al., 2010) 
 
1.1.3.1. Activation  
The mammalian target of rapamycin (mTor) complex 1 (mTORC1) plays a central role in the 
initiation of autophagy. It consists of mTOR, Raptor, mLST8/GßL, Deptor, and PRAS40 (Kroemer et al., 
2010). Under normal conditions, mTor phosphorylates the unc-51-like kinases (ULK) 1 and 2 (the 
mammalian orthologues of Atg1) and sequesters them in a complex with Atg13, Atg101 and FIP200, 
thereby inhibiting autophagy. During nutrient starvation, mTor activity is decreased, which leads to the 
dephosphorylation of ULK1/2 and Atg13, dissociation of mTORC1 from the ULK complex and induction of 
autophagy (Kroemer et al., 2010;Yang and Klionsky, 2010).  
The adenosine monophosphate (AMP)-activated protein kinase AMPK is a major positive 
regulator of autophagy. It serves as a sensor for AMP/ATP ratio in cells and under low ATP conditions 
can activate autophagy. It is thought to do this by activating ULK1 through phosphorylation while at the 
same time inhibiting mTORC1 via phosphorylation of Raptor (Murrow and Debnath, 2013). 
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1.1.3.2. Initiation 
Initiation of phagophore formation at the PAS is dependent on the Beclin 1 core complex. It 
contains Beclin 1, p150, the class III phosphatidylinositol-3 kinase (PI3K) Vps34 and either 
Ambra1/Atg14L or UVRAG. Activation of Vps34 in this complex is thought to recruit other factors that play 
a role in the induction of membrane curvature and elongation, although the exact mechanisms are only 
starting to emerge (Dall’Armi et al., 2013; Kroemer et al., 2010; Murrow and Debnath, 2013). The pro-
apoptotic factor Bcl-2 competes with Vps34 for binding to Beclin 1 and can thereby block autophagy 
(Kroemer et al., 2010). 
 
1.1.3.3. Formation of the autophagosome 
Elongation of the phagophore is dependent on two ubiquitin-like conjugation systems, Atg12 and 
Atg8/LC3. Atg12 is conjugated to Atg5 in a process that is catalyzed by the E1-like enzyme Atg7 and the 
E2-like enzyme Atg10. The Atg12-Atg5 conjugate then interacts with Atg16L, forming the multimeric 
Atg16L complex. This complex is localized to the PAS and acts as an E3-like ligase. It is thought to 
specify the site for LC3-I lipidation. Phosphatidylethanolamine (PE) is conjugated to Atg8/LC3-I by Atg7 
(E1-like enzyme) and Atg3 (E2-like enzyme). This leads to the conversion of cytosolic LC3-I to LC3-II, 
which is stably associated with the autophagosome membrane. In fact, the conversion of LC3-I to II is 
frequently used to measure autophagy biochemically and microscopically (Kroemer et al., 2010; Yang 
and Klionsky, 2010).  
 
1.1.3.4. Maturation 
The molecular mechanisms underlying autophagosome maturation and fusion with lysosomes 
remain unclear. UVRAG, part of the Beclin 1 complex, may facilitate maturation via its interaction with the 
class C vacuolar protein sorting complex, which mediates fusion. Interaction of UVRAG with Rubicon 
negatively regulates autophagosome maturation (Dall’Armi et al., 2013; Wong et al., 2011).  
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1.1.4. Role of autophagy in health and disease 
While autophagy is essentially considered a pro-survival pathway in response to stress, it is 
important in human health and disease. Basal autophagy is necessary for cellular homeostasis and clears 
cells of debris, misfolded proteins, and ‘old’ organelles. It was also recently found to aid in lipid 
metabolism (Singh et al., 2009) through lipophagy. Autophagy is essential for proper functioning of the 
immune system where it plays a role in adaptive immune responses such as antigen presentation. In 
addition, it assists the immune system during infection by degrading intracellular bacteria and viruses by 
xenophagy (Choi et al., 2013; Ravikumar et al., 2010). 
	  
Figure 1.2. Regulation of mammalian autophagy.  
Autophagy activation (A) is regulated by the mTORC1 complex and AMPK. Initiation of phagophore formation is 
under control of the Beclin 1 core complex (B). The formation (C) of the phagosome depends on two ubiquitin-
like systems, Atg12 and LC3. During maturation (D) the phagosome fuses with late endosomes and lysosomes 
and cargo is degraded. See text for details. Taken from (Kroemer et al., 2010). 	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Aberrant autophagy has been implicated in a host of diseases including heart disease (ischemia), 
lung disease (chronic obstructive pulmonary disease, COPD), Crohn’s disease, and diabetes (Murrow 
and Debnath, 2013). It has been extensively studied in cancer; mutations of Beclin 1, part of the 
autophagic core machinery, are associated with 75% of human breast, ovarian, and prostate tumors 
(Choi et al., 2013). Lastly, autophagy defects have been linked to neurodegenerative diseases such as 
Parkinson’s disease (PD), Alzheimer’s disease (AD), and Huntington’s disease (HD). 
 
1.1.4.1. Autophagy in neurodegenerative diseases 
PD, AD, and HD are all characterized by intracellular accumulation of disease proteins. HD is 
caused by an expansion of the CAG repeat in the huntington gene. The resulting long polyglutamine 
repeat makes the Huntingtin protein (Htt) aggregate-prone. Unlike wild-type, mutant Htt cannot be cleared 
by the ubiquitin-proteasome system, but can be degraded through the autophagic pathway (Williams et 
al., 2006). Using HD mouse models and cells from HD patients we recently found that although 
autophagosome formation and clearance are normal, the autophagic vacuoles contain little cargo. This 
suggests that cargo recognition in HD leads to an accumulation of protein aggregates, rather than a 
defect in autophagy per se (Martinez-Vicente et al., 2010).  Thus, overall increase in autophagy levels 
may be therapeutically relevant, and the group of David Rubinsztein has indeed shown that treatment 
with an mTor-inhibiting drug such as rapamycin reduces Htt aggregates in mouse models (Harris and 
Rubinsztein, 2012).   
AD is characterized by the intracellular buildup of neurofibrillary tangles containing 
hyperphosphorylated tau and the extracellular presence of β-amyloid plaques. Immuno-electron 
microscopy studies of post-mortem AD brains showed an accumulation of autophagosomes and 
lysosomes, suggesting that autophagy plays a role in AD pathogenesis (Nixon et al., 2005). The group of 
Ralph Nixon has shown that defective targeting of the v-ATPase V0a1 to lysosomes leads to a failure in 
lysosomal acidification, and is the cause of autophagy dysfunction in AD (Lee et al., 2010a).  
Although the majority of PD cases are sporadic, about 10% are familiar, i.e. are caused by a gene 
mutation. At least three of these genes are thought to be linked to defects in autophagy. Mutant α-
synuclein is present in intracellular Lewy bodies, a pathological hallmark of PD. Like Htt, it can be 
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degraded by autophagy. However, α-synuclein has been shown to impair not only macroautophagy but 
also chaperone-mediated autophagy in PC12 cells (Cuervo et al., 2004; Webb et al., 2003; Winslow et 
al., 2010). Whether this is true also in vivo and in human brain remains to be established. Mutations in 
PARK2 (Parkin) and PARK6 (PINK1) affect mitochondrial autophagy (mitophagy) and will be discussed in 
more detail in section 1.3.2.2.2. 
 
1.1.5. Selective vs non-selective autophagy 
Autophagy has long been considered a bulk degradation process whereby cytosolic content is 
sequestered in autophagosomes non-selectively. A number of recent reports, however, have provided 
evidence for the existence of selective autophagy including the specific degradation of protein aggregates 
(aggrephagy), lipid droplets (lipophagy), peroxisomes (pexophagy), ER fragments (reticulophagy), 
ribosomes (ribophagy), viruses and bacteria (xenophagy) and mitochondria (mitophagy) (Jin et al., 2013; 
Johansen and Lamark, 2011). The latter of which is the topic of this thesis. 
These selective forms of autophagy are thought to use the same machinery as macroautophagy, 
but use an adaptor protein to link the specific cargo with LC3 on the autophagosomal membrane. The 
most extensively studied cargo receptor in mammalian cells is p62/SQSTM1. The Johansen group first 
hypothesized that p62/SQSTM1might be involved in the clearance of ubiquitinated protein aggregates by 
autophagy (Bjorkoy et al., 2005). They showed that p62/SQSTM1 was present on these aggregates and 
that it was degraded by autophagy. p62/SQSTM1 was subsequently shown to directly interact with LC3 
through its LC3 interacting region (LIR) (Komatsu et al., 2007; Pankiv et al., 2007). It preferentially 
recognizes those substrates with K63-linked poly-ubiquitin chains, rather than K48-linked chains that are 
associated with proteasome degradation. 
Other adaptor proteins identified include NBR1, HDAC6 and Nix, which will be further discussed 
in section 1.3.2.2.1. For a review see (Johansen and Lamark, 2011). The remainder of this chapter will 
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1.2. MITOCHONDRIA 
Mitochondria are known to many people as ‘the powerhouse of the cell’, since they provide 
energy to cells in the form of ATP, generated by oxidative phosphorylation along the respiratory chain. 
Mitochondria are present in all cells except erythrocytes, and their number varies from one to thousands 
per cell (Schon and Przedborski, 2011). They are often depicted in biology textbooks as oval shaped 
singular organelles, but in fact their shape constantly changes and they form dynamic networks that 
undergo fusion and fission. During spermatogenesis they appear threadlike, hence their name (mitos = 
thread, chondros = granule) (Galluzzi et al., 2012). 
 
1.2.1 Energy production and membrane potential 
 Mitochondria are composed of a mitochondrial outer membrane (MOM) and inner membrane 
(MIM), separated by the inter membrane space (IMS). The components of the respiratory chain, or 
oxidative phosphorylation (OxPhos) system, a set of four multisubunit complexes (I-IV) and two electron 
carriers (ubiquinone/coenzyme Q10 and cytochrome c), are embedded in the inner membrane (see 
Figure 1.3). This membrane is convoluted, forming invaginations known as cristae, which highly increases 
the surface area.  The space inside the 
inner membrane is called the matrix 
and this is where pyruvate and fatty 
acids from food are broken down to 
acetyl CoA. Acetyl CoA is metabolized 
by the tricarboxylic acid cycle, which 
reduces NAD+ and FAD to NADH and 
FADH2. Electrons from NADH and 
FADH2 are then carried along the 
respiratory chain, generating a proton 
gradient across the inner membrane 
and transferring the electrons to O2, 
producing water. The energy of the 
 
Figure 1.3. Mitochondrial electron transport chain  
Taken from Wikimedia.org. 
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proton gradient drives synthesis of ATP by the ATP synthase, complex V. The proton gradient created by 
pumping protons from the matrix to the IMS generates not only a pH gradient, as well as a voltage 
gradient known as the mitochondrial membrane potential ΔΨm. (Alberts et al., 2002; Galluzzi et al., 2012; 
Schon and Przedborski, 2011) 
 
1.2.2. Mitochondrial DNA 
It is thought that mitochondria evolved from bacteria that were engulfed by nucleated ancestral 
cells (Alberts et al., 2002). As a leftover from this evolutionary past, they contain their own genome, as 
well as the machinery to synthesize RNA and proteins. The circular, 16.6kb double-stranded 
mitochondrial DNA (mtDNA) contains 37 genes. Of these, 22 code for tRNAs, 2 for rRNAs, and 13 for 
proteins that are part of the OxPhos system (seven subunits of Complex I, one subunit of Complex III, 
three subunits of Complex IV, and two subunits of Complex V) (Schon et al., 2012). Mitochondrial DNA is 
maternally inherited. 
 
1.2.3 Mitochondrial protein import 
Mitochondria cannot be generated de novo. Rather, they proliferate by division (fission) and 
growth of pre-existing organelles. Only about 1% of mitochondrial proteins are encoded by mtDNA. The 
rest of the mitochondrial proteins are nuclearly encoded and synthesized in the cytosol as precursor 
proteins. They are subsequently imported to the mitochondria and sorted to the different mitochondrial 
compartments (MOM, IMS, MIM or matrix). The final intramitochondrial destination of a precursor protein 
is dependent on its mitochondrial targeting sequence (MTS). This MTS typically consists of a positively 
charged, 15 to 50 amino acid long sequence at the N-terminal that is cleaved off after import. Some 
proteins, however, contain internal targeting signals that remain part of the mature protein. 
Import of mitochondrially targeted proteins starts with translocation across the outer membrane 
through the Translocase of the Outer Membrane (TOM) complex.  This complex consists of several Tom 
proteins, including the β-barrel protein Tom40, which forms pores through which the imported proteins 
can enter. Tom20 and Tom70 recognize the MTS and serve as initial docking sites. Tom22 and Tom5 
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also bind the precursor protein on the cytosolic side, while Tom40, Tom7 and the IMS side of Tom22 
contact the protein once it has reached the IMS side of the pore. 
Proteins that are destined for the IMS usually contain a Cx3C or Cx9C motif and are further 
handled by the mitochondrial intermembrane space assembly. Precursors targeted to the MIM or matrix 
are handed off to the Translocase of the Inner Membrane (TIM) complex. At the core of this complex is 
the channel forming protein Tim23. Tim50, Tim23 and Tim21 can transiently connect to the TOM complex 
and Tim50 is the first to bind the precursor protein once it is emerging from the TOM complex. Tim50 also 
regulates the opening of the Tim23 channel, allowing the peptide to pass through the channel. 
Mitochondrial membrane potential is essential for the translocation across the MIM. Not only is it 
important for the activation of the Tim23 channel, it can also help pull proteins through since it is negative 
on the matrix side while the MTS are positively charged.  
Precursor proteins can either be laterally released to the MIM or be completely imported in the 
matrix by the presequence translocase associated motor (PAM). There, the presequence is cleaved off 
by mitochondrial processing peptidase (MPP) and proteins sometimes undergo additional proteolytic 
processing. 
The outer membrane contains two types of integral proteins: α-helix proteins and β-barrel proteins. 
The former can be anchored to the membrane at the N-terminal, the C-terminal or at middle regions. 
They appear to be inserted from the cytosolic side of the MOM through mechanisms that are only starting 
to be understood. In contrast, β-barrel proteins are imported through the TOM complex and are inserted 
in the MOM from the intermembrane space with the help of the sorting and assembly machinery (SAM). 
SAM is integrated in the MOM and has been suggested that it aids in folding of the β-barrel precursors. 
How it subsequently releases the mature proteins in the MOM remains unknown (Chacinska et al., 2009; 
Dudek et al., 2013; Schmidt et al., 2010). 
 
1.2.3. The need for mitochondrial quality control 
In theory, mitochondria are under constant threat of being damaged. Although most electrons that 
flow through the respiratory chain are used to generate H2O, a small percentage (up to 0.15% (Brand, 
2010)) leaks out and creates a superoxide anion, a free radical. This is normally converted to H2O2 by 
	   11 
 
superoxide dismutases (SODs), which are present in the intermembrane space and cytosol (SOD1), in 
the matrix (SOD2) and tethered to the extracellular matrix (SOD3) (Sena and Chandel, 2012). These 
antioxidants are not perfect, however, and an increase in superoxide production as a result of OxPhos 
malfunction can lead to an accumulation of H2O2 and the appearance of other oxygen-derived free 
radicals. These so-called reactive oxygen species (ROS) can damage cellular components, including 
mitochondrial proteins, lipids, and mtDNA (Morán et al., 2012). It is thought that this damage to 
mitochondria and mtDNA causes malfunction of the respiratory chain, leading in turn to production and 
release of even more ROS, creating a vicious cycle ending in the release of high levels of Ca2+ and 
cytochrome c, thereby triggering apoptosis (Ashrafi and Schwarz, 2013; Morán et al., 2012).  
Relevant to the idea that intramitochondrial ROS could be responsible for an acquired 
mitochondrial dysfunction with age and contribute to the pathogenesis of neurodegenerative disorders 
such as PD is the work of Bender and collaborators (Bender et al., 2006). This elegant work has shown 
that dopaminergic neurons within affected brain regions of PD patients contain copious amounts of 
mtDNA damage and defects in the activity of the respiratory chain enzyme cytochrome c oxidase. While 
the authors have not proven that the origin of these acquired mtDNA mutations is linked to ROS, both the 
type of damage and its intramitochondrial location are strongly suggestive. Furthermore, Guzman et al. 
have shown that nigral dopaminergic neurons, at least in mice, exhibit higher baseline ROS signals within 
the mitochondria (Guzman et al., 2010). Thus, while the notion that ROS is linked to acquired defects in 
bioenergetics in pathological situations like PD is, by all means, not definite, it remains quite an appealing 
hypothesis. 
Aside from energy production, mitochondria are involved in many housekeeping processes, such 
as the biosynthesis of amino acids and steroids, beta-oxidation of fatty acids, calcium homeostasis, and 
apoptosis. A healthy population of mitochondria is thus essential for proper functioning of cells.  Neurons 
in particular are dependent on mitochondria to meet their high-energy demands and, as they are post-
mitotic, are thought to be especially susceptible to the consequences of mitochondrial damage (Chen and 
Chan, 2009). To prevent cellular damage by sick mitochondria, several quality-control mechanisms have 
evolved (Ashrafi and Schwarz, 2013). First, unfolded membrane proteins can be degraded by either the 
cytosolic proteasome or by two AAA protease complexes present inside mitochondria. Second, 
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mitochondrial components may be shuttled directly to lysosomes in mitochondria-derived vesicles. This 
pathway is activated in response to oxidative stress and potentially serves to remove damaged proteins 
while leaving the organelle intact (Soubannier et al., 2012). Finally, entire mitochondria can be 




1.3.1. Mitophagy and neurodegeneration 
As mentioned above, mitochondria play several roles essential for cellular function, including 
energy production, calcium homeostasis, and regulation of apoptosis. They generate ROS as a byproduct 
of oxidative phosphorylation and are therefore under constant threat of being damaged.  
 Mitochondrial dysfunction is seen in a number of adult-onset neurodegenerative diseases. For 
example, HD has been associated with changes in mitochondrial trafficking (Schon and Przedborski, 
2011), and AD with alterations in fussion/fission and with respiratory chain deficiency (Morán et al., 2012).  
Several studies have found an increase in mtDNA mutations and mitochondrial dysfunction in substantia 
nigra neurons of PD patients compared to age-matched controls (Bender et al., 2006; Mann et al., 1994; 
Schapira et al., 1990). Since mitophagy is thought to be important for maintaining a healthy population of 
mitochondria (Twig et al., 2008a), it is not a big leap to think that a defect in mitophagy may be an 
underlying pathophysiological mechanism in these diseases. Thus far there is no clear link between HD 
or AD and mitophagy. On the other hand, mitophagy has been a major focus in PD research in recent 
years. Mutations in PARK6 (PINK1) and PARK2 (Parkin) cause familial forms of PD. The discovery that 
Parkin is recruited to damaged mitochondria in a PINK1 dependent manner and that this is important for 
mitophagy provided a direct link between PD and mitophagy. 
 
1.3.2. Mitophagy regulation 
1.3.2.1. Specific mitophagy adaptors in Saccharomyces cerevisiae 
In the yeast Saccharomyces cerevisiae, the number of mitochondria can be regulated depending 
on the growth medium. When yeast are grown on glucose, mitochondria are not necessary for energy 
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production since yeast obtains energy by anaerobic respiration (fermentation). On lactate or 
glycerol/ethanol on the other hand, mitochondrial respiration is essential and the number of mitochondria 
is increased. Switching yeast from a lactate or glycerol/ethanol medium to glucose induces mitophagy 
(Kanki and Klionsky, 2008). By making use of this property of yeast, two groups simultaneously identified 
two genes that are necessary for mitophagy but not for general autophagy, namely Atg32 and Atg33. 
Atg32 is located on the outer mitochondrial membrane and acts as an adaptor protein that interacts with 
Atg11 and Atg8, linking mitochondria to the autophagic machinery. Atg33 is thought to be necessary for 
the detection of sick mitochondria for mitophagy (Kanki et al., 2009; Okamoto et al., 2009).  
 
1.3.2.2. Mitophagy regulation in mammalian cells 
1.3.2.2.1. Nix is a mitophagy adaptor in erythrocytes 
Although the Atg32 and Atg33 genes do not have known mammalian homologues, the 
mitochondrial protein Nix seems to play a role similar to that of Atg32. Nix plays an essential role in 
mitophagy during reticulocyte maturation, when the cells lose all mitochondria and other organelles to 
become erythrocytes. In Nix–/– cells, AV formation and LC3-I to LC3-II conversion are intact, but 
mitochondria are seen on the outside of AVs instead of inside (Schweers et al., 2007; Zhang and Ney, 
2009; Zhang et al., 2009). General autophagy in these cells is not affected and conversely, mitophagy in 
Atg5–/– and Atg7–/– (two genes essential for macroautophagy) cells is functional (Novak et al., 2010). In 
pull-down and co-localization studies, Nix was found to interact with Atg8 in yeast and LC3A and 
GABARAP (two forms of LC3) in mammalian cells, but not with LC3B. This interaction was stronger after 
cells were treated with the mitochondrial depolarizing drugs carbonyl cyanide m-chlorophenylhydrazone 
(CCCP) or rotenone. The LC3 interacting region (LIR) located near the N-terminal is mainly responsible 
for this interaction (there is another LIR near the BH3 domain of Nix) and mitochondrial clearance was 
disrupted when the N-terminal LIR was missing (Novak et al., 2010).  
Only one study has assessed the role of Nix in mitophagy in cell types other than erythrocytes. 
Ding et al. (2010) showed that autophagy induction by CCCP in Nix-/- Mouse Embryonic Fibroblasts 
(MEFS) was inhibited. They found that Nix was necessary for the mobilization of the autophagic 
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machinery by mediating mitochondrial ROS generation and translocation of Parkin to mitochondria (see 
below). 
 
1.3.2.2.2. PINK1 and Parkin regulate mitophagy in mammalian cells 
 (adapted from (De Vries and Przedborski, 2012)) 
Mutations in the genes encoding phosphatase and tensin homolog-induced putative kinase 1 
(PINK1) and Parkin lead to recessive, early onset forms of PD (Nuytemans et al., 2010). These proteins 
were first suggested to share a pathway based on the observation that Parkin and PINK1 knock-out 
Drosophila melanogaster have a similar phenotype (muscle degeneration, cell death and mitochondrial 
abnormalities). Over-expression of Parkin can rescue the PINK1 knockout phenotype, but not vice versa, 
placing Parkin downstream of PINK1 (Clark et al., 2006; Park et al., 2006). Subsequent to these seminal 
contributions, PINK1 and Parkin have emerged as important regulators for mitophagy in mammalian cells.  
PINK1 is a ubiquitously expressed protein of 63kDa that localizes to the outer membrane of 
mitochondria (although a proportion of the protein has been reported to possibly reside in the cytosol (Lin 
and Kang, 2008). It consists of a serine/threonine kinase domain which we reported to face the cytoplasm 
(Zhou et al., 2008) and at least one predicted transmembrane domain, which together with the C-terminus 
seems to operate as a stop-transfer signal anchoring PINK1 to the MOM (Becker et al., 2012). Under 
basal conditions, PINK1 appears to be rapidly turned over, keeping protein levels low (Lin and Kang, 
2008). According to current models, which are primarily based on studies in cell lines such as HeLa cells 
and MEFs, a portion of full-length PINK1 (PINK163) is imported into the mitochondria. In the presence of 
mitochondrial membrane potential, it is transported first through the TOM20 complex and seems to 
transiently cross the mitochondrial inner membrane via the TIM23 machinery (Becker et al., 2012). There, 
PINK163 is believed to be cleaved by mitochondrial processing peptidase (MPP) (Greene et al., 2012), 
forming PINK160, and then by presenilin-associated rhomboid-like protease (PARL) (Becker et al., 2012; 
Greene et al., 2012; Jin et al., 2010), generating a 52 kDa (PINK152) fragment. Through as yet 
unidentified mechanisms, this PINK152 fragment is retrogradely translocated to the mitochondrial surface, 
where it either remains attached to the MOM or is released as a soluble protein to the cytosol and can be 
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degraded by the proteasome (Becker et al., 2012; Jin et al., 2010). A potential role for cytosolic PINK1 in 
regulation of mitophagy will be discussed in Chapter 2.  
Depolarization of ΔΨm, e.g. by the protonophore CCCP or the ionophore valinomycin, leads to a 
decrease in import and cleavage and a consequent rapid accumulation of full-length PINK163 at the MOM. 
The presence of full-length PINK1 on the MOM leads to recruitment of Parkin to the mitochondria (Geisler 
et al., 2010; Kawajiri et al., 2010; Michiorri et al., 2010; Narendra et al., 2010a; Vives-Bauza et al., 2010). 
Interestingly, both forms of PINK1 were found in high molecular weight complexes of 900 kDa (Becker et 
al., 2012) and 700 kDa (Becker et al., 2012; Lazarou et al., 2012) with a so far unidentified function.  
 
Parkin is a predominantly cytosolic protein characterized by an ubiquitin-like domain at the N-
terminus and a RING-between-RING domain at the C-terminus (Darios et al., 2003). It acts as an E3 
ubiquitin ligase and is capable of tagging proteins for degradation at different residues including Lys48 
and Lys63 (Pilsl and Winklhofer, 2012). How PINK1 is able to recruit cytosolic Parkin to the mitochondria 
remains unknown. Several studies have shown that PINK1 and Parkin can be co-purified, both in 
overexpression cell culture models and in brain tissue from either rats or humans (Kim et al., 2008; Sha et 
al., 2010; Shiba et al., 2009; Um et al., 2009). It is conceivable that PINK1 and Parkin interact by 
phosphorylating or ubiquitinating each other and although there have been reports of phosphorylation of 
Parkin by PINK1 and ubiquitination of PINK1 by Parkin (Kim et al., 2008; Sha et al., 2010), we were 
unable to find such an interaction (Vives-Bauza et al., 2010). 
The mechanisms by which PINK1 and Parkin regulate mitophagy have been a main focus of research 
in PD in recent years. Based on currently available data, we conceive of three potential scenarios for this 
regulation that are not necessarily mutually exclusive (see Figure 1.4); 1) PINK1 and Parkin may regulate 
mitochondrial size by affecting fusion and fission, allowing fragmented mitochondria to be taken up in 
autophagic vesicles. 2) PINK1 and Parkin may skew the movement of mitochondria towards the 
autophagosome- and lysosome-rich perinuclear area, where the probability of being taken up by AVs is 
higher. 3) PINK1 and Parkin may directly recruit the autophagic machinery to damaged mitochondria for 
degradation. It must be noted that the majority of studies have been performed in non-neuronal cells 
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types such as HeLa and MEF cells and that protonophores such as CCCP are frequently used to collapse 
membrane potential, which is thought to be a functional correlate of mitochondrial damage. 
 
1) PINK1 and Parkin shift the balance towards fission 
Mitochondria form dynamic networks that constantly undergo fusion and fission. The core fission 
machinery in mammalian cells includes the cytosolic dynamin-related protein 1 (DRP1) and mitochondrial 
fission protein (FIS1), which is found on the MOM. Fusion is regulated primarily by the GTPase proteins 
mitofusin (MFN) 1 and 2, also located on the MOM, and the dynamin-like GTPase protein optic atrophy 1 
(OPA1), present in the mitochondrial intermembrane space (Liesa et al., 2009).  
This fusion and fission is thought to play a role in the quality control of the mitochondrial network 
(Twig et al., 2008a). Fission, for example, may create asymmetric daughters where one mitochondrion is 
“healthy‟ and has normal membrane potential while the other has low membrane potential or contains 
damaged mtDNA. Twig et al. (2008b) found that in INS-1 cells, mitochondria that have low ΔΨm after 
fission are six times less likely to fuse back with the network. In addition, inhibition of the fission 
machinery by knock-down of FIS1, use of a mutant form of DRP1 or overexpression of OPA1 lead to 
decreased mitophagy, suggesting that fission is an essential step for mitophagy.  
Interestingly, Poole et al. (2008) found that PINK1 or Parkin loss in Drosophila led to a phenotype 
with elongated mitochondria, supposedly as a result of excess fusion. This phenotype could be rescued 
by either over-expression of DRP1 or knock-down of OPA1 or dMfn (the analog of MFN1/2 in fly), 
indicating that the PINK1 and Parkin pathway promotes fission. In a subsequent study by the same group 
(Poole et al., 2010), dMfn was shown to be ubiquitinated in a PINK1/Parkin dependent fashion, tagging it 
for degradation and allowing fission to take place. Kim et al. (2013) found that Parkin-mediated 
recruitment of valosin-containing protein (VCP) is essential for degradation of dMfn by the proteasome. In 
Drosphila PINK1 or Parkin mutants, an abundance of MFN promotes fusion, thus inhibiting mitophagy. 
In mammalian cells, the effects of alterations in PINK1 or Parkin on mitochondrial morphology are 
less well-defined. In line with the Drosophila data, Yu et al. (2011) recently reported that PINK1 knock-
down in rat hippocampal and dopaminergic neurons leads to elongation of mitochondria, while over-
expression of either PINK1 or Parkin results in an increased number of mitochondria that are smaller in 
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size. In contrast, in studies in cell lines such as HeLa (Exner et al., 2007), SH-SY5Y (Dagda et al., 2011; 
Lutz et al., 2009) and N27 (Cui et al., 2010), mitochondria were found to be fragmented upon knock-down 
of PINK1 or Parkin. Cui et al reported that this fragmentation was the result of excessive fission due to an 
increase in fission proteins and a decrease in fusion proteins at the mitochondria (Cui et al., 2010). Data 
from PD patient derived fibroblasts showed no clear morphological changes, although there was a trend 
towards mitochondrial fragmentation (Exner et al., 2007). 
In agreement with described findings in Drosophila, several studies (Gegg et al., 2010; Glauser et al., 
2011; Tanaka et al., 2010) in SH-SY5Y neuroblastoma cells showed that collapsing ΔΨm with CCCP 
leads to ubiquitination of MFN1 and MFN2. MFN1 and to a lesser degree MFN2 is then degraded by the 
proteasome. This degradation is inhibited when either PINK1 or Parkin is knocked-down and cannot be 
rescued by expression of disease related mutant forms of Parkin. MFN1 and Parkin appear to interact 
directly as they can be co-immunoprecipitated, although there is no conclusive proof that Parkin 
ubiquitinates MFN.  
In the absence of exogenously expressed Parkin, mitochondria in MEF cells were seen to form 
spheroids after CCCP treatment, which were not cleared by mitophagy. This was found to be due to a 
lack of MFN ubiquitination and degradation. In MFN1/2-/- cells, mitochondria did not form spheroids and 
mitophagy was able to proceed normally even in the absence of Parkin (Ding et al., 2012). 
Overall, the data suggest that PINK1 and Parkin accomodate mitophagy by promoting the 
degradation of MFN1 and shifting the balance towards fission, enabling mitochondrial take-up into 
autophagic vesicles. 
 
2) PINK1 and Parkin affect mitochondrial trafficking 
In neurons, mitochondria are transported along microtubules by two microtubule motors, the plus-end 
directed kinesins (specifically KIF1Bα and KIF5) and the minus-end directed dyneins. Mitochondria are 
bound to these microtubule motors through Miro and Milton. Miro is anchored to the outer membrane of 
mitochondria and binds to Milton, which in turn binds to KIF5. Exactly how mitochondria are bound to 
dynein and how plus-end and minus-end directed movement is coordinated is unknown, although a role 
for dynactin (a dynein-binding protein) and Miro has been proposed (Zinsmaier et al., 2009). 
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Recently, an unbiased screen performed by Weihofen and colleagues (Weihofen et al., 2009) 
identified Miro and Milton in a complex with PINK1. Interestingly, mitochondrial fragmentation seen after 
PINK1 silencing in M17 neuroblastoma cells was suppressed by overexpression of Miro, placing Miro 
downstream of PINK1. In contrast, in rat hippocampal neurons, mitochondrial fragmentation and an 
inhibition of overall mitochondrial movement were reported upon overexpression of PINK1 (Wang et al., 
2011). This effect was present also with a mutant form of PINK1 lacking the mitochondrial targeting 
sequence, but was not seen when a kinase dead mutant of PINK1 was used or when the experiments 
were performed in a Parkin-/-  background, suggesting that the kinase function of PINK1 and the presence 
of Parkin are both necessary. When the membrane potential was collapsed with the cytochrome c 
reductase inhibitor Antimycin A, Parkin was recruited to mitochondria and mitochondrial motility was 
decreased. Similarly, Cai et al. (2012) showed Parkin recruitment to mitochondria in mouse cortical 
neurons after CCCP treatment. They also observed a decrease in anterograde movement and an 
increase in retrograde movement of mitochondria. Knock-down of Parkin lead to an accumulation of 
mitochondria with low ΔΨm, as measured by tetramethylrhodamine. 
This is seemingly in disagreement with findings by Van Laar et al. (2011), who reported a lack of 
mitochondrial morphological changes, Parkin recruitment or mitophagy in rat cortical neurons upon CCCP 
treatment. This discrepancy could possibly be explained, however, by the difference in duration of the 
treatments. Cai et al. (2012) did not see Parkin recruitment until 12-24 hours of incubation with CCCP, 
while Van Laar et al. (2011) treated for no more than six hours. Even after 24 hours, Parkin recruitment 
was seen in no more than 26.7% of neurons. Both papers thus agree that the Parkin response is 
markedly suppressed in primary neurons compared to HeLa cells. 
The only in vivo study to date used a mouse model lacking mitochondrial transcription factor A 
(TFAM) in dopaminergic neurons (Sterky et al., 2011). In this MitoPark mouse, mtDNA is depleted over 
time, leading to respiratory chain deficiency and neurodegeneration. Although the authors found that a 
defect in anterograde transport leads to a decrease in distal mitochondria in the MitoPark mouse 
compared to WT, there was no evidence of Parkin recruitment to the dysfunctional mitochondria and a 
Parkin-/- version of the MitoPark mouse had the same phenotype as the Parkin+/+ one. 
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Two recent studies (Liu et al., 2012; Wang et al., 2011) in Drosophila neurons also showed that 
PINK1, Parkin and Miro function in a common pathway to regulate mitochondrial motility. Miro knock-
down can rescue the PINK1 mutant phenotype, while Miro overexpression gives a phenotype similar to 
that of PINK1 knock-down (increased motility, with a net anterograde movement and accumulation of 
mitochondria in the distal boutons). Unlike Wang et al. (2011), Liu and colleagues (2012) did not find that 
overexpression of PINK1 or Parkin results in phosphorylation and degradation of Miro, although they did 
find that CCCP treatment in HeLa cells leads to ubiquitination and degradation of Miro. 
Evidence thus exists that PINK1 and Parkin affect mitochondrial motility through effects on Miro. In a 
putative model, PINK1 and Parkin accumulation on the MOM leads to decreased Miro levels at the 
mitochondria, dislodging them from the microtubules and decreasing their anterograde movement (Wang 
et al., 2011). Data are quite divergent, however, for different cell models. It would be interesting to 
determine whether Miro levels are altered in cells derived from PD patients with PINK1 or Parkin 
mutations. 
  
3) PINK1 and Parkin recruit the autophagic machinery 
Aside from setting the stage for mitophagy, PINK1 and Parkin may directly link mitochondria to the 
autophagic machinery. Several studies have shown that MOM proteins are ubiquitinated upon Parkin 
relocalization, and that this leads to accumulation of p62/SQSTM1 at the mitochondria (Ding et al., 2010; 
Geisler et al., 2010; Lee et al., 2010b; Narendra et al., 2010b; Okatsu et al., 2010). Although exactly 
which proteins are modified remains unclear, two groups found that VDAC1 was one protein ubiquitinated 
at lysine residue 27 or 63 after CCCP treatment (Lee et al., 2010b; Narendra et al., 2010b). Sun et al. 
(Sun et al., 2012) showed that Parkin directly interacts with VDAC1 upon CCCP treatment and that the 
presence of at least one of three VDACs (VDAC1, 2 or 3) was necessary for Parkin recruitment to 
mitochondria. 
Whether p62/SQSTM1 is necessary for mitophagy is still controversial. While Lee et al. (2010b) 
and Geisler et al. (2010) reported that mitophagy is impaired in p62-/- cells, three groups (Ding et al., 
2010; Narendra et al., 2010b; Okatsu et al., 2010) found a role for p62/SQSTM1 in formation of 
perinuclear mitochondrial aggregates, but not mitophagy per se. 
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Based on a recent, more in depth analysis of Atg proteins involved in mitophagy, Itakura et al. 
(2012) proposed that the interaction between LC3 and adaptor proteins on the mitochondria is not the first 
step in activation of Parkin-mediated mitophagy. Rather, Parkin relocalization induces the formation of 
ULK1/FIP200 puncta and Atg9A structures at the mitochondria, which in turn initiates recruitment of 
downstream Atgs and formation of mitophagosomes. What role Parkin plays in this de novo 
mitophagosome formation, however, remains elusive.  





Figure 1.4. Three scenarios for the role of PINK1/Parkin in mitophagy. 
The figure depicts three potential scenarios for the role of PINK1/parkin in mitophagy. Each begins with the 
recruitment of Parkin to the mitochondria in a PINK1 dependent manner after membrane depolarization. This 
then leads to 1) a shift towards fission. MFN1/2 are ubiquitinated and degraded, allowing fission to take place 
over fusion. 2) a decrease in anterograde mitochondrial trafficking. Miro is ubiquitinated and consequently 
degraded, resulting in the detachment of mitochondria from the microtubules. 3) recruitment of the autophagic 
machinery. Mitochondrial outer membrane proteins like VDAC1 are ubiquitinated and as such recognized by p62. 
LC3 on the autophagic vesicles directly interacts with p62 that has accumulated on the mitochondria. 
Alternatively, the ULK1/FIP200/Atg13 complex and Atg9A, accumulate at the mitochondria and initiate the 
formation of mitophagosomes. Taken from (De Vries and Przedborski, 2012). 	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1.4. METHODS TO STUDY MITOPHAGY 
In Saccharomyces cerevisiae, mitophagy can be monitored by the generation of free green fluorescent 
protein (GFP) from e.g. Om45-GFP, either on Western Blot or by fluorescence microscopy (Kanki et al., 
2009). In mammalian cells, several methods are available to study macro-autophagy but no specific 
mitophagy assay exists. Rather, the study of mitophagy has relied on generic autophagy methods with 
some adaptations to mitochondria (Klionsky et al., 2012). First, electron microscopy (EM) can be used to 
directly visualize mitochondria in autophagosomes (see figure 1.5 A). Analysis of EM is time-consuming 
and this method can only be used to observe the early stages of mitophagy, before mitochondria have 
been degraded by lysosomal proteases. 
A frequently used method is the co-localization of a mitochondrial marker with an autophagy 
marker under confocal microscopy (see figure 1.5 B). MitoTracker or immunostaining for a mitochondrial 
protein such as Tom20 or cytochrome c may be used to visualize mitochondria. Autophagosomes are 
labeled by an antibody against LC3 or the ectopic expression of GFP-LC3. As explained in section 
1.1.3.3, LC3 undergoes lipidation to form LC3-II upon activation of autophagy. It will then appear punctate 
as it redistributes from the cytosol to the membrane of the autophagosome. Co-localization with a 
lysosomal marker such as LAMP1 or 2 is also often used to assess presence of mitochondria in/near 
lysosomes. Although co-localization shows that mitochondria and parts of the autophagy machinery are in 
proximity to each other, it does not prove that mitochondria are degraded through mitophagy. 
The third main method to study mitophagy is the quantification of remaining mitochondrial mass. 
This can be done either by Western Blot or microscopy, with the use of antibodies against mitochondrial 
proteins.  To be able to detect a change in mitochondrial mass, however, the decrease must be rather 
substantial. This is the case in HeLa cells stably expressing YFP. After 24 hours of treatment with CCCP, 
which dissipates membrane potential, a proportion of the cells end up with no detectable mitochondria 
(see figure 1.5 C)(Narendra et al., 2008). This decline does not happen in other cell types, where the 
effect is usually much more subtle.   
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1.5 DISSERTATION OUTLINE  
This dissertation consists of three parts that are connected through the common theme of mitophagy. 
First, the role of PINK1 and Parkin in the regulation of mitophagy is explored in Chapter 2. This chapter 
discusses our published and unpublished work on these two proteins. We show that PINK1 is imported to 
mitochondria, where it is cleaved and then retrotranslocated to cytosol. Under basal conditions, the 
cleaved form of PINK1 can bind Parkin and prevent its recruitment to mitochondria, thereby putting a 
break on mitophagy. In damaged mitochondria (i.e. after depolarization of the membrane potential), 
PINK1 import is impaired and full length PINK1 accumulates on the outer membrane. Parkin is 
consequently recruited and mitochondria undergo mitophagy.    
In the second part, we look at mitophagy in the context of diseases caused by mutations in 
mtDNA. Patients with these diseases usually carry a mixture of wild-type and mutant mtDNA 
(heteroplasmy) and the mitochondria are dysfunctional. If mitophagy recognizes and selectively 
eliminates dysfunctional mitochondria, the question is then why this does not happen in these cases. 
Using a homoplasmic cybrid model, we find that mitophagy of these dysfunctional mitochondria can 
 
Figure 1.5. Methods to study 
mitophagy 
A) EM image of mitochondrion in 
AV. Taken from (Vives-Bauza et al., 
2010). 
 
B) Co-localization between Tom20 
(blue) and LC3 (red) in a MEF cells 
treated with rapamycin for 24hr. 
Own image. 
 
C) HeLa cells without mitochondria 
after 24 hr of CCCP treatment. Own 
image. 
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happen but only if 1) macro-autophagy is activated by mTor inhibition, and 2) Parkin levels are sufficiently 
high.  
Finally, a new method to study mitophagy, mitophaGFP, is presented and validated in Chapter 4. 
This probe consists of a mitochondrially targeted chimeric mCherry-EGFP protein. Due to the differential 
pH sensitivity of mCherry and EGFP, the probe changes color from yellow to red once mitochondria enter 
lysosomes. This allows, for the first time, a qualitative and quantitative assessment of mitophagy in both 
live and fixed cells. 
A summary of our findings and future directions will be discussed in Chapter 5. Overall, this 
dissertation provides new insights in the mechanisms of mammalian mitophagy and it provides a new 
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As discussed in Chapter 1.3.2.2.2, PINK1 and Parkin have emerged in recent years as important 
regulators of mitophagy. The Richard Youle’s group at NIH was the first to show that Parkin is recruited to 
mitochondria upon dissipation of the mitochondrial membrane potential (ΔΨm), produced by carbonyl 
cyanide m-chlorophenyl hydrazone (CCCP), a chemical that acts essentially as an ionophore, hence 
causing an uncoupling of the proton gradient of the mitochondria. In studies of mitophagy, loss of ΔΨm is 
often used as a correlate for mitochondrial damage. After Parkin recruitment, mitochondria were cleared 
from cells in a process that requires Atg5. This led to the hypothesis that Parkin is essential for the 
turnover of damaged mitochondria by mitophagy (Narendra et al., 2008). 
Given these results, the previously reported interaction between PINK1 and Parkin in Drosophila 
(Clark et al., 2006; Park et al., 2006), and our report on the localization of PINK1 at the outer 
mitochondrial membrane (Zhou et al., 2008), we sought to determine whether PINK1 was involved in this 
recruitment. The first part of this chapter will describe the data that support our finding that, indeed, Parkin 
recruitment to mitochondria is dependent on PINK1. These data have been published in the Proceedings 
of the National Academy of Sciences USA (Vives-Bauza et al., 2010).  
Even though we and others have, by now, established that Parkin recruitment to mitochondria is 
PINK1 dependent, significant gaps in our knowledge of PINK1’s mode of action and subcellular partition 
still exist. We believe that these gaps hamper our understanding of the role of Parkin/PINK1 in mitophagy 
and the potential significance of this process in the pathogenesis of neurodegenerative disorders, such as 
Parkinson’s disease. In the second half of this chapter, in an attempt to gain insights into the biology of 
PINK1, we decided to revisit PINK1’s subcellular distribution and function, with particular focus on trying 
to identify a role for cytosolic PINK1. Full-length PINK1 is imported into mitochondria, where it is cleaved 
in two steps to form a 52kDa fragment, PINK152. According to a popular model proposed by others (Jin et 
al., 2010), cleaved PINK1 is rapidly degraded inside mitochondria under normal conditions. To us, it 
appeared quite burdensome to continuously synthesize, import, doubly cleave and then degrade the 
protein just to maintain low levels of PINK1 at the MOM. Instead, herein we propose that PINK152 is 
retrotranslocated to the cytosol, where it can bind Parkin. It thereby prevents Parkin recruitment to 
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mitochondria and puts a brake on mitophagy. The manuscript containing these data has been submitted 
and is under review by EMBO reports. 
 
2.2. RESULTS PART I: PINK1-DEPENDENT RECRUITMENT OF PARKIN TO MITOCHONDRIA IN MITOPHAGY 
 
2.2.1. Protonophores induce Parkin relocalization to mitochondria 
In the present study, we show that cytosolic Parkin translocates to mitochondria in transiently 
transfected embryonic kidney HEK293T cells, expressing YFP-tagged Parkin (Parkin-YFP), upon 
exposure to 10 µM of either CCCP or its analog, carbonyl cyanide p-trifluoromethoxyphenylhydrazone 
(FCCP) (Fig. 2.1). As in the study by Narendra et al. (2008), we found that >150 out of 250 (>60%) of our 
analyzed transfected cells, rather than showing a normal diffuse Parkin-YFP fluorescence, exhibited 1 
large or several smaller discrete Parkin-YFP spots after only 1-h exposure to these protonophores (Fig. 
2.1A). Under these experimental conditions, >85% of these spots co-localized with the mitochondrial 
protein TOM20, and >65% of the mitochondria colocalized with Parkin after protonophore exposure, vs. 
∼10% after vehicle exposure (Fig. 2.1B). Identical results were obtained with GFP-tagged Parkin (Parkin-
GFP) or c-Myc–tagged Parkin (Parkin-myc) and with Parkin-YFP–transfected human neuroblastoma SH-
SY5Y and cervical carcinoma HeLa cells. In contrast to HeLa cells transfected with WT Parkin (ParkinWT)-
myc, cells transfected with mutated ParkinT415N- or ParkinG430D-myc, which are two PD pathogenic 
mutations (Moore et al., 2005), retained a normal diffuse cytosolic fluorescence whether cells were 
incubated with a protonophore or vehicle (Fig. 2.2B). 
 
2.2.2. Dissipation of ΔΨm Triggers Parkin Relocalization 
To examine further the effect of protonophores on Parkin cytosolic/mitochondrial partition, we 
prepared subcellular fractions from both non–neuronal-like HEK293T and neuronal-like SH-SY5Y cells, 
as before (Zhou et al., 2008). These experiments demonstrated that endogenous Parkin was enriched in 





Furthermore, we found that Parkin contained in mitochondrial extracts from cells treated with 10 
µM CCCP was accessible to digestion with proteinase K (Fig. 2.2A). This result indicates that, upon 
translocation, Parkin associates with the outer surface of the mitochondria. Concentrations of CCCP or 
FCCP in excess of 1 µM, as used by Narendra et al. (2008) and by us here, can affect cellular functions 
other than ΔΨm (Maro et al., 1982; Zhang et al., 2000). Nonetheless, as much as 30–50% of WT Parkin-
YFP–transfected cells did show Parkin translocation to mitochondria triggered by mitochondrial 
depolarization, whether it was caused by lower concentrations of CCCP (10 nM–1 µM), by co-incubation 
with 1 µM of the complex III inhibitor, antimycin A, plus 1 µM of the F1F0 ATPase inhibitor, oligomycin, or 
by a complete loss of mitochondrial respiratory function in ρ0 cells (Fig. 2.2C and D). In each of these 3 
	  
Figure 2.1. CCCP exposure alters the 
subcellular distribution of Parkin from the 
cytosol to the mitochondria. (A) 
Relocation of Parkin-YFP in response to 1-h 
incubation with 10 µM CCCP (Middle row), 
but not with vehicle (0.1% DMSO) (Top row), 
in HEK293T cells studied 24 h 
posttransfection. Mitochondria, 
immunolabeled with the mitochondrial 
protein TOM20, show colocalization of 
Parkin-YFP and mitochondria. (Bottom row) 
A 6x magnification of the region outlined by 
the box in the image on the left of the middle 
row. (Scale bars, 10 µm for top and middle 
rows; 1 µM for bottom row.) (B) Percentage 
of cells with Parkin that colocalizes with 
mitochondria (Parkin puncta that are 
TOM20+) in transfected HEK293T cells 
incubated with DMSO or CCCP. This 
analysis is performed with the Image 
software J; values represent means ± SD of 
10 independent experiments. **, Different 
from vehicle DMSO controls (Student t-test, 
p < 0.01). (C) Western blot analysis showing 
endogenous Parkin recruitment to 
mitochondria on CCCP exposure. Cytosolic 
(Cytosol) and mitochondrial (Mito) fractions 
of HEK293T cells incubated for 1 h with (+) 
and without (–) 10 µM CCCP. TIM23 and β-
actin are used as mitochondrial and cytosolic 
markers, respectively. 
% Cells with mitochondrial Parkin 
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conditions, Parkin-YFP translocation to MitoTracker Deep Red-labeled mitochondria was observed in 
cells that consistently had the lowest ΔΨm as assessed using tetramethyl rhodamine methyl ester 
(TMRM) fluorescence (Fig. 2.2E). Thus, these results provide further support the notion that a marked 
mitochondrial depolarization triggers Parkin recruitment to the mitochondria.  
 
2.2.3. Parkin Translocation Is PINK1-Dependent 
Cereghetti et al. (2008) have reported that mitochondrial depolarization also can stimulate the 
translocation of the fission protein Drp1 from the cytosol to the mitochondria through a calcineurin-
dependent mechanism. Despite the apparent similarity between the Drp1 and Parkin observations, in our 
hands, the calcineurin inhibitor, cyclosporine A, failed to prevent CCCP-induced Parkin translocation (Fig. 
2.2D), thus suggesting that Drp1 and Parkin translocation to mitochondria is governed by distinct 
molecular underpinnings. Given the reported Parkin/PINK1 genetic interaction observed in Drosophila 
(Clark et al., 2006; Park et al., 2006; Poole et al., 2008) and our revised PINK1 topology (Zhou et al., 
2008), we then asked whether PINK1 plays any role in the mitochondrial recruitment of Parkin. To 
address this question, we used a PINK1 siRNA construct and HeLa cells, because we have previously 
shown that this reagent reduces PINK1 mRNA by >80% in these specific cells (Zhou et al., 2008). When 
PINK1 was silenced in ParkinWT-YFP–transfected HeLa cells, the CCCP-induced collapse of ΔΨm was no 
longer associated with a relocalization of cytosolic Parkin to the mitochondria (Fig. 2.3 A–C). A similar 
observation was made in primary cortical neurons from PINK1-knockout mice (Fig. 2.3D). The proto-
oncogene DJ-1, when mutated, also causes a familial form of PD (Moore et al., 2005) and was suggested 
to interact with Parkin and PINK1 to form a mitochondrial multiprotein complex (Xiong et al., 2009). 
However, unlike PINK1 silencing, DJ-1 knockdown by >75% in HeLa cells (Fig. 2.3B) had no effect on 
CCCP-mediated Parkin relocalization (Fig. 2.3C). Thus, whatever the functional nature of DJ-1 interaction 
with Parkin and PINK1 may be, our data exclude the possibility that DJ-1 is required for the PINK1-




   
	  
 
Figure 2.2. Mitochondrial depolarization recruits WT Parkin to mitochondria. (A) Once recruited to 
mitochondria, Parkin associates with the MOM. HeLa cells were incubated with vehicle (DMSO) or with 
10 µM CCCP for 1 h before mitochondrial isolation and protection assay by treatment with different 
concentrations of proteinase K (PK) (0, 0.2, 2, and 20 µg/mL). TOM20, cytochrome c, and COX-1 are 
markers of the outer membrane, intermembrane space, and inner membrane, respectively. (B) Parkin 
PD-linked mutant forms are not recruited to depolarized mitochondria. HeLa cells were transfected either 
with WT Parkin-myc or with mutant forms containing the pathogenic point mutations T415N and G430D. 
Twenty-four hours after transfection, cells were incubated with vehicle (DMSO) or with 10 µM CCCP for 
1 h before fixation. Bars represent percent of cells showing Parkin-myc colocalization with TOM20 
(Parkin+/TOM20+) ±SD of 3 independent experiments, determined by confocal microcopy. (B′) Western 
blot analysis shows that WT Parkin and its mutants T415D and G430P achieved comparable levels of 
protein expression. Parkin is immunodetected using anti-myc antibody. Loading is normalized by TIM23 
(C) Effects on HeLa cells of 1-h incubation with different concentrations of CCCP, 24 h after transfection 
with Parkin-GFP. Bars represent percent of cells showing Parkin colocalization with TOM20 
(Parkin+/TOM20+) ± SD of 3 independent experiments, determined by confocal microcopy. (D) Same as 
(B),but after 1-h incubation with 10 µM FCCP, 10 µM CCCP, 1 µM Antimycin A (AA), 1 µM Oligomycin 
(Oligo), or 1 µM AA and 1 µM Oligo (AA+Oligo) or after 30-min preincubation with 2 µM cyclosporine A 
(CsA), followed by 1-h incubation with 10 µM CCCP. Like FCCP and CCCP, AA+Oligo produce a 
significant percentage of cells with Parkin+/TOM20+. (E) Comparison of TMRM fluorescence acquired 
by live imaging and quantified as arbitrary units (A.U.) by Image J, among non-transfected and Parkin-
GFP–transfected WT HeLa cells incubated with vehicle (CTL), 100 nM CCCP, or 1 µMAA + 1 µM 
Oligo and non-transfected and Parkin-GFP–transfected ρ0 (Rho0) cells. Values represent mean ± SD (n 
= 35–50 cells) and are representative of 3 independent experiments. **, Different from CTL. *, Different 
from nontransfected and transfected cells with diffuse Parkin-GFP fluorescence 





2.2.4. PINK1 Causes Parkin Relocation in Cells with Normal ΔΨm 
Next, we sought to determine the effect of increased PINK1 expression on ΔΨm and Parkin 
subcellular distribution. To investigate this effect, we took advantage of stable rat fetal mesencephalic 
N27 cell lines developed by M.C. and K.T., which have an ecdysone-inducible mammalian expression 
system to regulate the expression of either human WT PINK1 (PINK1WT), 2 PD-linked PINK1 mutants (the 
truncating nonsense mutation PINK1W437X and the missense mutation PINK1L347P) (Moore et al., 2005), or, 
as control, an empty vector. These 4 cell lines, which share phenotypic similarities with dopaminergic 
 
 
Figure 2.3. PINK1 knockdown prevents Parkin recruitment to depolarized mitochondria. 
(A) Immunofluorescence of HeLa cells cotransfected with Parkin-YFP and scrambled (scr) PINK1 or 
DJ-1 siRNA, and incubated for 1 h with 10µM CCCP. Mitochondria are labeled with an anti-TOM20 
antibody (red).(Scale bars, 10 µM.) Zoom shows 6x magnification of the region outlined by the box. 
(Scale bars, 1 µM.) (B) Effects of siRNA on PINK1 and DJ1 mRNA levels. Total RNA extracted from 
each sample is quantified by real-time PCR (n = 3). (C) Percentages of cells from the same set of 
cotransfected HeLa cells as in (A) that exhibit Parkin puncta colocalizing with the mitochondrial marker 
TOM20 (Parkin+/TOM20+). (D) Percentages of WT and knockout (KO) PINK1 cortical neurons that 
exhibit Parkin+/TOM20+ puncta following 1-h incubation with or without 100 nM CCCP. Values 
represent means ± SD (n = 30–50 cells) and are representative of 2–3 independent experiments. 
**,Different from controls (Newman-Keuls post hoc test; P < 0.001). 
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neurons, were transfected transiently with Parkin-YFP as above and, 6 h later, were exposed to 
ponasterone A to induce the expression of human PINK1 (Fig.2.4). In these cells, ΔΨm was comparable 
to that of Parkin-YFP–transfected/PINK1-noninduced and Parkin-YFP–transfected/empty vector-induced 
cells (Fig. 2.5 A and B). However, despite having a normal ΔΨm—as evidenced by TMRM fluorescence in 
live-cell imaging (Fig. 2.5A)—cytosolic Parkin-YFP relocalized to the mitochondria at a time point 
corresponding to marked PINK1WT induction (Fig. 2.4 A–C). Although the PINK1W437X and PINK1L347P cells 
had expression levels comparable to that of the PINK1WT cells (Fig. 2.4F), no Parkin-YFP relocalization to 
the mitochondria was noted (Fig. 2.4 D and E). The effects of WT but not of mutated PINK1 on Parkin 
translocation were confirmed by Pink1/Parkin-YFP cotransfection in HeLa cells (Fig. 2.5). We also 
transfected these cells with the artificial kinase dead mutant PINK1K219M, which we showed to be 
overexpressed to comparable levels as PINK1WT (Zhou et al., 2008). Here, the proportion of cells 
overexpressing PINK1K219M with Parkin-YFP relocalization (4.9± 3.0%, n = 100) was lower than that of 
cells overexpressing PINK1WT (97.0 ± 1.4%, n = 100; Student’s t test: t(198) = 27.7, P< 0.001). These 
results suggest that WT PINK1, but neither pathogenic nor functionally dead PINK1 mutants, is 








Figure 2.4. Overexpression of PINK1 suffices to recruit Parkin to mitochondria with normal ΔΨm. 
(A) Representative images illustrating the time-dependent changes in Parkin-YFP fluorescence from 
diffuse to punctate in immortalized mesencephalic neuronal N27 cells, after PINK1 induction. Parkin 
distribution is followed by live imaging of N27 cells expressing WT PINK1 driven by an inducible 
promoter. (Scale bar, 10 µM.) (B) Percentages of N27 cells showing Parkin translocation to mitochondria 
at selected time points after PINK1 induction and Parkin-YFP transfection. Mitochondria are labeled by 
MitoTracker Red. **, Different from non-induced N27 cells (Newman–Keuls post hoc test; P < 0.001). (C) 
Western blot from total cell extracts showing PINK1 induction over time. Loading is normalized with β-
actin. (D) Representative images illustrating the recruitment of Parkin to mitochondria at 24 h after 
induction of WT PINK1 but not after induction of pathogenic PINK1 L347P and W437X mutants. (E) 
Percentages of N27 cells showing Parkin translocation to mitochondria at 24 h after induction of WT or 
mutant PINK1. Values represent means ± SD (n = 50 cells) and are representative of 3 independent 
experiments. **, Different from empty vector induction controls (Newman–Keuls post hoc test; P < 
0.001). (F) Western blot from total cell extracts showing that PINK1 expression levels were comparable 




2.2.5. Parkin Binds to PINK1 Without Modifying Each Other 
The data presented in the previous sections raise the possibility that, once recruited to 
mitochondria, Parkin is physically apposed to PINK1, and this apposition may have important functional 
consequences. To ascertain this physical proximity, we used fluorescence lifetime imaging microscopy 
(FLIM) in living HEK293T cells as reported previously (Grailhe et al., 2006). The fluorescence lifetime of 
CFP tagged at the C-terminus of PINK1 in transfected cells was 2.61 ± 0.04 ns (mean ± SEM; n = 7), but 
when cells were cotransfected with Parkin-YFP, the lifetime was reduced to 2.03 ±0.03 ns (n = 4; 
Student's t test: t(9) = 8.57, P < 0.001; Fig. 2.6). However, when cells were cotransfected with DJ-1-YFP 
 
 
Figure 2.5. PINK1-dependent recruitment of 
Parkin to mitochondria is independent of 
ΔΨm but requires PINK1 kinase activity. (A) 
Representative changes in ΔΨm assessed by 
TMRM fluorescence (red) in living Parkin-YFP–
transfected N27 cells without (– PINK1) and with 
(+ PINK1) PINK1 induction. (Scale bar, 10 µM.) 
(B) Quantification of TMRM fluorescence 
showing the lack of effect of overexpression of 
PINK1, Parkin-YFP, or both on ΔΨm (1-way 
ANOVA, F(3, 8) = 0.40, P = 0.75). Values 
represent means ± SD of 3 independent 
experiments performed on 15 cells per group 
and per experiment. (C) HeLa cells were  
cotransfected with Parkin-YFP and with either 
mock, WT PINK1, PINK1 or with PINK1 dead-
kinase mutant K219M. Twenty-four hours after 
transfection, cells were incubated with vehicle 
(DMSO; white bars) or with 10 µM CCCP (black 
bars) for 1 h prior to fixation. Bars represent 
percent of cells showing Parkin-YFP 
colocalization with TOM20 (Parkin+/TOM20+) ± 
SD of 3 independent experiments, determined 
by confocal microscopy. **, Different from 




instead of Parkin-YFP, the lifetime of PINK1-CFP was unchanged, 2.61 ±0.02 ns (n = 5; Student's t test: 
t(10) = 0.79, P = 0.449) (Fig. 2.6A). These results indicate that a positive energy transfer occurred 
specifically between PINK1-CFP and Parkin-YFP, supporting the close proximity of these 2 proteins. 
We further assessed the physical proximity of Parkin and PINK1 by co-immunoprecipitation using 
human neuroblastoma SH-SY5Y cells [because these cells have relatively high levels of endogenous 
parkin (Zhou et al., 2008)] stably transfected with a cDNA plasmid expressing full-length PINK1 tagged at 
the C-terminus with Flag (PINK1-Flag). On incubation of these cell extracts with a rabbit polyclonal anti-
Parkin antibody (Abcam), endogenous Parkin immunoprecipitated, and PINK1-Flag did, also (Fig. 2.6B). 
Because of the lack of anti-PINK1 antibodies that reliably immunoprecipitate endogenous PINK1, it 
	  
Figure 2.6. Parkin interacts with PINK1 in 
mammalian cells. (A) FLIM analysis of the 
Parkin-PINK1 interaction. CFP-tagged PINK1 
(PINK1-CFP) is transfected alone or in  
combination with YFP-tagged Parkin (Parkin-
YFP) or with YFP-tagged DJ-1 (DJ-1-YFP) in 
HEK293 cells. Donor fluorophore lifetimes are 
color-coded according to the scale indicated at 
top of the figure. “Warmer” color is indicative 
of shorter donor fluorophore lifetime (2.00 ns 
vs. 2.61 ns) for the interaction between PINK1 
and Parkin, compared with the control 
interaction between DJ-1 and PINK1. (B) 
Lysates prepared from SH-SY5Y cells  
transfected with full length WT PINK1 tagged 
with Flag or with V5 tags were subjected to 
immunoprecipitation with anti-parkin antibody, 
followed by anti-Flag immunoblotting. Arrow 
indicates full-length PINK1; arrowhead 
indicates cleaved PINK1. 
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cannot be determined at present whether the immunoprecipitation of endogenous PINK1 can pull down 
Parkin. 
These findings raise the possibility that Parkin may be a substrate for the kinase PINK1 or that 
PINK1 may be a client for the E3-ligase Parkin. Relevant to this view, studies have indeed shown Parkin 
phosphorylation by PINK1 and PINK1 ubiquitination by Parkin (Kim et al., 2008; Sha et al., 2010). 
However, in our hands we found no evidence for such an interaction (data not shown here). The question 
of whether Parkin and PINK1 can post-translationally modify each other thus remains to be clarified. 
Although we do not address this issue, we do further explore the physical interaction between PINK1 and 
Parkin in the second half of this chapter. 
 
2.2.6. Parkin/PINK1 Promotes Mitochondrial Clustering 
Because we found that increased PINK1WT expression suffices to recruit Parkin to the 
mitochondria, we assessed the effects of PINK1 and Parkin on mitochondrial distribution by 
overexpressing either or both proteins in SH-SY5Y cells to take advantage of their neuronal-like nature 
and their highly interconnected tubular mitochondrial network. Once transfected, these cells were 
immunolabeled to detect EndoG and TOM20 as validated previously (Zhou et al., 2008), and with 
MitoTracker 633. As expected, these different mitochondrial markers colocalized (Fig.2.7). In 
untransfected cells and cells transfected with empty vectors, mitochondria appeared to be primarily 
tubular and organized in an interconnected network throughout the cell body, as expected (Fig. 2.7). 
Neither PINK1WT nor ParkinWT overexpression alone caused overt alteration of the mitochondrial network 
(Fig. 2.8A). In contrast, when SH-SY5Y cells were cotransfected with PINK1WT and ParkinWT, the normal 
mitochondrial network became altered. By 24–48 h after transfection, ∼90% of the cells (n = 250) 
exhibited Parkin-positive fragmented mitochondria, primarily in the vicinity of the nucleus, and/or large, 
perinuclear clusters of MitoTracker-positive mitochondria (Fig. 2.8A and Fig. 2.7). Even at 48 h after 
transfection, ∼10% of the cotransfected cells still had a normal tubular mitochondrial network (Fig. 2.7). Of 
note, in our pilot studies, we found that these changes in the mitochondrial network were similar to those 
observed in Parkin-YFP–transfected cells exposed to 10 µM CCCP for ∼2 h. By co-overexpressing 
ParkinWT and PD-linked mutated PINK1 (A217D, G309D, L347P) or kinase dead mutant PINK1K219M —all 
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of which have markedly reduced kinase activities (Beilina et al., 2005)—these mitochondrial changes 
were attenuated (Fig. 2.8A and Fig. 2.9). A similar observation was made with co-overexpression of 
functionally defective Parkin (produced by deletion of the RING2 domain) and PINK1WT (Fig. 2.9). As 
confirmed by Western blots, in all the different combinations of coexpression, levels of mutated Parkin or 
PINK1 were at least comparable to those of their WT counterparts (Fig. 2.8B). These findings support the 
notion that the disruption of the mitochondrial network and the formation of mitochondrial aggregates and 
perinuclear clusters depend on both Parkin and PINK1 activity. We also found that the formation of 
perinuclear mitochondrial aggregates and clusters appeared to be specifically caused by Parkin and 
PINK1, because co-overexpression of Parkin/DJ-1 and PINK1/DJ-1 at comparable levels did not cause 
these mitochondrial structures (Fig. 2.9). Incidentally, we saw identical mitochondrial perinuclear 
phenotypes with PINK1/Parkin co-overexpression in other cell lines, such as human neuroblastoma M17 




Figure 2.7. Parkin and PINK1 co-
overexpression induces the 
formation of perinuclear 
mitochondrial clusters in SH-SY5Y 
cells. Transfected cells with empty 
vector (Mock) have even mitochondrial 
distribution throughout the cytoplasm, 
as shown with the mitochondrial  
markers endonuclease-G (EndoG), 
TOM20, and MitoTracker Deep Red 
633 (Mito633). By contrast, in the 
Parkin/PINK1 double-transfected cells, 
mitochondria are clustered at the 
perinuclear area. Dual immunostaining 
with PINK1 and TOM20 and EndoG 
and myc (for myc-Parkin) show that 
both PINK1 and Parkin are enriched at 
the periphery of the mitochondrial 
clusters. Moreover, PINK1-Parkin-myc 
dual immunostaining showed that  
indeed Parkin and PINK1 co-localize at 




2.2.7. The Mitochondrial Clustering Is 
Microtubule-Dependent 
The results reported in the previous 
sections support the view that Parkin and 
PINK1 may act in concert to modulate 
mitochondrial location, a complex function 
that typically relies on the microtubule motors 
(Hirokawa, 1998). Consistent with this notion, 
in PINK1-stable SH-SY5Y cells transfected 
with Parkin, we found that >90% of the 
perinuclear mitochondrial clusters that had 
formed dispersed after only 1-hr incubation 
with 1 µM nocodazole, a microtubule 
depolymerizing agent (Fig. 2.10A), indicating 
that microtubules play a role in keeping these 
clusters intact. Furthermore, in cells with 
perinuclear mitochondrial clusters, there was 
>80% colocalization between at least a part 
of these large perinuclear clusters and γ-
tubulin, suggesting that they gather in the 
vicinity of the centrosome, an organelle that 
serves as the main microtubule-organizing center (Fig. 2.10B). However, we saw no obvious effect of 
nocodazole on the smaller perinuclear mitochondrial aggregates nor a definite colocalization between γ-
tubulin and these mitochondrial aggregates. Further studies may be needed to elucidate whether these 
mitochondrial aggregates represent a distinct arrangement or a preceding stage [i.e., thanks to the 
microtubule motor, mitochondrial aggregates coalesce into larger perinuclear structures preferentially 




Figure 2.8. PINK1 PD mutations mitigate the formation 
of perinuclear mitochondrial clusters.  
(A) Three types of mitochondrial network morphology are 
defined in Parkin- and PINK1-cotransfected cells: no 
cluster (i.e., normal mitochondrial tubular network and 
distribution); incomplete cluster (i.e., mixture of perinuclear 
clustered mitochondria and dispersed linear 
mitochondria); and complete cluster (i.e., all mitochondria 
are clustered at the perinuclear area). Cells cotransfected 
with WT Parkin and PINK1 show mainly complete clusters 
while cells cotransfected with WT Parkin and PINK1 
disease mutations or artificial dead kinase mutation 
(K219M) show mainly incomplete or no clusters. Bars 
represent percentage of cells for each type of 
mitochondrial morphology ± SEM; n = 200 cells counted 
during 3 independent experiments. **, Different from 
PINK1/Mock (Newman–Keuls post hoc test; P < 0.01). 
(Scale bars, 5 µm.) (B) Western blot from total cell 
extracts showing that Parkin and PINK1 expression levels 
were comparable in WT PINK1 and PINK1 mutants L347P 
and W437X. Parkin is immunodetected using anti-myc 
antibody. Loading is normalized with GAPDH. 
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Nonetheless, microtubules serve as railways for the transport of organelle cargos other than 
mitochondria (Hirokawa, 1998). Remarkably, PINK1/Parkin co-overexpression seemed to modulate 
mitochondrial location specifically, because other microtubule organelle cargos, such as endoplasmic 
reticulum, never showed any change in their cellular organization (Fig. 2.11A). Thus, the interaction 
between PINK1 and Parkin may operate collaboratively on specific molecules of the mitochondrial 
trafficking machinery. In keeping with this idea is the demonstration that PINK1 can interact with the 
mitochondrial protein Miro and the adaptor protein Milton (Weihofen et al., 2009), which connects kinesin 
heavy chain to Miro on mitochondria. However, our view of Parkin/PINK1 collaboration in mitochondrial 
trafficking in mammalian cells does not agree with the idea that, in Drosophila, Parkin operates 
downstream of Pink1 and that Parkin overexpression makes Pink1 dispensable (Clark et al., 2006; Park 
et al., 2006; Poole et al., 2008). At this point, we cannot exclude the possibility that this apparent 
molecular divergence may result from an incomplete conservation of the Parkin/PINK1 pathway between 
invertebrate and vertebrate organisms. It also should be taken into account that, here, we investigated the 
role of Parkin/PINK1 interaction on mitochondrial distribution and disposition, whereas in all the 
Drosophila studies the authors ascertained mitochondrial morphology and fission/fusion, very different 
aspects of mitochondrial dynamics that are not necessarily governed by an identical molecular 
machinery.  
	  
Figure 2.9. Co-overexpression of 
PINK1K219M (KD)/Parkin, 
PINK1/ParkinΔR2, PINK1/DJ-1, and DJ-
1/Parkin in SH-SY5Y cells does not 
produce perinuclear mitochondrial 
clustering. MitoTracker Deep Red 633 
(Mito633) is used here to label 





2.2.8. Parkin/PINK1 May Regulate Mitochondrial Trafficking 
To examine the ultrastructure of perinuclear clustered mitochondria induced by Parkin/PINK1, we 
performed EM and observed a range of different types of mitochondrial perinuclear clusters that were not 
present in empty vector-transfected cells. In all cases, both the length and the width of perinuclear-
clustered mitochondria in Parkin/PINK1-cotransfected cells were smaller than in mock-transfected control 
cells (Fig. 2.11B), suggesting that Parkin/PINK1 co-expression distorts the mitochondrial network, 
perhaps by promoting mitochondrial fragmentation. Furthermore, in some cases, clusters were made of 
nearly normal-appearing mitochondria, and both PINK1 and Parkin localized to the outside boundaries of  
	  
Figure 2.10. Mitochondrial clusters 
dissipate upon microtubule 
depolymerization. (A) In empty vector-
transfected (Mock) SH-SY5Y cells stably 
overexpressing PINK1, treatment of 1 µM 
nocodazole (Nocod.) for 1 h depolymerizes 
the microtubule network, resulting in the 
disruption of the mitochondrial network. In 
Parkin-transfected SH-SY5Y cells stably 
overexpressing PINK1, perinuclear 
mitochondrial clusters are observed at ∼36 h 
posttransfection. However, the majority 
of perinuclear mitochondrial clusters are 
replaced by scattered mitochondrial 
aggregates on nocodazole treatment. (B) SH-
SY5Y cells cotransfected with empty vector 
(Mock) plus PINK1 or with Parkin plus PINK1 
and stained with the mitochondrial marker 
EndoG (green) and anti-γ-tubulin (red). As a 
highly conserved element of microtubule-
organizing centers (MTOCs), γ-tubulin is used 
as a MTOC marker (arrows), revealing a 
strong immunostained zone in the perinuclear 
area. In Mock/PINK1-transfected cells, anti-
EndoG staining shows widely distributed 
mitochondrial networks. In Parkin/PINK1-
transfected cells, perinuclear mitochondrial 
clusters are colocalized with perinuclear γ-




each individual mitochondrion (Fig. 2.12 A and B). In other cases, multiple mitochondria appeared fused 
together (Fig. 2.12 A and C), although the static nature of EM does not allow us to assess whether these 
mitochondria are functionally connected to each other. Among clustered mitochondria, the gap between 2 
mitochondria was ∼6 nm, similar to the gap of the mitochondria clusters induced by mitochondrial 
phospholipase-D (Choi et al., 2006). However, unlike mitochondrial phospholipase-D, Parkin/PINK1 
overexpression was associated with mitochondrial outer-membrane fusion (Fig. 2.12A). We also identified 
perinuclear lysosomal vacuoles as well as autophagosomes, and some of these contained mitochondria 
(Fig. 2.12Dand F), suggesting a mitochondrial autophagic event. The autophagic nature of these 
vacuoles was confirmed by fluorescence for the autophagosomemarker LC3-RFP and by 
immunofluorescence for the lysosome marker Lamp2 (Fig. 2.12 G and H). Notably, in untreated Parkin-
GFP/LC3-RFP cotransfected cells, the LC3-RFP signal was detected throughout the cytoplasm (Fig. 
2.12G). In contrast, in CCCP-treated cells, the LC3-RFP signal was localized mostly in the perinuclear 
region, where it colocalized with Parkin and the mitochondrial marker cytochrome c (Fig. 2.12G). 
	  
Figure 2.11. Effects of PINK1/Parkin 
cotransfection. (A) The endoplasmic 
reticulum (ER) network is not affected 
by Parkin-PINK1–induced mitochondrial 
clustering. In empty-vector (Mock)- and 
in Parkin transfected SH-SY5Y cells 
stably overexpressing PINK1, the ER 
network, visualized by immunostaining 
with the ER marker calreticulin, spread 
throughout the entire cytosol and was 
not affected by the formation of 
perinuclear mitochondrial clusters 
shownby Mito633. (Scale bar, 5 µm.) 
(B) EM analyses revealed that 
PINK1/Parkin co-transfected cells have 
smaller mitochondria than Mock-
transfected control cells. Bars represent 
average counts (n = 50 cells) ± SD of 3 
independent experiments. Mitochondrial 
length and size were measured using 
Image J software analyses. **, Different 
from mock-transfected cells (Mann-
Whitney, p < 0.001). 
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Consistent with the preferential subcellular localization of lysosomes, Lamp2 immunofluorescence was 
detected primarily in the perinuclear area, which is the only subcellular region where we observed definite 
colocalization between Lamp2 and Parkin (Fig. 2.12H). Together with our results for the microtubule 
experiments, these data suggest that autophagosomes containing Parkin/PINK1-enriched mitochondria 
may form at some distance from the lysosomes and then are delivered by the microtubule motor to the 
perinuclear lysosomes for degradation.  
  
	  
Figure 2.12. Perinuclear mitochondrial clusters 
undergo mitochondrial autophagy. 
(A–F) SH-SY5Y cells cotransfected with Parkin and 
PINK1 were fixed and processed for EM with anti-
Parkin or anti-PINK1 immunostaining (A, B) or 
without immunostaining (C, D). (A, B) With HRP-
labeled secondary antibodies, immuno-EM showed 
perinuclear mitochondrial clusters (arrows), and 
both Parkin and PINK1 localized to the periphery of 
both individual mitochondrion (insets) and fused 
mitochondria, consistent with immunofluorescent 
data that showed their colocalization (C) In some 
clustered mitochondria, mitochondrial outer 
membranes of 2 opposite mitochondria 
disappeared or fused but their inner membranes 
remained intact. (D) The autophagic vacuoles (AV) 
that contain mitochondria (white arrowhead) were 
found in the perinuclear area. (E, F) A mixture of 
clustered mitochondria (white arrowhead), 
autophagic vacuoles (black arrowhead in E), 
lysosomes (white arrow in F), and other nontypical 
vacuoles in the autophage–lysosome pathway 
(black arrow in E) are identified at the perinuclear 
area. (Scale bars, 500 nm.)  
(G, H) Immunofluorescence of HeLa cells 
transiently cotransfected with Parkin-GFP and LC3-
rFP incubated with vehicle DMSO or CCCP for 1 h 
before cell fixation. In the perinuclear area where 
mitochondrial clusters accumulate, Parkin-GFP 
colocalized with LC3-rFP (G) and with Lamp-2 (H). 
(Scale bars, 10 µm.) Zoom denotes a 6x 
magnification of the region outlined by the box in 
the CCCP images. (Scale bars, 1 µm.). ER, 
endoplasmic reticulum; Nuc, nucleus. 
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2.3. RESULTS PART II: THE DUAL LOCALIZATION OF PINK1 MODULATES PARKIN TRANSLOCATION TO 
MITOCHONDRIA 
 
2.3.1. Mitochondrial PINK52 is loosely attached to the MOM and translocates to the cytosol. 
As mentioned in Chapter 1.3.2.2.2, once imported into the mitochondria, full-length PINK1 undergoes two 
sequential proteolytic processing steps which, according to Greene et al. (2012), are mediated first by 
matrix processing peptidase (MPP) and then by presenilin-associated rhomboid-like protease (PARL) and 
the m-AAA protease.  
Based on the estimated molecular mass of the MPP-generated PINK1 fragment of ~60 kDa 
(Deas et al., 2011; Jin et al., 2010), it can be speculated that this first cleavage occurs around amino acid 
35, which is consistent with one of the predictions of the PINK1 cleavage site made by Silvestri et al. 
(2005). Then, PINK160 is apparently processed further by PARL (and/or m-AAA) (Cipolat et al., 2006; 
Deas et al., 2011; Greene et al., 2012; Jin et al., 2010; Meissner et al., 2011). This second cleavage site, 
as we have estimated (Zhou et al., 2008), should be between amino acids 91 and 104, hence clipping the 
N-terminal half of the transmembrane domain (TMD), which is proposed to span residues 94-111 
(Silvestri et al., 2005; Zhou et al., 2008). Subsequently, Deas and collaborators showed that PINK1 is 
indeed cleaved within the mitochondria by PARL between Ala-103 and Phe-104 (Deas et al., 2011). We 
showed that PINK163 only partially crosses the mitochondrial inner membrane (MIM), i.e., the PINK1 
sequence upstream of the TMD is within the matrix whereas the sequence downstream of the TMD is 
within the intermembrane space (Becker et al., 2012). Thus, in light of the above data supporting the 
notion that PINK152 sub-mitochondrial topology is primarily at the MOM, we speculate that, once this 
second cleavage occurs, PINK152 moves back from the intermembrane space to the surface of the 
mitochondria. Although the exact mechanism that would drive the retro-translocation of PINK152 remains 
to be established, we have already shown that the C-terminal part of PINK152, downstream of the kinase 
domain, determines the extent to which it exits the intermembrane space (Becker et al., 2012). 
Since the loss of most of the TMD allows PINK152 to be dislodged from the MIM, we hypothesize 
that PINK152 located at the MOM may likewise not be firmly integrated into that membrane. To test this 
idea, we subjected mitochondria isolated from HeLa cells transiently transfected with HA-tagged human 
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wild-type PINK1 to alkaline extraction and assessed the relative amounts of full-length and cleaved 
PINK1 in both the soluble and particulate fractions (Fig. 2.13A). We found that ~90% of full-length PINK1 
remained in the particulate fraction, even at pH 12, whereas less than 30% of cleaved PINK1 did so. This 
suggests that, as we expected, full length PINK1 is strongly integrated into the MOM, whereas cleaved 
PINK1 is only loosely anchored to the MOM, since it can be extracted from the MOM more easily. 
While the high pH used in this experiment is ideal for the in vitro extraction of proteins from 
membranes, we are left with the critical question of whether in vivo cleaved PINK1 is released 
spontaneously into the cytosol or is removed from the MOM by some kind of molecular-based extraction 
mechanism. Relevant to this view is the demonstration that PINK1 apparently interacts with cytosolic 
chaperone proteins such as HSP90 (Weihofen et al., 2008). While more work is required to determine 
how cleaved PINK1 finds its way to the cytosol, several studies, including our own (Lin and Kang, 2008; 
Narendra et al., 2010; Takatori et al., 2008; Zhou et al., 2008), have shown that proteasome inhibitors, 
such as MG132 or epoxomicin, lead to the preferential cellular enrichment of PINK152 over PINK63, as 
evidenced on Western blots of whole cell lysates. We therefore transfected HeLa cells transiently with 
wild-type HA-tagged human PINK1 and treated them with either 10 µM MG132 or 1 µM of the natural, 
neutral ionophore valinomycin (to collapse ΔΨm) for eight hours; control cells were treated with vehicle 
DMSO. Then, contents of full-length and cleaved PINK1 were compared by Western blot in whole cell, 
cytoplasmic and mitochondrial extracts (Fig. 2.13B). Interestingly, incubation with MG132 was associated 
with a marked increase in PINK152, not only in the cytosol, where the proteasome is located, but also in 
the crude mitochondrial fraction (Fig. 2.13B). This suggests that by impeding the turnover of cytosolic 
PINK152, less cleaved PINK1 enters the cytosol, raising the possibility that levels of cytosolic PINK152 
exert a negative feedback on the mechanism driving the mitochondrial/cytosolic partition of cleaved 
PINK1. As for incubation with valinomycin, it was associated with a dramatic decrease in PINK152 in both 
the mitochondrial and cytosolic fractions with a corresponding increase in PINK163 only in the 
mitochondrial fractions (Fig. 2.13B) supporting the notion that PINK152 is strictly generated by the 
processing of PINK163 within the mitochondria.  
The subcellular distribution of PINK1 in HeLa cells transiently expressing wild-type human PINK1 
under these different treatment conditions is illustrated by immunofluorescence in Fig. 2.13C. Under basal 
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conditions (i.e. incubation with DMSO), there was only a marginal co-localization between PINK1 and the 
mitochondrial marker TOM20 (co-localization coefficient c = 0.16) as PINK1 immunoreactivity was evenly 
distributed throughout the cytosol (Fig. 2.13C). In contrast, after only two hours of exposure to 
valinomycin, there was a much greater co-localization between PINK1 and TOM20 (c = 0.58) with PINK1 
immunoreactivity clearly displaying a prominent punctate distribution. Following the incubation of the cells 
with MG132, PINK1 was seen both to aggregate forming scattered TOM20-negative puncta in the cytosol 







Figure 2.13. Subcellular distribution of 
cleaved PINK1. (A) Alkaline extraction of 
PINK1 from isolated mitochondria. Upper panel 
shows a representative Western Blot using 
antibody against PINK1 using extraction buffer 
at different pH. The lower panel shows the 
quantification of PINK1 distribution from three 
independent experiments. Values are means ± 
SEM. Statistical value is the results of the 
Student-Newman-Keuls post-hoc tests between 
full-length and cleaved PINK1 at pH 11.5 and 
12. (B) Western Blot for PINK1 in total extract, 
cytoplasm and mitochondrial fractions after 
treatment with DMSO, Valinomycin or MG132. 
PKC is used as a cytoplasmic marker and 
TIM23 as a mitochondrial marker. (C) 
Immunofluorescence assay shows co-
localization of PINK1 and mitochondria in cells 
treated with DMSO, Valinomycin or MG132. 
TOM20 is used as a mitochondrial marker. The 
co-localization coefficients c between PINK1 
signals and mitochondrial signals are indicated. 





2.3.2. PINK152 binds Parkin and puts a break on mitophagy 
In light of the data presented above, it seems that PINK1 may have a dual localization, i.e. 
PINK163 mainly in the mitochondria and PINK152 mainly in the cytosol. However, we believe that the 
partitioning of PINK1 into these two intracellular compartments depends on the functionality of the 
mitochondria. For instance, we posit that, in cells with healthy mitochondria (i.e. normal ΔΨm) there will be 
relatively low levels of mitochondrial full-length PINK1 and high levels of cytosolic cleaved PINK1. 
Conversely, in cells with damaged mitochondria (i.e. low ΔΨm) there will be relatively high levels of 
mitochondrial full-length PINK1 (since it is no longer efficiently imported and processed) and low levels of 
cytosolic cleaved PINK1 (since it is no longer efficiently generated). Furthermore, while the present data 
support the notion that cleaved PINK1 is degraded by the proteasome, we doubt that the sole reason for 
mitochondrial PINK152 to enter the cytosol is to be degraded. Instead, we predict that cytosolic PINK152 
plays its own role and since, as suggested above, it is particularly abundant in the cytosol of cells with 
healthy mitochondria, we argue that its role may be related to the maintenance of the well-being of cells. 
Germane to this view is the demonstration that a mutant form of PINK1 devoid of the mitochondrial 
targeting sequence (ΔNPink1) that is similar to PINK152 not only accumulates in the cytosol, but also 
protects against a toxic insult both cultured COS-7 cells (that have been transfected with ΔNPink1) and 
nigra dopaminergic neurons in adult mice (that have been transduced with a viral vector expressing 
ΔNPink1) (Haque et al., 2008). 
Through co-immunoprecipitation experiments of whole cell extracts, PINK1 has been shown to 
physically interact with Parkin (Figure 2.6 and (Sha et al., 2010; Shiba et al., 2009; Vives-Bauza et al., 
2010)). Since specific domains of Parkin are necessary to allow cytosolic Parkin to translocate to 
mitochondria (Kim et al., 2008; Shiba et al., 2009), we asked whether cytosolic PINK152 binds to cytosolic 
Parkin, and if so, whether it might contribute to preventing Parkin translocation to mitochondria. Thus, first 
we sought to determine the Parkin binding domain of PINK1. Accordingly, we performed a series of 
immunoprecipitation experiments with several truncated forms of PINK1 carrying a C-terminal Flag-tag. 
All PINK1 constructs used were successfully expressed in transfected HEK293T cells (Fig. 2.14A). As 
shown in Fig. 2.14A (lower panel), endogenous Parkin was predominantly pulled-down by two PINK1 
fragments, both containing the middle section of the kinase domain (aa 156-507 and aa 310-428) and, to 
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a lesser extent, by the truncation encompassing the first part of the kinase domain (aa 156-309). The N-
terminal part of the protein that encompasses the mitochondrial targeting sequence and the TMD (aa 1-
155) and the C-terminal part of PINK1 (aa 429-581) did not bind to endogenous Parkin. The kinase 
domain of PINK1 is thus essential for the physical interaction between PINK1 and Parkin. In light of these 
results, we then used the whole PINK1 kinase domain fragment (aa 156-507) to determine the PINK1 
binding domain of Parkin. Co-immunoprecipiation was performed in HEK293T cells co-transfected with 
PINK1156-507-Flag and various truncated forms of Parkin carrying an N-terminal Myc-tag (Fig. 3B). This 
second set of experiments revealed that the product comprising the Ring-1 domain of Parkin consistently 
pulled-down the PINK1 kinase domain (Fig. 2.14B). Thus, our co-immunoprecipitation results indicate that 
the PINK1 kinase domain binds to the Parkin Ring-1 domain. Since both PINK1 kinase and Parkin E3 
ubiquitin ligase activities have been shown to be crucial to cytosolic Parkin translocation to mitochondria 
(Narendra et al., 2010; Sha et al., 2010; Vives-Bauza et al., 2010), such binding by PINK152 in the cytosol 
may interfere with these two enzymatic activities, hence preventing any unwanted Parkin translocation 
and the ensuing mitophagy in cells with healthy mitochondria.  
To test this idea, we expressed either wild-type PINK1 or mutant PINK1 with an N-terminal 
deletion (PINKΔ1-111, mimicking PINK152) in HeLa cells stably expressing YFP-Parkin. Dissipation of ΔΨm 
in these cells led to Parkin recruitment to the mitochondria (Geisler et al., 2010; Kawajiri et al., 2010; 
Narendra et al., 2008, 2010; Rakovic et al., 2010; Vives-Bauza et al., 2010; Ziviani et al., 2010). Hence, 
cells were treated for two hours with either the vehicle DMSO or 10 µM CCCP to collapse ΔΨm as 
previously done (Geisler et al., 2010; Kawajiri et al., 2010; Narendra et al., 2008, 2010; Rakovic et al., 
2010; Vives-Bauza et al., 2010; Ziviani et al., 2010). After fixation, cells were immunostained for PINK1 
and for the mitochondrial marker TOM20. The proportion of HeLa cells with mitochondrial-localized Parkin 
was determined in untransfected cells, in cells expressing wild-type PINK1, and in cells expressing 
PINK1Δ1-111 (Fig. 2.14C). Parkin was recruited to mitochondria after CCCP treatment in about 90% of 
untransfected cells, but, in cells expressing PINK1Δ1-111, only about 55% of cells exhibited Parkin 
recruitment to mitochondria after CCCP treatment (Fig. 3C). Overexpression of wild-type PINK1 led to 
accumulation of Parkin at the mitochondria even without CCCP treatment, which is consistent with 
previous observations (Vives-Bauza et al., 2010). 
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Upon exposure to 10 µM CCCP for 24-48 hours, HeLa cells stably expressing YFP-Parkin appear 
to have lost their mitochondria, as evidenced by both immunostaining for TOM20 and cytochrome c, as 
well as by transmission electron microscopy (Narendra et al., 2008). While this counterintuitive 
observation raises the question as to how it is possible that mammalian cells survive for a prolong period 
of time without mitochondria, it remains that ever since this finding was published (Narendra et al., 2008) 
the combination of collapsing ΔΨm with chemicals and overexpressing Parkin has become a popular 
model of mitophagy in eukaryotes. Thus, next we sought to assess the potential significance of our 
finding that Parkin recruitment is prevented in cells expressing PINK1Δ1-111 on mitochondrial turnover by 
using the aforementioned model of mitophagy. Accordingly, YFP-Parkin-expressing HeLa cells were 
again transfected with wild-type PINK1 or PINK1Δ1-111 and then treated with DMSO or 10 µM CCCP for 24 
hours. After fixation and immunostaining for PINK1 and TOM20, we assessed the richness of the 
mitochondrial network within 30-50 randomly selected cells as an indirect measure for mitophagy. Cells 
were categorized for having either normal, reduced or no detectable mitochondrial network (see Fig. 
2.14D, upper panel for examples). Consistent with the results of Parkin translocation (Fig. 2.14C), we 
found that, at baseline (i.e. DMSO exposure), the percentage of cells with reduced and no detectable 
mitochondrial networks was highest in wild-type PINK1-expressing cells followed, to a much lower extent, 
by PINK1Δ1-111-expressing cells (Fig. 2.14D). Also in keeping with the results of Parkin translocation (Fig. 
2.14C), we found that, in response to CCCP exposure, the percentage of cells with reduced mitochondrial 
networks was comparable among the three cell genotypes (X2 = 1.79, df = 2, p = 0.409) whereas the 
percentage of cells with no detectable mitochondrial networks was markedly smaller in PINK1Δ1-111-
expressing cells compared to untransfected and wild-type PINK1-expressing cells (X2 = 24.51, df = 2, p < 
0.001; Fig. 2.14D). Since all of the cells express endogenous levels of PINK1, the attenuation in Parkin 
translocation (Fig. 2.14C) and mitochondrial disappearance in PINK1Δ1-111-expressing cells (Fig. 2.14D) is 
consistent with the idea that PINK152 exerts a dominant negative effect on Parkin recruitment and 











2.4. CONCLUSIONS AND DISCUSSION 
The data presented in this chapter help elucidate a role for PINK1 and Parkin in the regulation of 
mammalian mitophagy. First, in keeping with the study of Narendra et al. (Narendra et al., 2008), we 
found that, normally, cytosolic WT Parkin relocalizes to the mitochondrial outer membrane upon 
depolarization of the membrane potential. This recruitment appeared to be selective for those 
mitochondria with the lowest membrane potential (Fig. 2.2E). Interestingly, we did not see recruitment to 
depolarized mitochondria when we used forms of with PD-linked Parkin mutants.  
We next showed that this relocalization is dependent on the presence of functional PINK1 (Figs. 
2.3 and 2.5). Knock-down of PINK1 – but not DJ-1 – or the expression of disease-related mutant forms of 
PINK1 led to a significant decrease in Parkin recruitment upon depolarization. On the other hand, 
concomitant overexpression of WT PINK1 and Parkin sufficed to induce Parkin accumulation at the MOM, 
even in mitochondria with normal membrane potential. After our initial publication, several other groups 
confirmed our finding that Parkin recruitment is PINK1 dependent (Geisler et al., 2010; Kawajiri et al., 
2010; Michiorri et al., 2010; Narendra et al., 2010).  
Since PINK1 is a kinase and Parkin an E3-ubiquitin ligase, we wondered whether PINK1 and 
Parkin were able to modify each other. We did not find that PINK1 phosphorylates Parkin or that Parkin 
ubiquinitates PINK1, despite reports of others to the contrary (Kim et al., 2008; Sha et al., 2010). Through 
FLIM, we showed that Parkin and PINK1 are in close proximity to each other, suggesting that they may 
Figure 2.14. Identification of the PINK1-Parkin binding site and assessment of mitophagy. (A) PINK1 kinase 
domain binds Parkin as indicated by co-immunoprecipitation assay. Upper panel shows a schematic 
representation of PINK1 constructs used. Lysates from HEK293T cells transfected with C-terminal FLAG-tagged 
human PINK1 (PINK1-Flag) or PINK1 fragment constructs are immunoprecipitated with an anti-Flag antibody, 
followed by immunoblotting against Flag and Parkin (lower panel). (B) Parkin Ring-1 (R1) domain binds PINK1. 
Co-immunoprecipitation assay is performed using lysates of HEK293T cells co-transfected with PINK1 kinase 
domain (PINK1156-507-HA) and selected myc-tagged Parkin domain constructs. Bead control is included to monitor 
non-specific protein binding. (C) Parkin recruitment to mitochondria is significantly inhibited in cells transfected with 
PINK1Δ1-111 (mimicking cleaved PINK1) after CCCP treatment. Values are mean ± SEM from 3 independent 
experiments (~100-300 cells per construct and condition). Statistical value is the results of the Student-Newman-
Keuls post-hoc tests. (D) Mitophagy, estimated by the disappearance of mitochondrial TOM20 staining, is inhibited 
when cells express PINK1Δ1-111. Mitochondrial network is assessed in cells expressing YFP-Parkin and wild-type 
PINK1, PINK1Δ1-111 or no PINK1 as a control. Upper panel: Representative pictures of cells with normal, reduced 
and no mitochondrial network. Scale bar = 20 µm. Lower panel: Quantification of mitochondrial network in 30-50 




directly interact. Indeed, we were able to demonstrate, through co-immunoprecipitation experiments, that 
the PINK1 kinase domain and the Parkin RING1 domain bind each other. 
We observed that Parkin-decorated mitochondria accumulated in the perinuclear area, where 
they co-localized with the autophagosome marker LC3 and the lysosomal marker LAMP2. This clustering 
turned out to be microtubule-dependent, suggesting that PINK1/Parkin may regulate the trafficking of 
damaged mitochondria to the lysosome-rich perinuclear area, where they can be degraded by autophagy. 
At the time of our study, an unbiased screen by Weihofen and colleagues (2009) had just identified 
PINK1 in a complex with the microtubule motors Miro and Milton, supporting the notion that PINK1 may 
affect trafficking. Since then, there have been several conflicting reports on the interaction between 
PINK1, Parkin and Miro/Milton (reviewed in Chapter 1), although these reports do seem to agree that 
these proteins may affect the trafficking of (damaged) mitochondria.   
Based on the data discussed in the first half of this chapter and on the numerous studies that 
have followed since the publication of our paper, PINK1 and Parkin are thought to act as important 
regulators of mitophagy. Although they are not homologues of the yeast Atg32 and Atg33 genes, they 
may serve a similar function in that both of these proteins mark mitochondria for mitophagy. In our study, 
Parkin was recruited to those mitochondria with the lowest membrane potential after depolarization. Since 
loss of membrane potential is used here as a correlate of mitochondrial damage, this may suggest that 
Parkin specifically tags ‘sick’ or damaged mitochondria, hence making sure that only those ‘sick’ 
mitochondria get degraded.  
Interestingly, at least four papers (Cui et al., 2011; Dagda et al., 2009, 2011; Liu and Lu, 2010) 
have shown that autophagy is induced upon PINK1 knock-down and that blocking autophagy in this 
situation increased cell death.  In these studies, mitochondria were found inside lysosomes and there was 
a decrease in mitochondrial markers, implying that mitophagy can still take place in a PINK1 deficient 
background. This may, however, be the result of the upregulation of macroautophagy in general and a 
process distinct from Parkin-mediated mitophagy of damaged mitochondria, in particular.  
The majority of studies on PINK1/Parkin thus far, have focused on what happens once 
membrane potential is dissipated. In the second half of this chapter, we instead addressed the question of 
the seemingly wasteful life cycle of PINK1 under baseline conditions. We showed that the PINK1 
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cleavage product, PINK152, is present on the MOM just like full length PINK163. It is, however, more easily 
extracted from the MOM than PINK163 at pH 12. When we blocked proteasomal degradation with MG132, 
we observed an increase in PINK152 in the cytosol and in mitochondria. From these data, we concluded 
that PINK152 is retrotranslocated to the cytosol rather than degraded inside mitochondria, as had been 
proposed before (Jin et al., 2010).  
To elucidate a potential role for cytosolic PINK152, we induced mitophagy in YFP-Parkin 
expressing HeLa cells transfected with either full-length PINK1 or a fragment mimicking PINK152.  As we 
had seen before (see part I), overexpression of full length PINK1 in combination with YFP-Parkin was 
sufficient to induce mitophagy, even under baseline conditions. On the other hand, Parkin-recruitment 
and mitophagy were markedly decreased in cells expressing the fragment, even after 24 hr of treatment 
with CCCP. Our IP experiments showed that the fragment could bind Parkin at the RING1 domain. We 
thus propose that PINK152  retrotranslocates to the cytosol, where it can bind Parkin and prevent its 
recruitment to the mitochondria, thereby putting a break on mitophagy.  
 
As is the case for the majority of studies on PINK1 and Parkin, we used the protonophore CCCP 
to dissipate membrane potential and to induce Parkin recruitment and mitophagy. Protonophores have 
been shown to affect the plasma membrane (Friedberg et al., 1985) and the lysosomes (Connop et al., 
1999; Zhang et al., 2000), preventing their acidification, which is necessary for autophagic protein 
degradation.  The use of a high concentration of this drug creates an artificial situation whereby ΔΨm for 
all mitochondria is completely collapsed, which is not representative of ΔΨm loss as a result of 
mitochondrial damage and mtDNA mutations in vivo, as will be discussed in the next chapter (Gilkerson 
et al., 2012). It also leaves us with the question of why, if membrane potential is dissipated in all cells, do 
only 50-80% of the cells show Parkin recruitment. We have considered the possibility that PINK1 and/or 
Parkin expression levels are dependent on cell cycle phase. This hypothesis, however, proved rather 
challenging to test (data not shown).  
In addition to the artificial situation created by the use of CCCP, we conducted our experiments in 
cell lines such as HeLa and HEK293. These cells are relatively easy to work with but are not 
representative of the dopaminergic neurons that are affected in PD. They provide a good starting point for 
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testing a model, however our findings should be confirmed in a more relevant cell type, such as 
dopaminergic neurons generated from induced pluripotent stem cells derived from PD patients (Cooper et 
al., 2012).  
 
In summary, we propose the following model for PINK1/Parkin regulation of mitophagy (Fig. 
2.15): under baseline conditions, PINK1 is imported into the mitochondria, doubly cleaved, then 
retrotranslocated to the cytosol. There, the cleavage product, PINK152, binds Parkin and prevents it from 
inadvertently being recruited to healthy mitochondria. Upon dissipation of the membrane potential (as a 
result of mitochondrial dysfunction), PINK1 import ceases and full length PINK1 accumulates at the MOM. 
PINK152 is no longer generated and its cytosolic levels decrease as it is rapidly degraded by the 
proteasome. Full length PINK1 is now able to recruit Parkin to the sick mitochondria and this tags these 
mitochondria for degradation by mitophagy. Since the loss of PINK1 repression of Parkin translocation 
will rely on PINK1 proteasomal degradation, a time-lag between the loss of ΔΨm and the translocation of 
Parkin is expected, which is exactly what is observed experimentally, i.e. upon exposure to CCCP, the 
loss of ΔΨm, evidenced by fluorescent probes such as tetramethyl rhodamine methyl ester, is almost 
instantaneous while evidence of overt Parkin translocation is noticeable only after ~30 minutes. As one 
can imagine that the import/cleavage/retrotranslocation process can be overloaded and lead to a ‘traffic 
jam’ of full length PINK1 at the MOM, this model could also explain our observation that overexpression 
of full length PINK1 induces mitophagy, even without dissipation of ΔΨm;  
Exactly how Parkin affects the actual mitophagic process is not yet known, but our data indicates 
that this is, in part, through the trafficking of the mitochondria to the perinuclear area where they can be 
taken up into autophagic vesicles and lysosomes. Other scenarios include the direct recruitment of the 
autophagic machinery by interaction with LC3 or the mediation of fission. See Chapter 1 for a review of 
these scenarios. 
In cell lines, we did not see recruitment of Parkin to mitochondria when we used PD-related 
PINK1 or Parkin mutants. It could thus be expected that mutations in PINK1/Parkin affect mitophagy. 
Thus far, there is no direct evidence of impaired mitophagy in the brain of PD patients with such 
mutations. An increase in the expression of PINK152 has, however, been reported in PD brain (Muqit et 
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al., 2006). If our model is correct, this may suggest that there may be a deficit in mitophagy in PD by 
virtue of the fact that cleaved PINK1 may prevent Parkin translocation. We thus postulate that 
mitochondrial quality control by PINK1/Parkin cannot take place sufficiently in PD, leading to an 
accumulation of ‘sick’ mitochondria over time. These sick mitochondria, in turn, damage other cellular 
































































2.4.1. Methods for part I  
Molecular Cloning and Transfections. Human PINK1 cDNA (Ori-Gene) was subcloned into 
mammalian expression vector pIRES2-EGFP and its derivative with IRES-EGFP was removed. An HA 
epitope tag was inserted into the frame at the C terminal of PINK1 by PCR. Human DJ-1 and parkin 
cDNAs (OriGene) were subcloned into pRK5-myc vector. PINK1 point mutations (PINK1A217D, PINK1G309D, 
PINK1L347P, and the PINK1 dead kinase PINK1K219M) were generated using the QuikChange II Site-
Directed Mutagenesis Kit (Stratagene). Full-length PINK1 cDNA was cloned into a pshuttle-1–3XFlag-
IRES-GFP vector (Stratagene) to generate Flag-tagged PINK1. To generate V5-tagged PINK1, WT full-
length PINK1 cDNA was cloned into a pcDNA3.1 vector (Invitrogen). The parkin RING2 deletion construct 
(ParkinΔR2) was a gift from Hardy Rideout (Columbia University, New York). PINK1-ECFP, Parkin-EYFP, 
and EGFP-Parkin were constructed by inserting PINK1 and Parkin cDNA into the frame of the 
mammalian expression vectors pAmCyan1-N1, pZsYellow1-N1, and pEGFP-C2 (Clontech), respectively. 
All constructs were confirmed by sequencing. DNA transfections were performed using FuGENE 6 
(Roche Diagnostics GmbH) or Lipofectamine 2000 (Invitrogen), following the manufacturer’s guidelines. 
Generation of PINK1 N27-Inducible Cells. The expression of human WT and mutant PINK1 in 
the 1RB3AN27 (N27) neurons (provided by Anumantha Kanthasamy, Iowa State University, Ames, IA) 
was accomplished using an ecdysone-inducible system (Stratagene) with some modifications to the 
manufacturer’s instructions: First, N27 were stably transfected with the repressor pERV3 vector to 
express constitutively the ecdysone receptor and the retinoid-X-receptor heterodimer. Transfected cells 
were selected for a couple of weeks by the addition of G418 (500 µg/mL;Gibco). The most inducible clone 
was selected for the subsequent stable transfection of the modified pEGSH vector, which contains the 
ecdysone-responsive element that, in the absence of ponasterone A, tightly suppresses transcription. 
pEGSH vector (Stratagene) was modified by introducing a DNA fragment containing IRES-emerald GFP 
(provided by Pradip Roy-Burman, University of Southern California, Los Angeles). The cDNAs of full-
length human PINK1, PINK1L347P, and PINK1W437X (1) were subcloned into the multiple cloning site. Stably 
transformed cells were selected and maintained in RPMI containing 10% FBS, G418 (500 µg/mL), and 
	   
58 
hygromycin (200 µg/mL). Higher expressors of GFP were selected by a FACSVantage cell sorter (BD 
Biosciences). Each cell type was sorted 3 to 4 times for the top 10% of cells with the highest GFP signal. 
The inducible expression of PINK1 was confirmed using  immunocytochemistry, immunoblotting, and 
quantitative real-time PCR (with primers designed to amplify a segment that is common to both rat Pink1 
and human PINK1: Fwd 5′-TGTCAGGAGATCCAGGCAATT-3′ and Rev 5′- 
GCATGGTGGCTTCATACACAGC-3′). 
Cell Culture. Human neuroblastoma SH-SY5Y and M17 cells were maintained in DMEM/Ham's 
F-12 medium (Invitrogen) supplemented with 10% FBS and 1% (vol/vol) penicillin-streptomycin. HeLa 
and HEK293T cells were maintained in DMEM supplemented with 10% FBS and 1% (vol/vol) penicillin-
streptomycin. Primary cortical neuronal cultures were done as previously described (2). 
Immunoblotting. For Western blot analyses, 50 µg of protein from whole-cell lysates were 
separated on 4–16% Bis-Tris gels and electroblotted. Immunoblots were probed with primary antibodies 
(PINK1 (100-494; Novus), Parkin, GAPDH, Hsp60, and HA (Santa Cruz Biotechnology),TIM23, 
cytochrome c, and COX-I (Invitrogen)). Incubation with fluorescent-conjugated secondary antibodies was 
followed by infrared detection (Odyssey Detection System; Li-COR). For isolated mitochondria, 25 µg of 
protein were loaded. For protease protection assay, 50 µg of mitochondrial protein from HEK293T cells 
were treated with 0.2, 2, or 20 µg/mL proteinase-K for 20 min on ice. Then, the proteinase-K was 
inactivated with 2 mM phenylmethanesulphonylfluoride for 10min on ice. For immunoprecipitation, cells 
were harvested and resuspended in lysis buffer (50 mM Tris, pH 7.4/150 mM NaCl/1 mM EDTA/0.1% 
Triton-100) supplemented with 2Å~ protease inhibitor (Roche) and homogenized with a Dounce 
homogenizer (Kontes Glass Co, Vineland, NJ). The cell homogenates then were centrifuged at 11,000 x 
g for 10 min, and cell lysates were collected. Cell lysates first were precleared with protein A & G agarose 
beads for 1 h at 4 °C and then were incubated with rabbit anti-Flag or rabbit anti-V5 antibody for at least 2 
h at 4 °C with constant agitation, followed by 4 washes of 20 min each with the lysis buffer. The beads 
that captured PINK1 complexes were mixed with an equal amount of 2x SDS sample buffer and heated at 
95 °C for 10 min to elute the complex proteins. Eluents were used for SDS/PAGE, followed by Western 
blot analyses with mouse anti-Flag antibody (Ab; Sigma). Human Parkin antibody (sc-32282; Santa Cruz) 
was used for the detection of endogenous Parkin. 
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Immunostaining. Cells were grown on coverslips, fixed in 4% paraformaldehyde, permeabilized 
with 0.1% Triton-X100, and blocked with 5% BSA. Primary antibodies used were PINK1 (Novus), myc 
(9E10; Abcam), EndoG (ProSci), TOM20 (BD Biosciences), α- and γ-tubulin (Sigma-Aldrich), calreticulin 
(AbCam), and tyrosine hydroxylase (Chemicon-Millipore). Samples were analyzed using a Zeiss LSM510 
Laser Scanning Confocal Microscope (Carl Zeiss Microimaging, Inc.). Z-sections were acquired (0.7-µm 
interval), and final images were obtained after merging planes. To label mitochondria, 25 nM MitoTracker 
Red CMXRos or MitoTracker Deep Red 633 (Invitrogen) was added to the medium for 25 min at 37 °C, 
followed by a quick wash in PBS and fixation. To study mitochondrial morphology and distribution, images 
from at least 20 random fields from 3 independent experiments were taken and analyzed. 
Live-Cell Organelle Marker and Immunofluorescence Microscopy. To study the subcellular 
distribution of Parkin-eYFP and eGFPParkin on induction of PINK1 expression, N27-stable cells were 
grown on 4-welled chamber slides (Nalgene Nunc International). Single XY scans of live cells were 
acquired in sequential scanning mode on a Zeiss LSM510 Laser Scanning Confocal Microscope (Carl 
Zeiss Microimaging, Inc.) equipped with a 63Å~/1.25 NA oil lens. Z-sections were acquired (0.7-µm 
interval), and final images were obtained after merging planes. All signals were acquired in the same 
order with all laser lines at 10% intensity and with the following parameters: excitation 488 nm, emission 
read 513–527nm for Parkin-GFP; excitation 543 nm, emission read 603–750 nm for MitoTracker Red; 
and excitation 515 nm, emission read 406–480 nm for Parkin-eYFP. Samples with 1 of the fluorophores 
omitted were scanned first to establish gain and offset acquisition settings to ensure that each acquired 
signal was caused by the emission by individual fluorophores only. All scans were acquired using 
identical settings and were compiled into panels and processed identically by adjusting image brightness 
and contrast in Adobe Photoshop 7.0 (Adobe Systems, Inc.).  
Live-Cell ΔΨm microscopy. Cells grown on 4-welled chamber slides were incubated in regular 
growth medium with 10 nM TMRM (Invitrogen) for 20 min. Images were acquired on a Zeiss LSM510 
Laser Scanning Confocal Microscope (Carl Zeiss Microimaging) equipped with live-imaging station (CTI-
Controller 3700 and incubator S; Leica) with temperature controller (heating insert P;PeCon). Acquisition 
parameters were chosen to allow the use of minimal laser intensity to prevent photodamage. TMRM 
signal was acquired at 37 °C using excitation and emission wavelengths of 543 and 575 nm, respectively. 
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A series of optical z-sections was taken at 0.5-µm intervals capturing the entire signal of each cell. 
Imaging following mitochondrial depolarization with the uncoupling agent CCCP (100 nM) was used to 
confirm minimal background fluorescence. All imaging settings were kept constant for all experiments to 
allow direct comparison between control and treated cells expressing or not expressing Parkin-GFP.  
TMRM Fluorescence Quantification. Single-cell shapes were outlined and selected for each 
field. The integrated morphometric analysis feature in Image J (National Institutes of Health) was used to 
quantify the fluorescence intensity of each individual z-plane, yielding a numerical value representing 
signal intensity. The sum of all z-plane signals yielded the TMRM intensity value for individual cells.  
Electron Microscopy. SH-SY5Y cells co-transfected with PINK1 and myc-Parkin were fixed in 
4% paraformaldehyde and 0.5% glutaraldehyde for 20 min at room temperature, stained sequentially 
in 2% osmium oxide and 1% uranyl acetate, dehydrated in a series of ethanol washes, and embedded in 
Spur resin for sectioning and analysis. Samples were analyzed with an electron microscope (Bio-Imaging 
Resource Center, Rockefeller University, New York). For immuno-EM, anti-PINK1 antibody (100-494) and 
anti-myc antibody (9E10) were used for overnight labeling at 4 °C; then HRP-labeled secondary 
antibodies were applied for 1 h at room temperature. The 3,3ʹ-diaminodbenzidine substrate was used for 
color development, followed by EM procedure. 
Fluorescence Lifetime Imaging Microscopy. FLIM was performed as described previously (3). 
Statistical Analysis. Differences among means were analyzed using 1- or 2-way ANOVA, 
followed, when showing significant differences, by pair-wise comparisons between means using 
Newman–Keuls post hoc testing. When only 2 groups were compared, Student’s t test or Mann-Whitney 
test was used. In all analyses, the null hypothesis was rejected at the 0.05 level. 
 
2.4.2. Methods for part II  
Plasmids. Untagged and HA-tagged PINK1 plasmids used for in vivo expression and in vitro 
transcription/translation were described previously (Becker et al., 2012). The Flag-tagged PINK1 
constructs were generated as follows: Full-length human PINK1 cDNA (OriGene) was cloned into a 
pshuttle-1–3×Flag-IRES-GFP vector (Stratagene) to generate C-terminally Flag-tagged PINK1 (PINK1-
Flag). Flag-tagged PINK1 fragment constructs (PINK1 156-507-Flag, PINK1 1-155-Flag, PINK1 156-309-
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Flag, PINK1 310-428-Flag and PINK1 429-581-Flag) were generated by PCR. All constructs were 
confirmed by sequencing. 
Antibodies. Antibodies used in the study were as follows: PINK1 and TOM70 (Novus), SMAC 
(Santa Cruz), TOM20 and TIM23 (BD transduction laboratories), PKC and Flag (Sigma), Parkin (Abcam).  
Cell culture and transfection. HeLa and HEK293T cells were cultured in DMEM (Gibco) 
supplemented with 10% heat-inactivated FBS (Gibco) supplemented with 100 Units/ml of penicillin and 
100 µg/ml of streptomycin (Gibco). Transient transfection was performed with Lipofectamine LTX 
(Invitrogen) or Lipofectamine 2000 (Invitrogen) according to manufacturer’s protocol. HeLa cells stably 
expressing YFP-Parkin were a generous gift from Dr. R.J. Youle, NIH, Bethesda, MD, USA.  
Cell fractionation. HeLa cells were harvested by trypsinization and washed 3 times with ice-cold 
PBS (5 min, 200 × g, 4°C). Cells were disrupted on ice in a glass-glass homogenizer with 30 strokes in 
210 mM Mannitol, 70 mM Sucrose, 1 mM EGTA, 5 mM Hepes, pH 7.2 supplemented with protease 
inhibitor cocktail (Roche). Unbroken cells were pelleted (10 min 1500 × g, 4°C) and subjected to 
homogenization for a total of 3 times. The supernatants were combined and spun (10 min 1500 × g, 4°C). 
An aliquot of the supernatant was collected (total extract) and the rest was subjected to centrifugation (15 
min 15000 × g, 4°C) to collect the cytoplasmic fraction in the supernatant and the crude mitochondria in 
the pellet. The pellet was then resuspended in wash buffer (250 mM Sucrose, 1 mM EGTA, 10 mM Tris, 
pH 7.5 and supplemented with protease inhibitor cocktail (Roche) and centrifuged again (15 min 15000 × 
g, 4°C) to pellet crude mitochondria. 
Proteinase K assay. HeLa cells were transiently transfected with PINK1 and harvested 24 h post 
transfection. Crude mitochondrial fraction was isolated as described above. Half of the fraction was 
diluted in isotonic buffer (250 mM Sucrose, 10 mM Hepes, 10 mM KCl, 2 mM MgCl2, 1 mM EDTA, pH 
7.4) supplemented with 0.5 % Triton X-100; the other half was diluted without Triton X-100. After 10 min 
of incubation on ice, samples were aliquoted and treated with 0-200 µg/ml of Proteinase K for 30 min on 
ice, followed by addition of 5mM of PMSF to terminate the digestion. 
Western blotting. Samples (15-30 µg of protein) were run on precast 4-12% Bis-Tris gels 
(Invitrogen) with MOPS buffer according to manufacturer’s protocol. Proteins were transferred onto a 0.45 
µm nitrocellulose membrane (or PVDF when probed with the anti-SMAC antibody). Membranes were 
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blocked with blocking buffer (Rockland), incubated with primary antibodies as indicated and fluorescent-
conjugated secondary antibodies 1:5000 (Odyssey). Signals were then scanned with the Odyssey 
infrared imager (Odyssey Detection System; Li-COR). 
Alkaline extraction. Crude mitochondria from HeLa cells transfected with HA-tagged wild-type 
PINK1 were re-suspended in 1 mL of 0.1 mM Na2CO3 at pH 7.3, 10, 11.5 or 12, respectively. After 30 min 
incubation on ice, samples were ultra-centrifuged (1 h, 100000 × g, 4°C). The supernatant was then 
concentrated on centrifugal filters with10 kDa cutoff (Millipore). Both supernatant and pellets were 
resuspended in SDS sample buffer and run on 4-12% Bis-Tris gels (Invitrogen). 
Co-Immunoprecipitation. HEK293T cells were transfected with PINK1-Flag or Flag-tagged 
PINK1 fragments using Lipofectamine 2000 (Invitrogen) according to manufacturer’s guidelines. After 24 
h, cells were harvested and resuspended in lysis buffer (50 mM Tris pH 7.4, 50 mM NaCl, 1 mM EDTA, 
0.1% Triton-X100) supplemented with 2 × protease inhibitor (Roche) and agitated at 4 °C for 1h. Cell 
homogenates were then centrifuged (10 min, 11000 × g) and cell lysate supernatants were collected. Cell 
lysates were then incubated with prewashed anti-FLAG M2 affinity gel (A2220; Sigma) overnight at 4 °C 
with constant agitation, followed by washes with lysis buffer. The resins that captured PINK1 complexes 
were then eluted in 2 × SDS sample buffer. 
Immunofluorescence and imaging. 24 h post-transfection, HeLa cells stably expressing YFP-
Parkin were treated with 10 µM CCCP or vehicle DMSO for 2 or 24 h, respectively. Cells were then fixed 
with 4% paraformaldehyde and incubated with primary antibodies and fluorescent secondary Cy3 and 
Cy5 antibodies (Jackson ImmunoResearch) according to the instructions of manufacturer. Images were 
taken using Leica TCS SP5 II confocal microscope and quantified manually as indicated in the figure 
legend. 
Statistical analysis. Difference among means was analyzed by two-way ANOVA analysis 
followed by a Student-Newman-Keuls post-hoc test. Difference among proportions was analyzed by X2. In 
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In the previous chapter, we presented a model whereby PINK1 recruits Parkin to damaged or 
‘sick’ mitochondria. This model is based on studies in cell lines in which we artificially induced 
mitochondrial damage by dissipating ΔΨm with chemicals such as FCCP, CCCP and 
Antimycin/Oligomycin. If it is correct that PINK1/Parkin recognize damaged mitochondria and mediate 
their clearance by autophagy, then one may wonder what the role for PINK1/Parkin might be in primary 
mitochondrial disease, which is a naturally occurring example of ‘sick’ mitochondria. Mitochondrial 
diseases can be caused by mutations in either mitochondrial DNA (mtDNA) or nuclear DNA encoding 
mitochondrial components (DiMauro and Schon, 2003). Pathogenic mutations in mtDNA are often 
present in only some of the thousands mtDNA molecules in a cell. Cells thus carry a combination of wild-
type and mutated mtDNA and, consequently, contain a mix of healthy and ‘sick’ mitochondria, a situation 
called heteroplasmy (DiMauro and Schon, 2003). Why, then, do these ‘sick’ mitochondria not get 
recognized by the PINK1/Parkin system and cleared by autophagy? If they did, cells would simply get rid 
of the ‘sick’ mitochondria, be left with the healthy ones and mitochondrial disease would not exist.  
In this chapter, we examine this question by studying autophagy in so-called homoplasmic 
cybrids. These cytoplasmic hybrid cells contain mitochondria and mtDNA from patients with mitochondrial 
disease in a standard nuclear background. They are created by enucleating patient cells and fusing the 
resulting ‘cytoplasts’ with host cells that contain a nucleus and mitochondria devoid of mtDNA (ρ0 cells). If 
heteroplasmic cells were used as donors, the cybrid clones would have variable proportions of wild-type 
and mutated mtDNA after fusion. It is possible to isolate clones that have from 0% mutant (homoplasmic 
WT) to 100% mutant (homoplasmic mutant) and anything in between (heteroplasmic) mtDNA. They all 
have the same nuclear DNA (Schon et al., 2012).  
For our studies, we used cybrids derived from patients with neuropathy, ataxia, retinitis 
pigmentosa (NARP), mitochondrial encephalopathy, lactic acidosis, strokelike episodes (MELAS) and 
Kearns-Sayre syndrome (KSS). These are all diseases caused by mutations in mtDNA. In general, 
mitochondrial diseases are multisystem diseases, since mitochondria are present in all cell types except 
erythrocytes. As a result of heteroplasmy, there is a threshold effect, which means that a minimum 
number of mutant mtDNAs must be present in a cell before mitochondrial dysfunction occurs. Tissues 
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that are highly dependent on oxidative metabolism, such as brain, heart, skeletal muscle, retina, renal 
tubules and endocrine glands have the lowest thresholds and are the most vulnerable to the effects of 
mtDNA mutations. The proportion of mutant mtDNA present in a specific tissue then determines the 
symptoms and severity of the disease and patients carrying the same mutations can have different 
clinical outcomes (DiMauro and Schon, 2003). 
NARP is caused by a mutation in the ATP6 gene, which codes for a component of ATP synthase 
in the respiratory chain (see Chapter 1.2.1). As a result, ATP synthesis is affected and patients suffer 
from neuropathy, ataxia (lack of voluntary coordination of muscle movements) and loss of vision caused 
by retinitis pigmentosa (Schon et al., 2012). 
There are many gene mutations that can cause MELAS syndrome, but a common one is the 
m.3243A>G mutation (Davis and Sue, 2011). This mutation is within a tRNA gene and this, consequently, 
decreases mitochondrial protein synthesis in general. All proteins encoded by mtDNA are components of 
the OXPHOS system, and a mutation like this thus affects the entire respiratory chain. As a consequence, 
pyruvate is not processed and accumulates in the cytosol, where it is converted to lactate and accounts 
for the increased lactic acid found in the blood of patients (lactic acidosis) (Schon et al., 2012).  
Kearns-Sayre syndrome is associated with progressive external ophtalmoplegia (inability to move the 
eyes), ptosis (drooping eyelids), retinitis pigmentosa and heart block. The onset is before 20 years of age; 
this disease usually occurs sporadically, i.e. it is not maternally inherited. KSS is associated with a single 
mtDNA deletion that varies in size and can be up to 10 kb long. Interestingly, about one third of patients 
has a common deletion of 4977 bp (Davis and Sue, 2011). The deletion is thought to arise during 
embryogenesis and then penetrate all three germ layers (DiMauro and Schon, 2003). 
 
If mitophagy does indeed clear damaged mitochondria, then the homoplasmic mutant cybrids that we 
used for our studies should have constitutively high levels of mitophagy. We started by assaying 
autophagy in our cell lines, but did not find an increase of autophagy/mitophagy at baseline. Instead, we 
discovered that we could induce a widespread mitophagy in response to two conditions: (1) the loss of 
ΔΨm, resulting in recruitment of Parkin to the organelle, and (2) the activation of macroautophagy through 




3.2.1. Cells carrying mtDNA mutations do not have elevated levels of macroautophagy.  
We employed a panel of cybrid cell lines, in which a human 143B osteosarcoma nuclear 
background was depleted of all endogenous mtDNA (King and Attardi, 1989) and repopulated with 
patient-derived mtDNAs (Pallotti et al., 2004). The WT (FLP6a39.2), Δ (FLP6139.32), A3243G (RN164), 
T8993G (JCP261), and ρ0 (143B206) cell lines have been described previously (Gilkerson et al., 2008; 
Pallotti et al., 2004; Santra et al., 2004). Briefly, the WT cell line carries homoplasmic WT-mtDNA; the Δ 
cell line is homoplasmic for a 1.9 kb Δ-mtDNA from a patient with KSS; the A3243G cell line is 
homoplasmic for its respective point mutation derived from a patient with MELAS; the T8993G cell line is 
homoplasmic for a point mutation derived from a patient with NARP; and the ρ0 cell line is depleted of all 
mtDNA. 
 We infected each cell line with a lentivirus containing LC3-GFP (Twig et al., 2008) and established 
clonal cultures  to ensure consistent LC3-GFP expression. Cytosolic LC3-I is recruited to the 
autophagosome upon induction of autophagy via conjugation to phosphatidylethanolamine, producing the 
autophagic LC3-II form (Boya et al., 2005). When fused to GFP (~27 kDa), the two LC3 forms migrate on 
gels with apparent molecular weights of ~43 and ~41 kDa, respectively. In western blots of cells 
expressing LC3-GFP-II, a band of ~27 kDa is also observed, as fusion of the autophagosome with the 
lysosome results in cleavage of LC3-GFP-II, producing "free" GFP as an additional marker of autophagy 
(Mizushima et al., 2010). When visualized by fluorescence microscopy, LC3-GFP-I is present diffusely in 
the cytosol; upon autophagic induction, LC3-GFP-I is processed to LC3-GFP-II and recruited to 
autophagosomes as discrete punctae, providing a useful visual marker of autophagosomes (Kim and 
Lemasters, 2011; Shvets and Elazar, 2009). 
 Upon anti-GFP western blotting of lysates from the cybrid cell lines, we observed a predominant band 
for cytosolic LC3-GFP-I at ~43 kDa in all samples (Fig. 3.1A). We also observed bands corresponding to 
the autophagic LC3-GFP-II (~41 kDa) and free GFP (~27 kDa) species, but at lower levels (i.e. a ratio of 
(LC3-GFP-II + free GFP)/(LC3-GFP-I) of ~0.2-0.5), with only Δ cells showing a 2.5-fold higher ratio than 
WT (Fig. 3.1B, gray bars). In agreement with the western blotting, live-cell fluorescence microscopy 
revealed that none of the cell lines examined had any appreciable proliferation of autophagosomes  
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(Suppl. Fig. 3.S1A, upper panels). Even though the Δ cells had increased amounts of autophagic LC3-
GFP-II and free GFP (Fig. 3.1A), confocal fluorescence microscopy showed that there was no difference 
between WT and Δ cells in the number or size of the LC3-GFP punctae (Figs. 3.1C and 3.1D). Thus, our 
	  
Figure 3.1. Autophagic status of 
cybrid cell lines. (A) Western blot 
analysis of total protein (20 µg per 
lane), probed with anti-GFP (n=4); 
lower panel shows anti-tubulin 
loading control. (B) Quantification of 
bands from anti-GFP Western 
blotting using ImageJ. Band 
intensities of autophagic LC3-GFP-II 
and free GFP bands were combined 
and expressed as a ratio with 
cytosolic LC3-GFP-I (means of n = 4 
± SD). * indicates difference from 
untreated cells (p<0.001, Newman-
Keuls post-hoc test following a two-
way repeated measure ANOVA). (C) 
Confocal fluorescence microscopy of 
fixed cells from LC3-GFP-infected 
WT and Δ cybrid cell lines grown in 
the absence or presence of 250 nM 
rapamycin for 48 h (n=4). Scale bar = 
20 µm. (D) Quantitation of the 
average number of LC3-GFP 
autophagosome punctae per cell and 
the average size of LC3-GFP 
autophagosome punctae (means of n 
= 4 ± SD). * Indicates difference from 
untreated cell lines (p=0.034, 
Newman-Keuls post-hoc test 





data indicate that there is no increase in autophagy in cells carrying mtDNA mutations relative to WT 
cells. Western blotting against endogenous LC3 revealed that both Δ and ρ0 cells actually have 
decreased endogenous LC3 levels, compared with two independently-derived WT lines (Suppl. Fig. 
3.S1D). 
 
3.2.2. Rapamycin challenge reveals increased macroautophagy in Δ cells.  
As none of the cloned cybrid lines had elevated levels of autophagosomes, we asked whether 
they could respond to an autophagic stimulus. We therefore treated them with the mTORC1 inhibitor 
rapamycin (Kim et al., 2002), a canonical inducer of macroautophagy. 
 Treatment with 250 nM rapamycin for 48 hours (Suppl. Fig. 3.S1B) caused no appreciable 
increase in LC3-GFP-II in WT, A3243G, T8993G, or ρ0 cells, but Δ cell lysates revealed a striking ~4-fold 
increase in the LC3-GFP-II and free GFP bands (Figs. 3.1A and 3.1B, black bars). We obtained similar 
results both by LC3-GFP fluorescence microscopy (Suppl. Fig. 3.S1A, lower panels) and by 
immunolabeling against endogenous LC3-II (Suppl. Fig. 3.S1C). Using confocal fluorescence microscopy, 
compared to untreated cells, neither rapamycin-treated WT nor Δ cells showed significant increases in the 
number of autophagosomes per cell, but rapamycin-treated Δ cells displayed an increase in the average 
size of autophagosomes (61±5 pixels vs. 27±10 pixels in untreated Δ cells) (Fig. 3.1D), reflecting a 
proliferation of numerous large LC3-GFP punctae (Fig. 3.1C). Similar results were obtained using 
uncloned mass culture of LC3-GFP-infected WT and Δ cybrids (Suppl. Fig 3.S1E), indicating that these 
results were not confined to any particular clonal cell line. To determine the nature of this increased 
autophagosomal content, we examined Δ cell response to chloroquine, an inhibitor of autophagosomal 
degradation (Degtyarev et al., 2008) (Suppl. Fig. 3.S2A-C), as well as lysosomal acidification in response 
to rapamycin (Suppl. Fig. 3.S2D). These experiments demonstrated that the observed proliferation of 
autophagosomes in rapamycin-treated Δ cells was due to a bona fide increase in autophagic flux, rather 
than to a defect in autophagosome maturation caused by the loss of mitochondrial function in Δ cells. 




3.2.3. Autophagosomes within rapamycin-treated Δ cells contain mitochondria with severely 
decreased mitochondrial transmembrane potential.  
 To determine whether the autophagic induction observed in rapamycin-treated Δ cells resulted in 
mitophagy, we examined LC3-GFP-infected cells that had been counterstained with MitoTracker Red. As 
expected from Fig. 3.1, only rapamycin-treated Δ cells showed a proliferation of large autophagosomes, 
as demonstrated by the ~2-fold increase in the average size of autophagosomes (Fig. 3.1D); strikingly, 
many of these abnormally large structures were MitoTracker-positive (Fig. 3.2A, arrowheads), indicating 
that these autophagosomes had indeed engulfed mitochondria. Quantitative image analysis revealed that 
	  
Figure 3.2. Confocal microscopy of 
mitochondria and autophagosomes from 
WT and  Δ  cells. (A) WT and Δ cybrid cell 
lines incubated in the absence or presence 
of 250 nM rapamycin for 48 h, followed by 
staining with MitoTracker Red (MTR) (n=4). 
Scale bar = 20 µm. Note co-localization of 
mitochondria with LC3-GFP-positive 
autophagosomes (arrowheads) (B) 
Quantification of mitochondria colocalizing 
with LC3-GFP punctae (means of n = 4 ± 
SD). * Indicates difference from all other cell 
lines (p=0.005, Newman-Keuls post-hoc test 





the rapamycin-treated Δ cells had, on average, 23±7% of their total mitochondria colocalizing with 
autophagosomes, compared with just 4±2% for untreated Δ cells, which was similar to the value in 
rapamycin-treated WT cells (5±1%) (Fig. 3.2B). Collectively, these findings demonstrate robust uptake of 
mitochondria by autophagosomes in rapamycin-treated Δ cells.  
We examined the involvement of the mitochondrial-specific Parkin and p62 autophagic factors in 
this mitophagy. Following treatment with rapamycin, GFP-Parkin was recruited to mitochondria of Δ cells 
(Fig. 3.3A). WT cells showed a diffuse GFP fluorescence throughout the cell that was essentially 
unchanged upon treatment with rapamycin. Untreated Δ cells showed a mosaic distribution of 
fluorescence, with some cells showing punctate signals that colocalized with MitoTracker (Fig. 3.3A, 
arrows), while rapamycin-treated Δ cells displayed a striking recruitment of GFP-Parkin to large 
mitochondria (Fig. 3.3A, arrowheads). Anti-p62 immunolabeling showed a strong signal only in 
rapamycin-treated Δ cells, appearing as large punctae which frequently colocalized with mitochondria 
(Fig. 3.3B, arrowheads). Moreover, p62 immunolabeling also showed colocalization with LC3-GFP 
autophagosomes in rapamycin-treated Δ cells (Fig. 3.3C, arrowheads). These experiments demonstrate 
that the autophagic uptake of mitochondria in rapamycin-treated Δ cells was mediated by Parkin and p62. 
Since Parkin-mediated mitophagy would presumably require the loss of ΔΨm (Narendra et al., 
2008, 2010; Vives-Bauza et al., 2010), we examined basal ΔΨm in the cybrid lines using tetramethyl 
rhodamine ester (TMRE). Notably, Δ cells had the lowest TMRE fluorescence of all the cell lines studied 
(Fig. 3.4A and B). WT cells maintained an average peak fluorescence intensity of 446±194 units, whereas 
Δ and ρ0 cells (both with essentially no respiratory chain function (Pallotti et al., 2004)) maintained low 
peak TMRE values (138±53 and 234±70, respectively), similar to values in which ΔΨm was dissipated 
completely by the protonophore uncoupler carbonyl cyanide m-chlorophenylhydrazone (CCCP) (148±85 
units). On the other hand, T8993G cells (with relatively intact respiratory chain function (Mattiazzi et al., 
2004)) and A3243G cells (with ~30% residual respiratory chain function (King et al., 1992)) exhibited 
more WT-like peak TMRE values (280±76 and 448±43, respectively). Live-cell imaging essentially 
recapitulated these results (Fig. 3.4C). Thus, the strong autophagic induction observed in Δ cells 





Figure 3.3. Confocal fluorescence microscopy of Parkin and p62 in mitochondrial autophagy. (A) 
WT and Δ cells were transiently transfected with GFP-Parkin, grown in the absence or presence of 
rapamycin, and stained with MitoTracker Red (n=2). Scale bar = 20 µm. (B) WT and Δ cells were grown 
in the absence or presence of rapamycin, immunolabeled with anti-p62 antibody, and stained with 
MitoTracker Red. Note recruitment of p62 to large, swollen mitochondria (arrowheads) (n=2). (C) 
Confocal fluorescence microscopy of LC3-GFP-infected WT and Δ cells grown in the absence or 




















































3.2.4. mTOR inhibition and loss of ΔΨm are both necessary for mitophagy.  
Rapamycin appears to induce mitophagy in Δ cells by a mechanism involving low ΔΨm. But if the 
loss of ΔΨm were the sole requirement for mitophagy, why did Δ cells show no elevated basal level of 
macroautophagy? We therefore asked whether loss of ΔΨm, in and of itself, was sufficient to induce 
autophagy, by treating WT cells with low levels of CCCP, which is sufficient to collapse ΔΨm, inducing 
	  
Figure 3.4. Analysis of mitochondrial transmembrane potential in cybrid cell 
lines. (A) Average peak TMRE fluorescence values of cybrid cell lines (means of n = 
3 ± SD). Peak fluorescence values were normalized to unstained cells for each 
experiment. * indicates difference from WT, (p<0.001, Dunnett post-hoc test following 
a one-way ANOVA). (B) Representative flow cytometry experiment of cybrid cell lines 
incubated with 2.5 nM TMRE. 50,000 events per cell line. Histogram (Y-axis) is 
expressed as % of cells at maximum value. (C) Live-cell fluorescence microscopy of 
cybrid cell lines incubated with 2.5 nM TMRE. Note low TMRE fluorescence of Δ cells. 




recruitment of Parkin to mitochondria (Narendra et al., 2008; Vives-Bauza et al., 2010) without adversely 
affecting other cellular functions (Maro et al., 1982). In WT cells incubated with increasing concentrations 
of CCCP (up to 10 µM), we observed little or no change in the levels of LC3-GFP-II by anti-GFP western 
blotting, relative to untreated WT cells (Fig. 3.5A). Thus, CCCP treatment alone was insufficient to induce 
macroautophagy. (On the other hand, treatment of WT cells with exceedingly high levels of CCCP [100 
µM] resulted in proliferation of autophagosomes and striking increases in LC3-GFP-II relative to untreated 
WT cells (Suppl. Fig. 3.S3A); however, these concentrations of CCCP affect microtubule dynamics (Maro 
et al., 1982) and lysosomal permeability (Zhang et al., 2000), and as such are not specific to 
mitochondrial ΔΨm.) 
 This lack of autophagic induction prompted us to consider other potential signaling requirements for 
mitochondrial autophagy beyond the collapse of ΔΨm. While Δ cells constitutively maintain a low ΔΨm, 
they only induced mitophagy when challenged with rapamycin. Accordingly, we examined mTORC1 
signaling, which controls macroautophagy, in our cells. When mTORC1 kinase signaling is active (i.e. 
macroautophagy is repressed), downstream targets are phosphorylated, including the ribosomal S6 
protein (Schieke et al., 2006). In all CCCP-treated WT cells, we observed a strong band for phospho-S6 
(Fig. 3.5A), consistent with the lack of 
autophagic induction in response to 
CCCP treatment observed above. 
  We then monitored mTORC1 
signaling in our panel of mutant cybrids, 
including the rapamycin-treated Δ cells 
that had displayed robust autophagic 
induction. In agreement with our previous 
results (Fig. 3.1), all untreated cell lines 
maintained a strong phospho-S6 signal, 
indicating that mTORC1-mediated 
signaling was active (Fig. 3.5B), 
	  
 
Figure 3.5. Autophagy and mTORC1 signaling. (A) Western 
blot analysis of lysates from WT cells (20 µg) incubated for 1 h 
with increasing concentrations of CCCP, probed with anti-GFP, 
anti-phosophoS6, and anti-tubulin antibodies (n=2). (B) 
Western blot analysis of lysates from cybrid cell lines incubated 
in the absence or presence of 250 nM rapamycin for 48 h, 




precluding the induction of macroautophagy. However, in rapamycin-treated cells, none of the samples 
exhibited a signal for phospho-S6, indicating a complete inhibition of mTORC1 signaling, allowing for 
induction of macroautophagy (Fig. 3.5B). In spite of the derepression of mTORC1 in all of our cell lines, 
autophagy was induced only in the Δ cells, but not in the WT, T8993G, A3243G, or ρ0 cells, indicating that 
mTORC1 inhibition alone is not sufficient to induce mitochondrial autophagy. 
 Thus, neither the loss of ΔΨm alone, nor the inhibition of mTORC1 alone was sufficient to induce 
mitophagy in Δ cells; both were required. 
 
3.2.5. Chemical uncoupling does not fully recapitulate the genetic loss of ΔΨm.  
These data demonstrate that although Δ cells have a severely impaired basal ΔΨm, mitophagy is 
induced only upon the addition of rapamycin. Accordingly, we hypothesized that the autophagic induction 
in rapamycin-treated Δ cells was due to the synergistic combination of the loss of ΔΨm coupled with 
mTORC1 inhibition. To test this hypothesis, we examined whether CCCP-mediated loss of ΔΨm, 
combined with rapamycin treatment, might recapitulate the autophagic phenotype in a WT mtDNA 
background. As expected, neither treatment of WT cells with 10 µM CCCP alone, nor with 250 nM 
rapamycin alone, yielded the proliferation of large autophagosomes that we saw in rapamycin treated Δ 
cells (Figs. 3.6A and 6B). Contrary to our expectations, however, treatment first with rapamycin for 48 
hours followed by CCCP for 1 hour also did not show autophagic induction (Fig. 3.6A and B). We 
therefore attempted to mimic more closely the constitutive loss of ΔΨm in Δ cells by incubating WT cells 
first with CCCP for one hour and then treating the cells with rapamycin for 48 hours in the presence of 
CCCP, but in spite of the presence of both agents, autophagic induction was still minimal (Figs. 3.6C and 
D). When we examined the WT cells that had been treated with CCCP for short (1 h) or long (49 h) 
periods for colocalization of autophagosomes with mitochondria (Suppl. Fig. 3.S3B), they displayed few 
colocalizing LC3-GFP punctae (Suppl. Fig. 3.S3C). Furthermore, CCCP did not induce the formation of 
autophagosomes in either of two independent WT cell lines, as assayed by anti-LC3-II immunolabeling  
(Suppl. Fig. 3.S3D). 
 Thus, in no case did CCCP treatment, whether short- or long-term, either singly or in combination 
with rapamycin, elicit an autophagic induction in WT cells equivalent to that seen in rapamycin-treated Δ 
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cells. Thus, there appears to be an essential difference in the 143B osteosarcoma background between 
chemically-induced dissipation of ΔΨm by CCCP and naturally-occurring loss of ΔΨm due to authentic 
mtDNA mutations. 




and autophagy. (A) Top, 
schematic of experiment. 
Confocal fluorescence 
microscopy of WT cells 
grown in the absence or 
presence of 10 µM CCCP 
for 1 h, without or with 
pretreatment with 
rapamycin for 48 h. (n=3) 
Size bar = 20 µm. (B) 
Quantitation of the 
average number of LC3-
GFP autophagosome 
punctae per cell and 
average size of LC3-GFP 
autophagosome punctae 
of the cells in A (means of 
n = 3 ± SD). Δ cell data 
from Fig. 1. (C) Top, 
schematic of experiment. 
Confocal fluorescence 
microscopy of WT cells 
grown in the absence or 
presence of 10 µM CCCP 
for 49 h, in the absence or 
presence of rapamycin for 
48 h (n=3). (D) 




3.2.6. Parkin is necessary for mitophagy in cells carrying mtDNA mutations.  
The inability of CCCP to induce mitochondrial autophagy in WT cells raised a mechanistic 
question: what were the relative levels of PINK1 and Parkin in our cell lines? If PINK1 and Parkin were 
greatly decreased or absent in WT or ρ0 cells, no amount of uncoupling would have induced mitochondrial 
autophagy; conversely, if Δ cells had much greater expression of PINK1 and Parkin than other cells, this 
might explain their differential propensity to undergo rapamycin-induced mitochondrial autophagy. 
 We therefore used quantitative reverse transcription PCR (qRT-PCR) to examine PINK1 and 
Parkin mRNA expression in our panel of cybrids (endogenous levels of these proteins are very low and 
thus difficult to observe with antibodies), both constitutively and in response to rapamycin. WT cells 
contained ample amounts of PINK1 and Parkin (more than 4-times as much as in human SH-SY5Y or 
HeLa cells (Chan et al., 2011; Rakovic et al., 2011)). However, basal endogenous transcript levels of 
PINK1 were significantly lower than WT in several of the mtDNA mutant cybrids: an average of 15% of 
WT in T8993G, 26% in A3243G, and 36% in ρ0 cells (Fig. 3.7A). Similarly, basal expression of Parkin was 
frequently lower: 47% in Δ, 35% in T8993G, and only 21% in ρ0 cells (Fig. 3.7A). Treatment with 
rapamycin did not result in significant changes in these levels (Suppl. Fig. 3.S4A and B). 
 Thus, the lack of autophagy in WT cells was probably due not to low levels of PINK1 or Parkin but 
rather to high ΔΨm. However, the lack of autophagy in ρ0 cells (with low ΔΨm) could indeed have been 
due to low levels of PINK1 and Parkin expression, as ρ0 cells had dramatically decreased levels of these 
factors. We therefore examined the ability of the different cybrid lines to recruit Parkin to mitochondria 
(Suppl. Fig. 3.S4C). Upon transfection with GFP-Parkin, we found that both Δ and ρ0 cells had increased 
proportions of cells with mitochondrial recruitment of Parkin (39% and 37%, respectively) compared to 
WT cells transfected in a similar manner (1%) (Fig. 3.7B). As expected, there was little recruitment of 
GFP-Parkin in the A3243G and T8993G cells (Fig. 3.7A), as they had essentially WT levels of ΔΨm. Thus, 
reduced ΔΨm in ρ0 cells causes recruitment of Parkin to mitochondria in a manner identical to that in Δ 
cells when exogenous Parkin is introduced. Upon addition of CCCP, WT, ρ0, Δ, and A3243G cells showed 
dramatic recruitment of Parkin to mitochondria, as expected, given the total collapse of ΔΨm. 
 As Parkin is genetically downstream of PINK1 (Park et al., 2006), we therefore overexpressed 
GFP-Parkin in ρ0 cells to ask if increasing Parkin levels could induce the formation of autophagosomes 
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like that seen in rapamycin-treated Δ cells. As expected, in the absence of exogenous Parkin, rapamycin-
treated WT and ρ0 cells showed very few cytoplasmic LC3-GFP autophagosomes, whereas rapamycin-
treated Δ cells showed a characteristic proliferation of large autophagosomes (Fig. 3.7C). Strikingly, 
however, Parkin-transfected ρ0 cells showed a marked proliferation of LC3-GFP autophagosomes in 
response to rapamycin treatment (Fig. 3.7C). Quantitation of LC3-GFP punctae per cell and average 
puncta size (Fig. 3.7D) confirmed that the addition of Parkin to ρ0 cells results in an autophagic phenotype 
identical to that seen in rapamycin-treated Δ cells. Microscopic analysis of the LC3-GFP autophagosomes 
in Parkin-expressing ρ0 cells revealed that these autophagosomes frequently colocalized to mitochondria, 
with concomitant Parkin recruitment to those organelles (Fig. 3.7E). In agreement with Suen et al. (Suen 
et al., 2010), these results suggest that ρ0 cells are essentially similar to Δ cells in terms of mitophagic 
induction; they merely have less endogenous Parkin. 
 
  
Figure 3.7. PINK1 and Parkin mRNAs in cybrid cell lines. (figure on next page) (A) qRT-PCR analysis of 
endogenous levels of PINK1 (grey) and Parkin (black) transcripts in cybrid cell lines (means of n = 3 ± SD). * 
Indicates difference from WT (p<0.05, Dunnett post-hoc test following a one-way ANOVA). (B) Parkin 
recruitment in cybrid cell lines. Indicated cell lines were transiently transfected with GFP-Parkin and scored for 
their recruitment of Parkin to mitochondria (Fig. 3.S4C) in the absence or presence of 10 µM CCCP. * indicates 
difference from untreated cells (p<0.001, Newman-Keuls post-hoc test following a two-way repeated measure 
ANOVA; n=3). (C) LC3-GFP-expressing WT, Δ, and ρ0 cells were incubated with rapamycin for 48 h. Lower 
panels show cells transiently transfected with mCherry-Parkin (* denote cells expressing mCherry-Parkin [not 
shown in figure]) and provide representative illustration of three independent experiments. Size bar = 20 µm. (D) 
Quantitation of LC3-GFP punctae numbers and puncta sizes per cell, as in Figs. 1D, 6B, and 6D. n=3 
experiments. * indicates difference from untransfected cells (p=0.031, Newman-Keuls post-hoc test following a 
two-way repeated measure ANOVA). (E) LC3-GFP-expressing ρ0 cells were transiently transfected with 
mCherry-Parkin (red) and incubated with rapamycin for 48 h, followed by staining with MitoTracker DeepRed 







3.3. CONCLUSIONS AND DISCUSSION 
Our data indicate that widespread mitophagy (defined here as mitochondria sequestered within 
autophagosomes) can be achieved in cells carrying mtDNA mutations, and that the level of Parkin is 
critically important to the cell’s ability to undergo mitophagy. Strikingly, the loss of ΔΨm, in and of itself, is 
not sufficient to activate mitophagy: the mitophagic response requires the synergistic activation of (1) the 
loss of ΔΨm (activating recruitment of Parkin to mitochondria) and (2) rapamycin-mediated inhibition of 
mTORC1 signaling (activating general macroautophagy), in order to accomplish robust autophagic 
sequestration of dysfunctional mitochondria. Our results indicate that a crucial distinction exists between 
recruitment of Parkin to mitochondria (due to loss of ΔΨm) and uptake of mitochondria within 
autophagosomes (true mitophagy). In other words, while loss of ΔΨm is necessary for mitophagy, it is not 
sufficient. 
 We find that mtDNA mutations resulting in loss of ΔΨm cause increased recruitment of Parkin to 
mitochondria, consistent with and extending recent studies demonstrating that chemical dissipation of 
ΔΨm results in recruitment of Parkin to mitochondria (Chan et al., 2011; Narendra et al., 2008, 2010). 
However, our studies suggest that the loss of ΔΨm alone, whether chemically-induced or as a result of 
mtDNA mutation, does not induce the formation of autophagosomes to any appreciable extent. Basally, 
cells carrying Δ-mtDNAs did not have a significantly greater number or size of autophagosomes than did 
WT cells. We also found that addition of CCCP to WT cells failed to induce proliferation of 
autophagosomes, mirroring findings in cortical neurons (Van Laar et al., 2011). These findings are 
consistent with the observation that Δ-mtDNAs, which cause reduced ΔΨm, can exist in patients without 
being degraded (in fact, they are often amplified preferentially to those containing WT-mtDNA (DiMauro 
and Schon, 2003)). These data argue that an additional signaling requirement exists for autophagic 
degradation of mitochondria in vivo. 
 One such requirement appears to be activation of macroautophagy, via inhibition of mTORC1 
signaling. It was only when mTORC1 was inhibited via rapamycin that we observed a proliferation of 
autophagosomes containing mitochondria. Interestingly, while we examined a series of different 
pathogenic mtDNA mutations, only Δ cells (with low ΔΨm), but not A3243G or T8993G cells (with 
relatively high ΔΨm), showed a robust induction in response to rapamycin. Thus, loss of mitochondrial 
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function per se (i.e. impaired respiratory chain function [A43243G] or reduced ATP synthesis [T8993G]), 
is apparently not an important determinant in recruiting pro-mitophagic factors to mitochondria, consistent 
with recent findings showing a similar lack of mitochondrial Parkin recruitment in mice with transgenic loss 
of mitochondrial function (Sterky et al., 2011). These observations support the idea that loss of ΔΨm is 
sufficient for recruitment of mitophagic factors to the mitochondria, but does not result in widespread 
delivery of mitochondria to autophagosomes. Moreover, in our hands, CCCP treatment of WT cells failed 
to recapitulate the robust mitophagic phenotype seen in Δ cells, underscoring a distinction between 
pharmacological uncoupling and mitochondrial dysfunction due to authentic mtDNA mutations. MtDNA 
mutations represent a constitutive, mitochondrial-specific loss of ΔΨm; accordingly, this system more 
closely mimics the in vivo environment than do chemical uncouplers. 
 Our results also demonstrate the importance of Parkin levels to the cell’s ability to undergo 
mitophagy. Initially, we had expected that ρ0 cells (with a low ΔΨm, similar to that in Δ cells) would display 
mitophagy when challenged with rapamycin, as Δ cells did. However, we subsequently determined that ρ0 
cells had the lowest basal level of Parkin transcripts of all examined cell lines. When exogenous Parkin 
was expressed in ρ0 cells, we found that they were able to recruit Parkin to mitochondria and they 
responded to rapamycin treatment with a mitophagic phenotype identical to that found in rapamycin-
treated Δ cells. These experiments highlight the importance of Parkin expression to the cell’s ability to 
undergo mitophagy. 
  Most mechanistic studies of mitochondrial autophagy to date have relied on overexpression of 
PINK1 and Parkin (Suen et al., 2010), but relatively little is known about the intrinsic biology of these two 
factors. In our analysis of the relative levels of PINK1 and Parkin mRNAs in cybrids, mtDNA mutant cell 
lines, regardless of the specific mtDNA defect, had decreased steady-state levels of these transcripts 
relative to WT cells. Similarly, we found that cells carrying Δ-mtDNAs, as well as ρ0 cells, showed 
decreased levels of endogenous LC3. Knockdown of PINK1 results in mitochondrial dysfunction 
(Friedberg et al., 1985). Our findings suggest that the converse may also be true: mtDNA-mutant cells 
have depressed PINK1 and Parkin expression, as well as decreased endogenous LC3 levels. These data 
suggest that mtDNA-based mitochondrial dysfunction represses transcription of pro-mitophagic factors, 
although the mechanism by which this ‘retrograde’ signaling occurs is currently unknown. 
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 These experiments demonstrate the physiological potential of mitophagy as a therapeutic 
strategy to treat mitochondrial diseases, such as KSS, and neurodegenerative disorders, such as PD. 
High levels of Δ-mtDNAs in substantia nigra neurons of both normal aged individuals (Kraytsberg et al., 
2006) and PD patients (Bender et al., 2006) suggest that the accumulation of Δ-mtDNAs may combine 
with environmental insults and other nuclear mutations to elicit neuronal cell death. We note that gene 
profiling of dopaminergic neurons from patients with sporadic PD revealed a decrease in PINK1 and 
Parkin expression (Simunovic et al., 2009), mirroring the expression of these factors observed here. This 
loss of mitophagic factors may contribute to the persistence of pathogenic mtDNAs in patients. Thus, 
therapeutic approaches in PD employing pro-autophagic agents such as rapamycin may induce 
autophagic degradation of mitochondria carrying Δ-mtDNAs (Malagelada et al., 2010). 
 In summary, our findings suggest a ‘two-hit’ model for mitochondrial autophagy: (1) activation of 
mitophagic targeting (via loss of ΔΨm) and (2) activation of general macroautophagy (via mTORC1 
inhibition). These studies indicate that mtDNA-mediated mitochondrial dysfunction has retrograde 
signaling effects on pro-mitophagic factors such as PINK1, Parkin, and LC3, and that the endogenous 
autophagic machinery is sufficient for autophagy of mitochondria carrying Δ-mtDNAs. These findings 
provide a mechanistic basis for mitochondrial autophagy, suggesting that pro-autophagic strategies may 
be effective against diseases associated with Δ-mtDNAs, such as KSS and PD, using activation of 
endogenous autophagic pathways against physiological forms of mitochondrial dysfunction. 
 
3.4. MATERIALS AND METHODS 
Cell culture. Cells were grown in Dulbecco’s High Glucose MEM (Gibco) with 10% FBS 
(Invitrogen) and supplemented with 10 µg/mL uridine (Sigma) at 37C and 5% CO2. Lentiviral LC3-GFP 
infection was performed as described previously (Twig et al., 2008). LC3-GFP-expressing clonal cybrid 
lines were isolated using cloning rings (Scienceware). Rapamycin, chloroquine diphosphate salt, and 
CCCP were from Sigma. Cells were seeded at 50,000 cells per well in 6-well dishes and allowed to 
recover overnight prior to treatment. Unless otherwise indicated, all rapamycin treatments were for 48 hrs 
at 250 nM. For flow cytometry, 500,000 cells were seeded to 6 cm-diameter dishes overnight, followed by 
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20 min. incubation with 2.5 nM TMRE, washing, and analyzed using a LSRII Cell Analyzer (50,000 events 
per trial). 
Fluorescence microscopy. Cells were incubated with MitoTracker Red CMXRos or LysoTracker 
Red (Invitrogen) for 30 min, washed, and fixed with 4% paraformaldehyde in PBS for 30 min. 
Immunofluorescence microscopy used anti-p62 monoclonal antibody (Abcam 56416), anti-TOM20 
polyclonal antibody (Santa Cruz sc-11415), or anti-LC3B polyclonal antibody (Sigma L7543) in 
conjunction with AlexaFluor-conjugated goat anti-mouse and goat anti-rabbit secondary antibodies 
(Invitrogen). Coverslips were mounted with 50% glycerol in PBS. Confocal microscopy utilized a Zeiss 
LSM510 META inverted confocal microscope with a 40x oil immersion objective. Confocal images were 
adjusted equally using ImageJ. Conventional oil immersion and live cell imaging used an Olympus IX70 
inverted fluorescence microscope and SPOT RT digital camera. Image quantitation was performed using 
MetaMorph. Images were processed equally. For TMRE, live-cell imaging was conducted by incubating 
cells in 2.5 nM TMRE for 20 min. followed by direct visualization. 
Western blotting. Cell lysates were washed with PBS and lysed in cold RIPA buffer (50 mM 
TrisHCl, 150 mM NaCl, 1 mM EDTA, 0.1% SDS) on ice for 5 min. Lysates (20 µg protein) were run on a 
10% SDS-PAGE gel overnight at 25V, 4C. Proteins were transferred to ZetaProbe PVDF (BioRad) for 1 h 
at 100V, 4C. Blots were probed with anti-GFP monoclonal antibody JL-8 (Clontech), anti-phospho 
ribosomal S6 monoclonal antibody (Cell Signaling, catalog # 2215), or anti-tubulin (Sigma) at 1:1000 
dilution in PBS overnight at 4C, followed by incubation with horseradish peroxidase-conjugated goat anti-
mouse antibody (Amersham). Blots were developed using WestDura Extended Duration Substrate 
(Thermo Scientific) and exposed films developed on a Kodak X-Omat. Western blot quantification was 
performed using ImageJ. 
Quantitative reverse transcription. cDNAs were produced using SuperScript® First-Strand 
Synthesis System (Invitrogen). 50 ng of cDNA were run in reactions using PINK1, Parkin, and actin 
primers from Qiagen (Hs_PINK1_2_SG QT01670459, Hs_PARK2_va.1_SG QT01005571, 




Statistical analysis. Differences among means were analyzed using one- or two-way repeated 
measure analysis of variance (ANOVA). When ANOVA showed significant differences, pair-wise 
comparisons between means were tested by Newman-Keuls post-hoc testing while comparisons against 
control group were tested by Dunnett post-hoc testing. In all analyses, the null hypothesis was be rejected 
at the 0.05 level. All statistical analyses will be performed using SigmaStat for Windows-3.5.  
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Figure 3.S1. Rapamycin 
treatment of cybrids. (A) 
Fixed-cell fluorescence 
microscopy of LC3-GFP in 
cybrid cell lines incubated in 
the absence or presence of 
250 nM rapamycin for 48 hrs. 
n= 2. Note that only Δ cells 
show proliferation of 
cytoplasmic autophagosomes. 
Size bar= 20 µm. (B) Live-cell 
fluorescence microscopy of 
WT and Δ cells incubated with 
indicated concentrations of 
rapamycin for 48 hrs. Note 
that Δ cells have strong 
induction of autophagosomes, 
while WT cells do not. Size bar 
= 20 µm. (C) Immuno 
fluorescence microscopy of 
endogenous LC3-II. Note that 
while untreated WT, Δ, or a 
second independent Δ cell line 
("Δ2") do not show 
autophagosomes, both Δ and 
Δ2 cells show cytoplasmic 
autophagosomes in response 
to rapamycin (arrows), 
indicating that cells carrying Δ-
mtDNAs have a general 
autophagic response to 
rapamycin. Size bar=20 µm. 
n=2 experiments. (D) Anti-LC3 
western blotting. While both 
WT and a second independent 
WT cybrid lines ("WT2"), as 
well as A3243G and T8993G 
cells, show no great changes 
in levels of LC3-I or LC3-II, the 
Δ, Δ2, and r0 cell lines show 
greatly decreased levels of 
endogenous LC3. n=3 
experiments. (E) Uncloned 
mass culture of GFP-LC3 










Figure 3.S2. Analysis of autophagic flux. (A) Western blot analysis of lysates (20 mg) from Δ cells incubated 
without or with rapamycin in the presence or absence of 10 mM Cq (n=2). (B) Quantification of bands from anti-
GFP Western blot using ImageJ. Bulk band intensities of cytosolic LC3-GFP-I and autophagic LC3-GFP-II + free 
GFP bands. Cq-alone or Cq+rapamycin treated cells showed a ~3-fold increase in LC3-GFP-II and free GFP 
signals, whereas rapamycin-treated cells without Cq displayed only a ~1.5-fold increase, indicating Δ cells are not 
intrinsically defective in autophagy (C) Live-cell fluorescence microscopy of cells from A. Cq-treated cells 
revealed a more massive accumulation of autophagic vacuoles than untreated or rapamycin-treated cells Scale 
bar = 20 mm. (D) Fixed-cell fluorescence microscopy of lysosomal acidification in cybrids stained with 
LysoTracker Red (n=2). Rapamycin-treated Δ cells displayed a massive increase in the number of LysoTracker-







Figure 3.S3. CCCP and macroautophagy. (A) Upper panel: live-cell fluorescence microscopy of WT cybrids 
incubated with 100 µM CCCP for 1 h, without or with rapamycin for another 48 h. (n=2). Scale bar = 20 µm. 
Compare with Fig. 3.6, where 10 µM CCCP was used. Lower panel: Western blot of cells in A probed with anti-
GFP (n=2). High concentrations of CCCP (which are not specific to Δψm) can elicit proliferation of 
autophagosomes, in contrast to lower concentrations (see Figs. 3.5 and 3.6). (B) TOM20 immunofluorescence 
microscopy. Cells labeled with anti-TOM20 polyclonal antibody (green) and MitoTracker Red. WT and ρ0 cells 
show clear colocalization of the two, whereas WT cells treated with CCCP show little or no signal for MitoTracker. 
These experiments show that MitoTracker is appropriate for visualization of mitochondria in cells with low 
transmembrane potential, but is not suitable for use in cells with completely-dissipated transmembrane potential. 
n= 2 experiments. (C) Left panel: Short-term (1 h) treatment with 10 µM CCCP fails to induce formation of LC3-
GFP punctae. Right panel: Long-term (49 h) treatment with 10 µM CCCP also fails to induce formation of LC3-
GFP punctae. All cells, in all conditions, contain mitochondria. n=3 experiments for each. (D) Immunolabeling 
against endogenous LC3-II shows that CCCP treatment fails to induce autophagosome formation in either of the 





Figure 3.S4. PINK1 and Parkin expression in rapamycin-treated cybrids. (A) qRT-PCR analysis of PINK1 
transcript levels in WT, Δ, and T8993G cells grown in the absence or presence of rapamycin ± SD (n=6). (B) 
qRT-PCR analysis of Parkin transcript levels in WT, Δ, and T8993G cells grown in the absence or presence of 
rapamycin ± SD (n=6). (C) CCCP results in recruitment of Parkin to mitochondria. GFP-Parkin transfected WT 
cells were incubated in the absence or presence of 10 µM CCCP for 1 h and immunolabeled for TOM20 (red). In 
the presence of CCCP, Parkin is recruited to aggregates that clearly colocalize with mitochondria. Size bar=20 
µm. n=2 experiments. 	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4.1. INTRODUCTION 
The turnover of mitochondria by macro-autophagy, or mitophagy, has emerged as an important 
mechanism of mitochondrial quality control (Schon and Przedborski, 2011). In mammalian cells, 
damaged mitochondria are degraded by the autophagic machinery via a process that depends, on the 
presence of two Parkinson’s disease related proteins, PTEN-induced putative kinase-1 (PINK1) and 
Parkin (Schon and Przedborski, 2011). PINK1 is present on the mitochondrial outer membrane (MOM) 
and a portion is imported in the mitochondria (Becker et al., 2012; Zhou et al., 2008). There, full-length 
PINK1 is processed in two steps (Greene et al., 2012; Jin et al., 2010), giving rise to a 52kDa species that 
is eventually degraded by the proteasome (Lin and Kang, 2008; Narendra et al., 2010a; Takatori et al., 
2008; Zhou et al., 2008). Under basal conditions, Parkin is predominantly cytosolic, but upon dissipation 
of the membrane potential ΔΨm, Parkin is recruited to the mitochondria (Narendra et al., 2008) in a 
PINK1-dependent manner (Geisler et al., 2010; Kawajiri et al., 2010; Narendra et al., 2010a; Rakovic et 
al., 2010; Vives-Bauza et al., 2010; Ziviani et al., 2010). The consensus is that the Parkin/PINK1 
interaction acts as a signal for the damaged mitochondria to undergo mitophagy (Schon and Przedborski, 
2011).  
In the yeast Saccharomyces cerevisiae, mitophagy is known to be a selective form of macro-
autophagy that can be monitored by the generation of free GFP from e.g. Om45-GFP, either on Western 
Blot or by fluorescence microscopy. The availability of this and other quantitative autophagy assays (such 
as the Ape1 degradation assay) has been essential for the study of autophagy in yeast and for the 
discovery of autophagy related genes (Abeliovich and Klionsky, 2001). In mammalian cells, several 
methods are available to study macro-autophagy, but no specific quantitative assay for mitophagy exists. 
Thus far, the study of mitophagy has relied on generic autophagy methods with some adaptations to 
mitochondria (Klionsky et al., 2012). These methods are often either qualitative or, if quantitative, quite 
challenging and include: 1) ultrastructural analysis of mitochondria in autophagosomes by electron 
microscopy (EM); 2) co-localization between a mitochondrial marker such as MitoTracker or antibody 
immunostaining and an autophagy marker such as GFP-LC3; or 3) quantification of the remaining 
mitochondrial mass by Western blot or microscopy using antibodies against mitochondrial proteins.  None 
of these methods can be used alone to assert that mitophagy occurs. For instance, co-localization 
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between mitochondrial and autophagy markers do not prove that mitochondria are being degraded by 
mitophagy. EM can provide proof that mitochondria have been engulfed in autophagic vesicles, but 
quantification of EM images is time consuming and only captures the early stages of mitophagy, when 
mitochondrial structures are still identifiable in the autophagosomes before being degraded. A decrease 
in mitochondrial mass can only be reliably measured when this decrease is substantial, as is the case for 
example in HeLa cells stably overexpressing Parkin-YFP (Narendra et al., 2008). After 24 hours of 
treatment with the protonophore carbonyl cyanide m-chlorophenylhydrazone (CCCP), which dissipates 
membrane potential, a proportion of the cells end up with no detectable mitochondria (Narendra et al., 
2008). This decline does not happen in other cell types, however, where the effect is usually much more 
subtle. To study mitophagy, it is thus necessary to combine more than one of these methods, which is 
burdensome. There is a need for a reliable, friendlier method to monitor mitophagy in mammalian cells 
that would provide the experimental advantages that were available in the initial studies with 
Saccharomyces cerevisiae. 
We report on the development and validation of a method to study mitophagy that can be applied 
to live and fixed cells and that allows real-time quantification of mitophagy. The basis of this new method 
rests on the utilization of a tandem fluorescent-tagged protein. This mRFP-GFP chimeric protein has 
been used before to study macro-autophagy. In that case, it has been fused to LC3 (Klionsky et al., 2012) 
and has been used to follow the flux of LC3 through autophagic vesicles and lysosomes by exploiting the 
differential pH sensitivity of GFP and mRFP (Kimura et al., 2007). Once in an acidic compartment such as 
a lysosome, GFP loses its fluorescence while mRFP retains fluorescence, changing the signal from 
yellow (green plus red) to red-only. We have adapted this method by targeting the tandem protein 
mCherry-EGFP to the mitochondrial outer membrane, so that we would be able to qualitatively and 
quantitatively monitor mitophagy, as it has been done before for use in S. cerevisiae (Mijaljica et al., 
2011). In this Toolbox, we show that our construct is localized at the mitochondria, that its fluorescence is 
pH sensitive and that it can be used to study mitophagy in live and fixed cells. As an example of its 
application, we quantify mitophagy in HeLa cells in the presence or absence of ectopically expressed 
Parkin, which we have previously shown to be important for the initiation of mitophagy (Vives-Bauza et 
al., 2010). 
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4.2. RESULTS 
We targeted mCherry-EGFP to the mitochondria by using the first 33 amino acids of the 
mitochondrial outer membrane protein TOM20, which is the shortest targeting sequence that will lead to 
mitochondrial rather than Golgi or ER localization (Kanaji et al., 2000); see the map of the construct in 
Fig. S1. We named our construct MitophaGFP for mitophagy fluorescent protein. 
To confirm that MitophaGFP is directed to the MOM, it was expressed by transient transfection in 
HeLa cells, mouse embryonic fibroblasts (MEF) and the neuroblastoma cell line SH-SY5Y. After fixation, 
the cells were immunostained using antibodies against the mitochondrial markers cytochrome c (Fig. 
4.1A) or TOM20 (Fig. 4.S2); in our experience, the TOM20 antibody does not recognize the TOM20 
targeting sequence used in MitophaGFP and can thus be used to stain mitochondria even in the 
presence of MitophaGFP (data not shown). HeLa cells were also stained for the endoplasmic reticulum 
(ER) marker protein disulfide isomerase (PDI; Fig. 4.1B). MitophaGFP expressed in all three cell types 
shows a clear mitochondrial pattern (Fig. 4.1 A) and it strongly co-localizes with mitochondrial markers 
(Pearson’s correlation coefficients Rr = 0.6-0.9), but not with ER marker (Rr = 0.2). If mitophagGFP is 
targeted to the MOM, we predict that it will behave similarly to a MOM protein in a Proteinase K (PK) 
protection assay. We isolated mitochondria from HeLa cells transiently transfected with MitophaGFP and 
exposed them to increasing concentrations of PK. Similar to the MOM protein TOM70, MitophaGFP was 
degraded at a PK concentration of 10 µg/ml (Fig. 4.1B). Conversely, the intra-mitochondrial protein 
Smac/diablo, used as a control for mitochondrial membrane integrity, was degraded by PK only after 
mitochondrial membranes were permeabilized with 0.5% Triton-X100. Based on the combination of the 
imaging and the PK assay results, we concluded that our chimeric protein displayed the characteristics of 
a mitochondrial outer membrane protein, which was expected because it possesses the Tom20 targeting 
sequence. 
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 (B) Conversely, HeLa cells prepared as in (A) do not show overt colocalization between MitophaGFP and the 
endoplasmic reticulum (ER) marker PDI as evidenced by the small Pearson’s correlation coefficient of 0.20. (C) 
Representative Western blot of the Protease K assay on mitochondria isolated from HeLa cells expressing 
MitophaGFP. The left panel shows results obtained for non-permeabilized mitochondria (i.e. no Triton-X100) which 
demonstrates that MitophaGFP (GFP) digestion profile is similar to that of the mitochondrial outer membrane protein 
TOM70 and distinct from that of the intramitochondrial protein SMAC. Yet, after permeabilization (0.5% Triton-
X100), mitochondrial membranes become permeable to the protease and SMAC is now digested similarly as 
TOM70 and MitophaGFP (GFP). Scale bar = 20 µm. 
	  
Figure 4.1. Mitochondrial localization of 
MitophaGFP. (A) MitophaGFP was transiently 
transfected in HeLa, MEF and SH-SY5Y cells. 
After fixation with 4% paraformaldehyde cells were 
immunostained for the mitochondrial marker 
cytochrome c. In all three cell types, MitophaGFP 
colocalizes with cytochrome c as evidenced by a 
high Pearson’s correlation coefficient: 0.59 for 
HeLa, 0.73 for MEF and 0.80 for SH-SY5Y cells. 	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Since the proper functioning of our chimeric protein as a mitophagy probe depends on the 
differential pH susceptibility of EGFP and mCherry, next we sought to assess whether MitophaGFP was 
indeed pH sensitive, i.e. its fluorescent signal would actually turn from yellow to red at low pH. We 
decided to address this question by decreasing the pH of the cytosol, so that the entire mitochondrial 
network would be in a low pH environment. To this end, we monitored MEF cells transiently transfected 
with MitophaGFP by live-imaging confocal microscopy. At first, cells were incubated in Phosphate 
Buffered Saline (PBS) at pH 7.0. Then, the incubation medium was exchanged for PBS with 10 mM 
sodium acetate at pH 5.0 (Sandvig et al., 1986), which should rapidly lower the cytosolic pH to a level 
similar to that of lysosomes. Within 1 minute, the entire mitochondrial network began to turn from yellow 
to red and over the course of ten minutes the ratio between EGFP and mCherry fluorescent signal 
(green/red ratio) had dropped from 1.0 to 0.1 as a result of loss of the EGFP signal (Fig. 4.2 and Fig. 
4.S3). We asked whether this effect was reversible and exchanged the incubation medium again for PBS 
pH 7.0 after 10 minutes at pH 5. Although we saw an increase in EGFP signal within a few minutes, 
recovery of green fluorescence was only partial (Fig. 4.2). This result is important because it means that 
the red-only signal should, at least in part, be retained upon fixation of cells, even though the fixation 
process may increase the pH in lysosomes. Control cells incubated for the total duration of the 
experiment (20 minutes) in PBS at pH 7.0 did not lose EGFP signal and retained a green/red ratio of 
around 1.0 (Fig. 4.2).  
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The above experiments established the mitochondrial localization and the pH sensitivity of 
MitophaGFP. Next, we asked whether this probe could be used to study mitophagy. During mitophagy, 
Figure 4.2. MitophaGFP is pH sensitive. (A) MEF cells transiently transfected with MitophaGFP were incubated 
either at neutral pH (7.0) for 20 minutes (top panel) or changing pH (lower panel). After images were captured at T 
= 0, the incubation medium was exchanged for PBS/10 mM sodium acetate at pH 5.0 and, after 10 minutes, 
exchanged again for PBS at pH 7.0. Images were acquired every minute and select time points are shown (for 
complete series see Fig. S3). Scale bar = 20 µm. (B) Quantification of the ratio between red and green signal of 
MitophaGFP at neutral pH (PBS, solid line) and changing pH (dashed line). Using ImageJ, integrated intensity for 
each channel was measured in a mitochondria dense area, of which an example is indicated in the top left panel 
of (A). 
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mitochondria are engulfed by autophagosomes and eventually end up in lysosomes after fusion of the 
autophagosomes with lysosomes. When inducing mitophagy in cells expressing MitophaGFP, we 
anticipate the appearance of red-only puncta where the MitophaGFP-tagged mitochondria have entered 
lysosomes. The best established and most dramatic model for mitophagy currently available is the drug-
induced dissipation of Δψm in HeLa cells overexpressing Parkin (Narendra et al., 2008b). Accordingly, we 
co-transfected HeLa cells with MitophaGFP and Parkin-myc (co-transfection rate >90%, data not shown) 
and, 24 hours after transfection, we induced mitophagy by treating the cells with 1 µM of the ionophore 
valinomycin, which, like CCCP, dissipates ΔΨm. Cells were followed by confocal live-imaging before and 
up to ten hours after valinomycin exposure began. Red-only puncta started to appear one hour after 
addition of valinomycin (Fig. 4.3). Within ten hours, all mitophaGFP-labeled mitochondria had 
disappeared and, as predicted, induction of mitophagy had led to a major accumulation of red-only puncta 
in the perinuclear area. 
We asked whether the red-only puncta co-localized with a lysosomal marker, confirming that the 
appearance of red puncta truly indicated the uptake of mitochondria in lysosomes. We treated HeLa cells 
transiently co-transfected with Parkin-myc and MitophaGFP for 20 hours with valinomycin. Cells were 
then either fixed and stained for the lysosomal marker LAMP1 or imaged live after incubation with 
LysoTracker Blue. Both lysosomal markers co-localized with the red-only puncta (Fig. 4.4). When co-
transfected cells were concurrently exposed to valinomycin and the macro-autophagy blocker 3-
methyladenine (3MA), we saw an aggregation of mitochondria in the perinuclear area, but we did not see 
the formation of red-only puncta (Fig. 4.S4). We concluded that the appearance of red-only puncta 
indicates that mitochondria were taken up by lysosomes through macro-autophagy. 
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Figure 4.3. See page 97 for legend 
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As a proof of concept, we used the construct in an experiment based on our previous study 
(Vives-Bauza et al., 2010) in which we show that Parkin recruitment leads to co-localization between 
Parkin-decorated mitochondria and the autophagy markers LC3 and LAMP2 in the perinuclear region of 
the cell.  
HeLa cells were transiently transfected with MitophaGFP as above, however in this case only half 
of the cells were co-transfected with Parkin-myc. Endogenous levels of Parkin in HeLa cells are very low 
and HeLa cells can be considered Parkin-null. Thus, if MitophaGFP works as expected, we predict an 
accumulation of red-only puncta after mitophagy induction in cells expressing both Parkin and 
MitophaGFP, but not in the cells transfected with MitophaGFP alone. Accordingly, cells were treated with 
1 µM of valinomycin or the vehicle DMSO for 20 hours. They were then fixed with 4% paraformaldehyde 
and immunostained for Parkin. Using a confocal microscope equipped with a 63x/1.40 objective z-
sections were collected at 0.4-µm intervals for a total of 10-14 slices. Laser intensity, scan zoom, and 
detector gain settings were kept equal throughout the acquisition process for all four conditions (DMSO or 
valinomycin and with or without Parkin). For analysis, we included only cells that had ‘intermediate’ 
expression of MitophaGFP (i.e. not overly bright or undetectably dim with the laser and gain settings 
chosen) and in the case of co-transfection with Parkin-myc, were Parkin positive.  
Since the take-up of mitochondria in lysosomes (mitophagy) leads to a loss of green signal but 
not of the red signal, we used the red/green ratio as a quantitative measure of mitophagy, expecting the 
ratio to increase as mitophagy rises. MetaMorph (Molecular Devices) was used for analysis of the 
Figure 4.3. Detection of mitophagy with MitophagGFP. (A) For the time-lapse imaging study of mitophagy in 
HeLa cells transiently transfected with MitophaGFP and Parkin-myc, images were taken immediately before 
(Pre-treatement) and after (T = 0) addition of 1 µM valinomycin to the incubation medium and then every hour for 
up to ten hours. Right panels are 3x digital zoom of the areas designated by red squares. Arrows indicate 
formation of red-only puncta after 1 hour of valinomycin treatment. These images show that overtime, the 
number of red-only puncta is increasing in the perinuclear area. (B) HeLa cells transiently transfected with 
MitophaGFP and Parkin-myc were treated with 1 µM valinomycin for 20 hours. Cells were either fixed and 
immunostained for the lysosomal marker LAMP1 (top panel) or co-incubated with 100nM LysoTracker Blue for 
the duration of valinomycin treatment and imaged live under confocal microscopy (bottom panel). These images 
indicate that at 10 hours, the red-only puncta colocalize with the lysosomal markers as evidenced by a Pearson’s 
correlation coefficient of 0.57 for LAMP1 and 0.31 for Lysotracker for the red channel. In contrast, for the green 
channel Pearson’s correlation coefficients are 0.12 for LAMP1 and -0.14 for Lysotracker. Scale bar = 20 µm. 
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red/green ratio; on a maximum 
projection of the z-stacks, the 
region of interest tool was used to 
select cells. Integrated intensity for 
the green and red channel was 
measured and the red/green ratio 
calculated and normalized to the 
ratio obtained for DMSO treated 
cells without Parkin.  
In DMSO exposed cells, 
there was no difference in 
mitophagy between Parkin 
positive and negative cells, as 
evidenced by a red/green ratio 
that remained ~1.0. However, in 
valinomycin exposed cells, the 
red/green ratio increased only in 
those cells transfected with Parkin 
(~2-fold, Fig. 4.4). Mitochondria 
accumulated in the perinuclear 
area in both cases (Fig. 4.4A), but 
were taken up in lysosomes only 
when Parkin was ectopically 
expressed. This result is in 
agreement with findings by 
Narendra et al. (2008), who found 
that mitochondria only disappear 
	  
Figure 4.4. Mitophagy is Parkin dependent. (A) Representative 
images of valinomycin-induced mitophagy in HeLa cells. Cells were 
transiently transfected with MitophaGFP only or MitophaGFP and 
Parkin-myc and fixed with 4% paraformaldehyde after being treated for 
20 hours with 1 µM valinomycin or the vehicle DMSO. Scale bar = 20 
µm. (B) Quantification of valinomycin-induced mitophagy in HeLa cells. 
The integrated intensity for the red and green channels was measured 
in 20-25 cells per condition and the red/green ratio calculated. The 
ratios were normalized to the no Parkin/DMSO condition. As shown, 
the ratio is significantly increased after valinomycin exposure, but only 
in cells overexpressing Parkin. Values represent mean ± SEM for 3 
independent experiments. Two-way ANOVA (Student-Newman-Keuls 
method) was used to test for differences. 	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in cells overexpressing Parkin-YFP. Using our method, however, we found that some mitophagy still 
takes place in the absence of Parkin. 
 
4.3. DISCUSSION 
We targeted the tandem fluorescent protein mCherry-EGFP to the MOM as a new method to follow 
mitochondria throughout the process of mitophagy. In the above-described experiments, we showed that 
the probe can be expressed in a variety of cells, is localized to the mitochondria and behaves as an outer 
mitochondrial membrane protein. While here we used transfection, we recognize that some cells, such a 
primary neurons or glia may not be that amendable to transfection in which case, MitophaGFP may have 
to be packaged into a viral vector. We also confirmed that it is pH sensitive and that its signal turns from 
yellow (red plus green) to red-only once mitochondria have been taken up in lysosomes. Using live 
confocal imaging, we were able to follow the process of mitophagy for up to ten hours, providing temporal 
data on mitophagy. Aside from its application in live imaging, we showed that the probe can also be used 
for quantification of mitophagy after cell fixation. This is particularly useful when a great number of cells 
needs to be analyzed (requiring a lot of time at the microscope), when duration of treatment would make 
it difficult to take all required microscopy images directly after treatment, or when immunostaining for a 
specific marker is desired. 
During the development of this probe, Katayama et al. (2011) published a similar method based 
on the fluorescent protein mKeima, which can be excited by different wavelengths at neutral or acidic pH 
(438 and 550 nm respectively), emitting at the same wavelength (620 nm) for both. The ratio between 
emissions at each excitation wavelength can then be used to determine pH. Although their probe has the 
advantage that it can be utilized in combination with other commonly used fluorescent proteins such as 
GFP, it cannot be fixed and can thus be used in live imaging only. If desired, MitophaGFP could be used 
in combination with a fluorescent protein that can be separated from EGFP, such as CFP. Furthermore, 
since mKeima emission is the same for both excitation wavelengths, images need to be acquired 
sequentially, while for our probe the red and green signal can be collected at the same time, giving 
	   100 
MitophaGFP a better spatial-temporal resolution. Analysis is also simpler for MitophaGFP, as one can 
simply observe the appearance of red puncta, while for mKeima one needs to analyze the 550/438 ratio 
before being able to tell where areas of low pH are in the cell. 
The analysis we provided above works well in case of major changes of mitophagy. When more 
sensitivity is required, we suggest subtracting the background fluorescence and using pixel intensity 
based thresholding to select mitochondria only. An alternative for more subtle mitophagy would be to 
count red-only puncta the same way LC3 puncta are counted. 
Overall, we believe we have generated an easy-to-use new method to study mitophagy both 
qualitatively and quantitatively, thereby fulfilling a need in the rapidly expanding field of mitophagy. Even 
at this initial stage, we believe that MitophaGFP has already brought new insights into the PINK1/Parkin 
role in mitophagy. Indeed, MitophaGFP showed that, once ΔΨm is lost, red-only puncta appear in the 
perinuclear region of the cells supporting the notion that while damaged mitochondria (i.e. mitochondria 
with low ΔΨm) may reside away from the perinuclear area, they will only be eliminated after trafficking to 
the perinucelar area where they will be destroyed by the lysosomes. The use of MitophaGFP also 
revealed that if low amounts of Parkin suffice to allow mitochondria with low ΔΨm to migrate to the 
perinuclear area, copious amount of Parkin seem to be necessary to allow these mitochondria to enter 
the lysosomes. Thus, Parkin may be important to the fusion of autophagosomes and lysosomes an idea 
that, thanks to MitophaGFP, is now formally testable.  
 
4.4. MATERIALS AND METHODS 
Plasmid construction. To engineer the MitophaGFP plasmid, mCherry-EGFP was amplified by PCR 
from the pBABE-puro mCherry-EGFP-LC3 construct, which was acquired from Addgene (plasmid 22418, 
deposited by Jayanta Debnath). The following primers were used to amplify mCherry-EGFP and to add 
on BamHI and XhoI restriction sites: 
Forward 5’ --> 3’: GGATCCAATGGCCATCATCAAGGAGTTCATGC 
Reverse 5’ --> 3’: CTCGAGCTCCGACGGCATTTATTCGGTACC 
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mCherry-EGFP was then ligated into a pCR-TOPO 2.1 vector (Invitrogen), excised using BamHI and 
XhoI and subcloned into a pcDNA3.1+ vector (Invitrogen). We generated the TOM20 targeting sequence 
by designing a forward and reverse primer spanning the length of the first 33 amino acids of TOM20, with 
a mimicked HindIII restriction site on the forward primer and a mimicked BamHI restriction site on the 
reverse primer. These primers were hybridized in vitro, generating a piece of double stranded DNA that 
could be subcloned into the pcDNA3.1+ vector already containing mCherry-EGFP. 
Forward primer 5’--> 3’: 
AGCTTATGGTGGGTCGGAACAGCGCCATCGCCGCCGGTGTATGCGGGGCCCTTTTCATTGGGT
ACTGCATCTACTTCGACCGCAAAAGACGAAGTGACCCCAACTCG 
Reverse primer 5’-->3’ 
GATCCGAGTTGGGGTCACTTCGTCTTTTGCGGTCGAAGTAGATGCAGTACCCAATGAAAAGGGC
CCCGCATACACCGGCGGCGATGGCGCTGTTCCGACCCACCATA 
Cell culture and transfection. HeLa cells were cultured in DMEM (Invitrogen) with 10% FBS 
(Invitrogen) and 1% (vol/vol) penicillin-streptomycin (Invitrogen). MEF cells were cultured in in the same 
medium supplemented with 1x Non-Essential Amino Acids (Millipore) and 8 µl/L beta-mercaptoethanol. 
SH-SY5Y cells were cultured in DMEM/Ham’s F-12 medium (Invitrogen) with 10% FBS (Invitrogen) and 
1% (vol/vol) penicillin-streptomycin (Invitrogen). All cells were maintained at 37ºC/5% CO2. Transient 
transfection was performed with Lipofectamine LTX (Invitrogen) according to manufacturer’s protocol. 
The Parkin-myc construct was described before.(Vives-Bauza et al., 2010) 
Imaging of fixed cells. Cells were seeded in 24-well plates on glass coverslips at 50,000 cells per 
well. Treatment was started 24 hours after transfection for the durations indicated. After fixation with 4% 
paraformaldehyde, cells were permeabilized with 0.1% triton X-100, blocked with 0.5% BSA and stained 
for either Tom20 (1:200, Santa Cruz 11415), Cytochrome C (1:200, BD556432), PDI (1:100, Enzo ADI-
SPA-891), Lamp1 (1:500, Abcam 24170) or Parkin (1:250, Cell Signaling #2132) for 1h at 37 degrees. 
Cells were then washed 3x with PBS and incubated for 30 min at 37 degrees with Cy5 secondary 
antibodies (1:250, Jackson Immuno Research). Images were acquired with a Leica SP5 confocal 
microscope equipped with a 63x objective. Pearson’s correlation coefficients were calculated on a single 
confocal plane using the Manders Coefficients plugin in ImageJ. 
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 Live Imaging. For live imaging studies, cells were seeded in either 4-well chamber slides (Nunc 
Lab-Tek, 50,000 cells per well) or 35 mm glass bottom dishes (MatTek, 250,000 cells per dish) and 
transfected with the plasmid as described above. Images were acquired using a Nikon A1R MP confocal 
system equipped with a 100x objective and a temperature and CO2 regulated live-imaging chamber. 
Proteinase K assay. HeLa cells were transiently transfected with TRG. Twenty four hours post 
transfection cells were harvested and the crude mitochondrial fraction was isolated as described 
before.(Becker et al., 2012) Half of the fraction was resuspended in in isotonic buffer (250 mM Sucrose, 
10 mM Hepes, 10 mM KCl, 2 mM MgCl2, 1 mM EDTA, pH=7.4) with 0.5 % Triton X-100, the other half 
was resuspended without Triton X-100. After 10 min on ice samples were aliquoted and 0-200 µg/ml 
Proteinase K was added. After 30 min on ice the reaction was stopped by the addition of PMSF (5 mM). 
Samples (30 µg protein) were run on precast 4-12% Bis-Tris gels (Invitrogen) with MOPS buffer 
according to manufacturer’s protocol. Proteins were transferred to 0.45 µm Nitrocellulose membrane 
(BioRad) (or PVDF when probed with the anti-Smac antibody). Membranes were blocked with blocking 
buffer (Rockland), incubated with primary antibodies as indicated and fluorescent-conjugated secondary 
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Figure 4.S1. Map of construct with restriction sites used. 
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Figure 4.S2. Mitochondrial localization of MitophaGFP. MitophaGFP was transiently transfected in HeLa, 
MEF, and SH-SY5Y cells. After fixation with 4% paraformaldehyde cells were immunostained for the 
mitochondrial marker TOM20. Pearson’s correlation coefficients between MitophaGFP and TOM20 are 0.89 for 
HeLa, 0.50 for MEF and 0.78 for SH-SY5Y cells. Scale bar = 20 µm.  
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Figure 4.S3. MitophaGFP does not change color at neutral pH. Complete time-
lapse series of MEF cells expressing MitophaGFP incubated in PBS for 20 minutes. 
Images were taken every minute. Scale bar = 20 µm. 
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Figure 4.S4. See 
page 107 for 
legend. 






Figure 4.S4. MitophaGFP turns red at low pH. Complete time-lapse series of pH change. MEF cells expressing 
MitophaGFP were initially incubated in PBS at pH 7.0 (T = 0), then the incubation medium was exchanged for 
PBS/10mM sodium acetate at pH 5.0. After ten minutes, medium was exchanged again for PBS at pH 7.0. 
Images were taken every minute. Scale bar = 20 µm. 
	  
	  
Figure 4.S5. Inhibition of autophagy prevents formation of red-only puncta. HeLa cells transiently 
transfected with MitophaGFP and Parkin-myc were treated for 20 hours with 1 µM valinomycin and 10 mM 3-
methyladenine. After treatment, cells were fixed with 4% paraformaldehyde and stained for Parkin. Scale bar = 
20 µm. 
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CHAPTER 5: CONCLUSIONS AND DISCUSSION 
 
5.1. SUMMARY OF RESULTS 
Since its discovery in the 1960’s, autophagy has been extensively studied. It has turned out to be 
an important intracellular maintenance system, and defects in autophagy have been linked to a wide 
range of diseases. My interest in the role of autophagy in neurodegeneration came partly from my work 
on cargo recognition failure in Huntington’s Disease with Ana Maria Cuervo and David Sulzer (Martinez-
Vicente et al., 2010). Specifically, the turnover of mitochondria by autophagy, or mitophagy, a rapidly 
emerging field of study, intrigued me. Not much was known about the regulation of mitophagy in 
mammalian cells, although it had just been shown that the PD-related protein, Parkin, is recruited to 
damaged mitochondria and that these tagged mitochondria are subsequently degraded by autophagy 
(Narendra et al., 2008). Since Parkin had been placed in a shared pathway with PINK1 in Drosophila 
(Clark et al., 2006; Park et al., 2006), we wondered if PINK1, in mammalian cells, could play a role in the 
regulation of mitophagy in conjunction with Parkin.  
 
5.1.1 PINK1 and Parkin regulate mitophagy 
 We found that cytosolic Parkin relocates to the mitochondrial outer membrane upon dissipation of 
ΔΨm, a correlate of mitochondrial damage, which is in line with the study by Narendra et al. (2008). When 
we silenced PINK1 in YFP-Parkin expressing HeLa cells, Parkin relocalization after CCCP treatment was 
markedly reduced. This was also the case in cortical neurons from PINK1 knock-out mice, indicating that 
the recruitment of Parkin to mitochondria was PINK1 dependent. Conversely, concomitant 
overexpression of wild-type PINK1 and Parkin in N27 and SH-SY5Y cells led to spontaneous 
relocalization of Parkin and clustering of mitochondria in the perinuclear area, without the need for ΔΨm 
dissipation. When we used mutant forms of PINK1, which have reduced kinase activity, or functionally 
defective Parkin (an E3-ubiquitin ligase), the formation of these clusters was attenuated. Parkin 
recruitment to the MOM and mitochondrial aggregation were thus dependent on the presence of both 
functional PINK1 and Parkin. We then asked whether Parkin and PINK1 were interacting directly and, in 
doing so, were modifying each other. In co-immunoprecipitation experiments, we showed that the kinase 
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domain of PINK1 is necessary for binding to Parkin in its RING1 domain. We found no evidence, 
however, of PINK1 ubiquitination by Parkin or of Parkin phosphorylation by PINK1. 
Since the Parkin-decorated mitochondrial clusters co-localized with the autophagosome marker 
LC3 and the lysosomal marker LAMP2, we concluded that PINK1 appears to play a role in the regulation 
of mitophagy in mammalian cells.  
PINK1 has a rather peculiar life-cycle, in that it is imported into the mitochondria, where it is 
doubly-cleaved to form a 52kDa fragment, PINK152. This fragment was proposed to be degraded inside of 
mitochondria, thereby keeping PINK1 levels at the MOM low (Jin et al., 2010). In terms of cellular 
resources, it seemed quite expensive to continuously produce and degrade a protein for the sole purpose 
of keeping levels low. Instead, we wondered if this PINK152 could also have a function in the regulation of 
mitophagy. Using alkaline extraction experiments on isolated mitochondria, we showed that PINK152 is 
only loosely attached to the MOM, unlike full length PINK1. We observed an increase in PINK152 levels in 
the mitochondrial fraction and in the cytosol after inhibition of proteasomal degradation by MG132. Based 
on these data, we proposed that PINK152 is retro-translocated to the cytosol, where it can be degraded by 
the proteasome, rather than remain inside the mitochondria. The next question then was what role might 
cytosolic PINK152 play? Since we knew from our co-immunoprecipitation experiments that this fragment is 
able to bind Parkin at its RING1 domain, we hypothesized that it would bind Parkin and prevent its 
translocation to mitochondria.  To test this, we compared CCCP-induced mitophagy between HeLa cells 
(stably expressing YFP-Parkin) that were either non-transfected, or transfected with full-length PINK1 or a 
PINK1 fragment mimicking PINK152. The decrease in mitophagy that we observed in cells transfected 
with the fragment confirmed our hypothesis that PINK152 can bind Parkin and prevent its translocation. 
Based on the data presented in the first part of this dissertation, we proposed the following model 
for regulation of mammalian mitophagy by PINK1 and Parkin: 
 
[Model 1] Under basal conditions, PINK1 rapidly cycles through the mitochondria and is cleaved to form 
a 52kDa fragment. This fragment returns to the cytosol, where it binds Parkin and prevents Parkin from 
translocating to the MOM, thereby putting a break on unwanted mitophagy. Upon ΔΨm dissipation, a form 
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of mitochondrial damage, PINK1 is no longer imported and accumulates at the MOM. Consequently, 
Parkin is recruited to the MOM and mitochondria are marked for degradation by the autophagic pathway.  
 
5.1.2 Mitophagy regulation in a disease background is more complex than we thought 
Many questions remain to be answered about mammalian mitophagy, but our studies and those 
of others have provided us with a better understanding of the roles of PINK1 and Parkin in this process. 
PINK1 and Parkin are generally thought to mediate the clearance of damaged mitochondria only, much 
like Atg32 and Atg33 in S. cerevisiae. This notion is highly speculative, however, since the data are all 
based on artificial models of chemically-induced ΔΨm dissipation. We tried to address this issue by 
looking at a model with constitutive mitochondrial damage instead; that is, a disease model caused by 
mtDNA mutations. We assessed autophagy in homoplasmic cybrids carrying mtDNA mutations from 
patients with MELAS, NARP and KSS, and in ρ0 cells depleted of mtDNA. Surprisingly, we did not find an 
increase in autophagy at baseline either by Western Blot (WB) or fluorescence microscopy (FM). We had 
expected to see an increase because, based on our [model 1], the presence of dysfunctional 
mitochondria should lead to activation of mitophagy. Upon inhibition of mTor with rapamycin, we saw a 
vast proliferation of autophagosomes in the KSS cells, as assessed by WB and FM. In these cells, Parkin 
was recruited to mitochondria after rapamycin treatment and the mitochondrial marker MitoTracker Red 
co-localized with the adaptor-protein p62 and the autophagosomal marker LC3-GFP. From this, we 
concluded that mTor inhibition led to massive mitophagy in these KSS cells. Why then, did this not 
happen in the other cybrid lines that were carrying mtDNA mutations? As it turned out, the KSS cells had 
the lowest ΔΨm of all the lines, equivalent to that seen in WT cells treated with CCCP, reiterating the 
importance of loss of membrane potential for the induction of mitophagy. ρ0 cells also had a significantly 
reduced membrane potential, but rapamycin did not induce mitophagy in these cells. We wondered if this 
could be due to a lack of PINK1 or Parkin and indeed, qRT-PCR analysis confirmed that mRNA levels for 
both were lowest in ρ0 cells. With overexpression of mCherry-Parkin, mitophagy as seen in KSS cybrids, 
could also be activated in ρ0 cells.   
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In this disease model, the mere presence of mitochondria with low membrane potential was thus 
not enough to induce mitophagy. We proposed a ‘two-hit’ model for mitochondrial autophagy in these 
cells: 
 
[Model 2] In a mtDNA disease background, mitophagy depends on (1) the activation of 
mitophagic targeting (via the loss of ΔΨm and Parkin recruitment) and (2) the activation of general macro-
autophagy (through mTor inhibition).  
 
5.1.3. A new method to study mitophagy 
In contrast to our findings in chemically-induced, artificial paradigms, in a real disease 
background, mitophagy activation turned out to be the result of a complex interaction between membrane 
potential, sufficient levels of PINK1 and/or Parkin and the activation of macro-autophagy by mTor 
inhibition.  Which model is correct? While conducting our research, we realized that to answer that 
question we needed a better method to assess mitophagy. Thus far, we (and everyone else in the field) 
had relied on the use of generic autophagy methods, slightly adapted for mitochondria. These include 
methods such as electron microscopy, the co-localization of mitochondrial markers with autophagy 
markers under confocal microscopy, or the monitoring of mitochondrial mass by Western Blot. We set out 
to design a user-friendly tool that would allow us to qualitatively and quantitatively assess autophagy in 
real-time or in fixed cells. The result is MitophaGFP, a tandem red-green fluorescent protein targeted to 
the MOM that changes color from yellow (red+green) to red when mitochondria enter an acidic 
compartment such as a lysosome. This is due to the differential susceptibility of mCherry and GFP to pH. 
GFP quickly loses its fluorescence at low pH while mCherry does not. In Chapter 4, we showed that this 
new probe is indeed localized at the mitochondria, as it has a high co-localization coefficient with the 
mitochondrial markers Tom20 and cytochrome c. A Proteinase K assay on isolated mitochondria 
confirmed that MitophaGFP is located on the MOM, which we expected since we used the first 33 amino 
acids of Tom20 to target the construct to mitochondria.   After we established that the probe changes 
color in an acidic environment, we applied it in an experiment to show its functionality. We expressed the 
probe in HeLa cells, either alone or together with Parkin-myc. We then induced mitophagy by collapsing 
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ΔΨm with valinomycin. We observed massive mitophagy in the cells expressing both the construct and 
Parkin, comparable to what we had previously seen in HeLa cells stably expressing YFP-parkin (Chapter 
2, part II). Since HeLa cells have barely detectable levels of Parkin and are essentially considered Parkin-
null cells, we predicted that we would find no mitophagy in cells transfected with the construct only. 
Surprisingly, we still saw a small increase in mitophagy in these cells, which could be result of accidental 
sequestration of mitochondria in autophagosomes, part of a Parkin-independent, aspecific 
macroautophagy process. Or, it could mean that even low levels of Parkin are sufficient for mitophagy to 
take place, albeit not on such a massive scale as seen with Parkin overexpression. This may, in fact, be 
more representative of what happens in vivo. After all, in real life, mitochondrial damage is not usually a 
sudden occurrence that affects all mitochondria at once, as with chemical ΔΨm dissipation. Cells are not 
likely to survive if they get rid of the majority of their mitochondria.  
On a related note, whether the engulfment of mitochondria by autophagosomes is a specific 
process or the result of ‘accidental’ sequestration due to an overall upregulation of macroautophagy 
remains an outstanding question in the field. In S. cerevisiae, Atg32 and Atg33 mediate the recognition 
and degradation of damaged mitochondria only, excluding other cargo (Kanki et al., 2009; Okamoto et al., 
2009). Homologues of these proteins have not been found in mammalian cells, thus far. As discussed in 
Chapter 1, Nix is often seen as a potential functional orthologue, but this protein mediates the 
degradation of all mitochondria in erythrocytes, not just those with low membrane potential. 
PINK1 and Parkin may serve the same purpose in mammalian cells as Atg32/33 by detecting sick 
mitochondria and somehow directing them to be degraded specifically, without the overall activation of 
macroautophagy. Or, maybe, the field has biased itself by looking only at the degradation of 
mitochondria, while in fact mitophagy is the result of a general upregulation of macroautophagy whereby 
mitochondria also happen to be sequestered. This would explain why we do not see mitophagy in cybrid 
cells until we inhibit mTor.  
To determine whether mitophagy in mammalian cells is a distinct process from general 
macroautophagy, one would have to compare the degradation of damaged mitochondria vs. 
macroautophagy-specific cargo under mitophagy induction or general macroautophagy induction. For 
example, rapamycin could be used to induce general macroautophagy while photo-irradiation is used to 
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damage a few mitochondria and induce mitophagy (Kim and Lemasters, 2011) (rather than using CCCP 
which may have non-specific effects on the autophagic machinery). The degradation of mitochondria 
under both conditions could then be compared to that of a macroautophagy substrate such as a mutant 
form of Htt which forms aggregates (polyQ80 (Ju et al., 2009)). 
 
5.2. OUTSTANDING QUESTIONS ON PINK1 AND PARKIN 
In recent years, major progress has been made in the understanding of the regulation of 
mammalian mitophagy. Our studies allowed us to propose two models for the role of PINK1 and Parkin in 
this process, but many questions remain.  
 
5.2.1. How do PINK1 and Parkin interact? 
To start, the way PINK1 and Parkin interact is still unknown. Although these proteins can clearly 
bind each other, different groups have reported contradictory findings on whether they modify each other 
through ubiquitination or phosphorylation (Kim et al., 2008; Sha et al., 2010; Vives-Bauza et al., 2010). 
For Parkin recruitment to occur, however, PINK1 must have kinase activity and Parkin must have E3-
ligase activity (see Chapter 2). It is well-established that this ligase activity is important for the 
ubiquitination of MOM proteins and it has recently been suggested that it is stimulated by PINK1 kinase 
activity (Lazarou et al., 2013).  In addition, we have evidence that PINK1 is ubiquitinated (unpublished 
data) upon ΔΨm dissipation. All of this does still not mean that PINK1 and Parkin interact directly. Rather, 
it suggests that there may be one or more additional players that are modified by PINK1/Parkin or that 
can ubiquitinate PINK1 or phosphorylate Parkin and mediate the interaction between the two. To further 
understand the interaction between PINK1 and Parkin, it is thus essential to identify these players. Two 
recent screening studies may serve as a starting point for this effort. First, a study by Sarraf et al. 
identified hundreds of Parkin ubiquitylation sites using quantitative diGly capture proteomics. Several of 
these targets were found on the MOM and were depolarization-dependent (Sarraf et al., 2013). A number 
of these had been previously implicated in mitophagy, including VDAC1, 2 and 3 (Sun et al., 2012), MFN1 
and 2 (Gegg et al., 2010; Glauser et al., 2011; Tanaka et al., 2010) and SQSTM1/p62 (Geisler et al., 
2010). Of particular interest, is the finding that the candidate autophagy receptor CALCOCO2 is 
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ubiquitylated upon depolarization and associates with Parkin. This protein selectively binds LC3 and was 
found to be essential for the autophagic clearance of salmonella (Von Muhlinen et al., 2012). It is an 
attractive candidate for a new mitophagy receptor linking mitochondria directly to the autophagic 
machinery.    
Second, Rakovic et al. (Rakovic et al., 2011) recently identified 14 new potential PINK1 
interacting proteins, of which four were found at the mitochondria. These four proteins, namely GRP75, 
HSP60, LRPPRC, and TUFM, have all been linked to neurodegenerative disease and warrant further 
investigation as potential components of the PINK1/Parkin pathway.  
The analysis of both of these studies focused on proteins found at the MOM, since that is where 
PINK1 and Parkin are thought to interact. Our new proposed model (model 1), postulates that PINK1 and 
Parkin also interact in the cytosol, so cytosolic substrates should not be disregarded. Along these lines, 
the intra-mitochondrial proteins TRAP1 and HtrA2/Omi had previously been reported to be putative 
substrates (Plun-Favreau et al., 2007; Pridgeon et al., 2007). Since PINK1 is imported, we could 
speculate that it exerts its kinase function inside of mitochondria, and regulates Parkin recruitment from 
the inside out. 
 
5.2.2. How does Parkin translocate to sick mitochondria? 
A second question that is still unanswered is how Parkin translocates to mitochondria. Is this 
through an active process, analogous to the recruitment of Drp1 through mitochondrial fission factor 
(Otera et al., 2010)? Or is it a stochastic event? The latter is consistent with our data as presented in 
Chapter 2. According to our proposed model, cytosolic PINK152 prevents the accidental translocation of 
Parkin to the MOM under basal conditions. This idea is also supported by the finding that overexpression 
of Parkin can rescue a PINK1-/- phenotype in Drosophila (Clark et al., 2006; Park et al., 2006). After all, 
when a protein is overexpressed, its high levels throughout the cell make it more likely to accidentally also 
end up at the mitochondria. On the other hand, if Parkin translocation were an active process, the 
presence of high levels of Parkin would not necessarily lead to more recruitment to the MOM since the 
recruitment machinery would be the rate-limiting factor. 
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Related to this issue of the mechanism of Parkin translocation, is the question of how Parkin 
‘knows’ toward which mitochondria it should move. If the presence of Parkin at the MOM is indeed 
sufficient to mark a particular mitochondrion for degradation, then decorating healthy mitochondria with 
Parkin is not desirable. In our proposed model, the accumulation of full length PINK1 at the MOM upon 
dissipation of ΔΨm serves as a ‘sick mitochondrion’ signal for Parkin. We imagine Parkin to be in 
equilibrium between a free-Parkin and a Parkin/PINK1-bound state, possibly with a higher affinity for 
PINK152 over full length PINK1. There is an increased likelihood for Parkin to bind to full length PINK1 on 
the MOM after membrane dissipation, especially once PINK152 has been degraded by the proteasome. 
The data we presented in Chapter 2 support this hypothesis, but the model is in need of further testing. 
For example, the differential affinity of Parkin for PINK152 and full-length PINK1 needs to be confirmed.  
It is clear that the presence of full length PINK1 on the MOM can serve as a signal for Parkin 
recruitment and mitophagy induction. PINK1 targeted to membranes of other organelles such as 
peroxisomes even appears to be able to recruit Parkin to these organelles and induce their autophagy 
(Lazarou et al., 2012). Since we already suspect that additional players mediate the effect PINK1 and 
Parkin have on each other, it would be interesting to test whether PINK1 needs to be localized at the 
MOM or whether it is sufficient to have PINK1 kinase activity anywhere in the cell. This could be done, for 
example, by targeting PINK1 away from mitochondria, e.g. to the plasma membrane, in a PINK1-/- 
background. If Parkin is still recruited to damaged mitochondria in this scenario, this suggests that PINK1 
is part of the signaling cascade, but that an additional mechanism is in place to help target Parkin to 
damaged mitochondria.  
 
5.2.3. What is the actual role of PINK1 and Parkin in mitophagy? 
Aside from clarifying the mechanisms underlying Parkin recruitment to sick mitochondria, the 
actual role of PINK1 and Parkin in the mitophagy process still needs to be elucidated. In Chapter 1, we 
presented three putative models whereby PINK1 and Parkin may affect mitophagy; 1) by shifting the 
balance between fusion and fission of the mitochondrial network, 2) by modulating mitochondrial motility 
and 3) by directly recruiting the autophagic machinery to damaged mitochondria. These different 
scenarios are not mutually exclusive and are all supported by data. PINK1 and Parkin thus seem to affect 
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different stages of mitophagy, but maybe, we should think about them more as central regulators 
controlling the maintenance of a healthy mitochondrial population? We can speculate that they control 
several, increasingly drastic steps of mitochondrial quality control, starting with the ubiquitination and 
degradation of unwanted proteins. Then, through the modification of fission and fusion, damaged 
components can either be diluted throughout the mitochondrial network or isolated in a daughter unit that 
can be targeted for autophagy (Twig et al., 2008).  Massive mitophagy would then be the final and most 
drastic step. 
Relevant to this idea is recent work by the group of Heidi McBride that has uncovered a new 
mitochondrial quality control pathway in which mitochondrial derived vesicles (MDVs) are generated by 
healthy mitochondria. These MDVs selectively transport oxidized mitochondrial proteins to either 
peroxisomes or lysosomes (Soubannier et al., 2012a, 2012b). Essentially, this could be seen as a form of 
very localized mitophagy, whereby the mitochondrion serves as the source for the isolation membrane 
and thus forms its own autophagosome. This process could be regarded as an intermediate step in the 
mitochondrial quality control hierarchy just described. MDV formation appears to be Parkin-dependent 
(unpublished data, personal communication), supporting the notion that the PINK1/Parkin pathway may 
be a central regulator. Interestingly, the MOM has earlier been suggested to be the membrane source for 
autophagosomes in starvation induced autophagy (Hailey et al., 2010). What if the formation of MDVs is 
just a first step and can eventually lead to the generation of full AVs engulfing the mitochondria, thereby 
assuring specificity of mitophagy?  
Finally, a small number of studies has found Parkin to be important for the activation of 
macroautophagy in general, possibly through interaction with Bcl2/Beclin 1 (Chen et al., 2010; 
Khandelwal et al., 2011). Could this be how the PINK1/Parkin pathway controls the most drastic step in 
mitochondrial quality control, i.e. massive mitophagy? We have found a ~30% decrease in overall 
lysosomal degradation in cortical neurons from Parkin knockout mice compared to wild-type littermates 
(unpublished data, not shown). This finding could be consistent with a role for Parkin in macroautophagy 
regulation. Additional experiments are needed to determine at what step autophagy is inhibited in these 
neurons and whether this 30% decrease can be accounted for by the lack of mitophagy or represents a 
defect in general macroautophagy. Tsvetkov et al. (2010) recently identified a small molecule, N10-
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substituted phenoxazine, that reliably induces autophagy in neuronal cells. Hopefully, with the use of this 
compound, we will be able to overcome some of the methodological problems of studying autophagy in 
neurons and answer these questions. 
 
5.3. MITOPHAGY IN NEURODEGENERATION: WHERE DO WE GO FROM HERE? 
 
5.3.1. We need better experimental models 
Some of the outstanding questions discussed above can be answered with currently available 
experimental methods and cell models. As our studies in cybrid cells made clear however, these models 
are most likely too simplistic and do not reflect the complex situation in disease in vivo. In addition, 
frequently used cell types such as HeLa and MEF do not resemble neurons and are thus not an 
appropriate system to study neurodegeneration. For instance, in mouse or rat cortical neurons, the Parkin 
response appears to be markedly reduced compared to HeLa cells (Cai et al., 2012; Van Laar et al., 
2011). Probably, the most relevant in vitro model that can be used to study neurodegeneration is that of 
PD patient-derived induced pluripotent stem cells (iPSC) differentiated into dopaminergic neurons 
(Cooper et al., 2012). This model was used in two recent reports, the first of which showed that 
exogenously expressed Parkin is recruited to mitochondria in control cells but not in those derived from 
patients with a PINK1 mutation (Seibler et al., 2011), similar to our findings in N27 and SH-SY5Y cells. In 
the second report (Rakovic et al., 2013), the authors found no evidence of degradation of mitochondrial 
proteins in iPSC derived neurons upon dissipation of ΔΨm. This, in contrast to the clear induction of 
mitophagy they saw in patient-derived fibroblasts, suggests that mitophagy in neurons may be different 
from the process in non-neuronal cells.  They measured mitophagy by Western Blot, however, and were 
thus only able to detect major changes in levels of mitochondrial proteins. It would be interesting to use 
our MitophaGFP probe in the patient-derived fibroblasts and iPSC neurons to see if we can detect low 
levels of mitophagy without overexpressing Parkin. This would be a model that better reflects the situation 
in patients, where mitophagy may fail for years before the disease becomes evident. 
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5.3.2. Why are only specific neurons affected? 
PINK1 and Parkin are both ubiquitously expressed proteins and one may thus ask why mutations 
in the PINK1 and Parkin genes lead to the death of neurons but not other cell types. More specifically, 
why are dopaminergic (DA) neurons in the substantia nigra (SN) preferentially affected? Although PINK1 
mRNA levels were found to be high in human SN, this was also the case for other brain regions such as 
the hippocampus and cerebellum (Blackinton et al., 2007; Kuhn et al., 2004). If PINK1 and Parkin are not 
specific to SN DA neurons, then are these neurons maybe more dependent on mitochondrial quality 
control than other types of neurons? 
Recent work by the group of Surmeier has indeed argued that SN DA neurons have a higher 
basal metabolic rate due to their Ca2+-dependent pace-making activity. This reported higher Ca2+ 
conductance was associated, due to an unclear mechanism, with an increased mitochondrial production 
of reactive oxygen species (Surmeier et al., 2011). Therefore, could SN neurons harbor a greater content 
of mtDNA mutations and mitochondrial damage? Or, is mitophagy in these neurons not as efficient in 
clearing damaged mitochondria as e.g. in cortical neurons? Now that we can detect low levels of 
mitophagy with MitophaGFP, we could compare rates of mitophagy between different types of neurons at 
basal conditions or under stress. 
 
5.3.3. How about mitophagy in sporadic neurodegenerative disease? 
Familial forms of PD comprise only about ten percent of all PD cases (De Lau and Breteler, 2006) 
and mutations in PINK1 and Parkin account for a fraction of those. Two other PD related proteins, alpha-
synuclein and DJ-1, have been found at the mitochondria and may be implicated in mitochondrial quality 
control. Alpha-synuclein has been reported to affect mitochondrial fusion/fission (Kamp et al., 2010; 
Nakamura et al., 2011; Xie and Chung, 2012), a mechanism essential to mitophagy (Twig et al., 2008). 
DJ-1 has been shown to interact with the PINK1/Parkin pathway, but has not been studied extensively 
(Hao et al., 2010; Irrcher et al., 2010; Thomas et al., 2010).  
Over ninety percent of PD cases are of unknown cause, and one may wonder what the 
importance of mitophagy is to this disease?. The main risk factor for the development of sporadic PD is 
advanced age (De Lau and Breteler, 2006) and mtDNA mutations have been shown to spontaneously 
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arise with aging (Schapira and Gegg, 2011; Soong et al., 1992). When the mitochondria carrying these 
mutations are not properly cleared, this may lead to mitochondrial dysfunction and, eventually, neuronal 
cell death.  It is not unthinkable that, with aging, the efficiency of the mitophagy process is affected. This 
can be at the initial stage of recognition of sick mitochondria, or at any of the following stages including 
autophagosomal engulfment, autophagolysosome formation or lysosomal degradation (Nixon and Yang, 
2012). There may be as of yet unknown risk factors, both genetic and environmental, that affect the 
deterioration of mitophagy with age. 
 
5.3.4 Mitophagy as a therapeutic target 
The idea that neurodegeneration or mitochondrial disease is the result of failed mitophagy opens 
the door to the possibility of treating these diseases by stimulating autophagy or mitophagy. This 
approach is already being investigated in the case of Huntington’s Disease, where the induction of 
autophagy helps clear aggregates of mutant huntingtin in vitro and in vivo (Berger et al., 2006; Ravikumar 
et al., 2002; Rose et al., 2010). An indication that this could potentially work for mitochondria as well 
comes from recent work by Dutta et al. (2013).  Their study in cardiomyocytes showed that autophagy 
induction could protect against mitochondrially-generated oxidative stress, presumably by clearing 
dysfunctional mitochondria.  
A logical follow-up to our own cybrid study would be to treat cybrid cells that contain mutant and 
wild-type mtDNA (heteroplasmic) with rapamycin. Over time, we would expect to see a change in the ratio 
between WT and mutant mtDNA as the mitochondria containing mutant mtDNA are being cleared. This 
could provide a proof-of-principle for mitophagy as a therapeutic target in a clear-cut model.  
The MitoPark mouse may be a good model to test mitophagy activation as a therapy for 
neurodegeneration. These mice lack the mitochondrial transcription factor A (TFAM) in dopaminergic 
neurons, leading to progressive mtDNA depletion and consequent respiratory chain dysfunction and 
neurodegeneration (Ekstrand et al., 2007). Unexpectedly, Sterky et al. (2011) found no recruitment of 
Parkin in these mice, despite the presence of damaged mitochondria. This does not mean that mitophagy 
cannot take place, however. Rather, this in vivo model may be similar to the situation in our cybrid cells, 
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where it was necessary to inhibit mTor and activate macroautophagy in order to see mitophagy. It would 
be quite interesting to treat these mice with, for example, rapamycin to try and alleviate their phenotype. 
 
5.4. CONCLUDING REMARKS 
The overall goal of this dissertation was to gain insight in the regulation of mammalian mitophagy. 
The data presented support a role for the PD-related proteins PINK1 and Parkin in this process and also 
made clear that its regulation is multi-faceted and complex. Many questions remain to be answered and 
our new tool should be helpful in further elucidating the mechanisms of mitophagy as a quality control 
mechanism.  
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